Trial Outcomes & Findings for A Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK-8150 (MK-8150-002) (NCT NCT01656408)

Results Overview

An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study drug, whether or not considered related to the use of the study drug. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which is temporally associated with the use of the study drug, is also an AE. The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.

Recruitment status

COMPLETED

Study phase

PHASE1

Target enrollment

103 participants

Primary outcome timeframe

Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period)

Results posted on

2018-09-25

Participant Flow

Participant milestones

Participant milestones
Measure	Panel A - Participants With Mild to Moderate Hypertension 6 participants were randomly assigned to receive MK-8150 5 mg once daily and 2 participants were randomly assigned to receive placebo once daily for 10 days	Panel B - Participants With Mild to Moderate Hypertension 6 participants were randomly assigned to receive MK-8150 10 mg once daily and 2 participants were randomly assigned to receive placebo once daily for 10 days	Panel C - Participants With Mild to Moderate Hypertension 6 participants were randomly assigned to receive MK-8150 20 mg once daily and 2 participants were randomly assigned to receive placebo once daily for 10 days	Panel D - Participants With Mild to Moderate Hypertension 5 participants were randomly assigned to receive MK-8150 15 mg once daily and 2 participants were randomly assigned to receive placebo once daily for 10 days	Panel E - Elderly Participants With Mild/Moderate Hypertension 6 participants were randomly assigned to receive a single dose of MK-8150 3 mg on Day 1 and to also receive MK-8150 2 mg once daily on Days 6-15 (10 days of multiple dose administration); 3 participants were randomly assigned to receive placebo (single dose) on Day 1 and once daily on Days 6-15	Panel F - Elderly Participants With Mild/Moderate Hypertension 6 participants were randomly assigned to receive a single dose of MK-8150 6 mg on Day 1 and to also receive MK-8150 4 mg once daily on Days 6-15 (10 days of multiple dose administration); 3 participants were randomly assigned to receive placebo (single dose) on Day 1 and once daily on Days 6-15	Panel G - Healthy Participants 8 participants were randomly assigned to receive MK-8150 once daily as follows: 20 mg (Days 1-7), 30 mg (Days 8-14), 40 mg (Days 15-21), 60 mg (Days 22-28); 2 participants were randomly assigned to receive placebo once daily on Days 1-28. Dose administered could be increased or decreased based on defined criteria	Panel H - Participants With Resistant Hypertension In Panel with crossover design, 4 participants were randomly assigned to receive active drug (MK-8150) in Period 1 and placebo in Period 2 and 4 participants were randomly assigned to receive placebo in Period 1 and active drug in Period 2. Active drug regimen was MK-8150 once daily as follows: 10 mg (Days 1-2), 20 mg (Days 3-10); placebo regimen was placebo once daily on Days 1-10	Panel I - Participants With Mild to Moderate Hypertension 12 participants were randomly assigned to receive MK-8150 once daily as follows: 5 mg (Days 1-7), 10 mg (Days 8-14), 20 mg (Days 15-21), 40 mg (Days 22-28); 6 participants were randomly assigned to receive placebo once daily on Days 1-28. Dose administered could be increased or decreased based on defined criteria	Panel J - Participants With Mild to Moderate Hypertension 12 participants were randomly assigned to receive MK-8150 once daily as follows: 10 mg (Days 1-7), 20 mg (Days 8-28); 6 participants were randomly assigned to receive placebo once daily on Days 1-28. Dose administered could be increased or decreased based on defined criteria
Overall Study STARTED	8	8	8	7	9	9	10	8	18	18
Overall Study COMPLETED	7	8	6	7	8	7	9	7	16	15
Overall Study NOT COMPLETED	1	0	2	0	1	2	1	1	2	3

Reasons for withdrawal

Reasons for withdrawal
Measure	Panel A - Participants With Mild to Moderate Hypertension 6 participants were randomly assigned to receive MK-8150 5 mg once daily and 2 participants were randomly assigned to receive placebo once daily for 10 days	Panel B - Participants With Mild to Moderate Hypertension 6 participants were randomly assigned to receive MK-8150 10 mg once daily and 2 participants were randomly assigned to receive placebo once daily for 10 days	Panel C - Participants With Mild to Moderate Hypertension 6 participants were randomly assigned to receive MK-8150 20 mg once daily and 2 participants were randomly assigned to receive placebo once daily for 10 days	Panel D - Participants With Mild to Moderate Hypertension 5 participants were randomly assigned to receive MK-8150 15 mg once daily and 2 participants were randomly assigned to receive placebo once daily for 10 days	Panel E - Elderly Participants With Mild/Moderate Hypertension 6 participants were randomly assigned to receive a single dose of MK-8150 3 mg on Day 1 and to also receive MK-8150 2 mg once daily on Days 6-15 (10 days of multiple dose administration); 3 participants were randomly assigned to receive placebo (single dose) on Day 1 and once daily on Days 6-15	Panel F - Elderly Participants With Mild/Moderate Hypertension 6 participants were randomly assigned to receive a single dose of MK-8150 6 mg on Day 1 and to also receive MK-8150 4 mg once daily on Days 6-15 (10 days of multiple dose administration); 3 participants were randomly assigned to receive placebo (single dose) on Day 1 and once daily on Days 6-15	Panel G - Healthy Participants 8 participants were randomly assigned to receive MK-8150 once daily as follows: 20 mg (Days 1-7), 30 mg (Days 8-14), 40 mg (Days 15-21), 60 mg (Days 22-28); 2 participants were randomly assigned to receive placebo once daily on Days 1-28. Dose administered could be increased or decreased based on defined criteria	Panel H - Participants With Resistant Hypertension In Panel with crossover design, 4 participants were randomly assigned to receive active drug (MK-8150) in Period 1 and placebo in Period 2 and 4 participants were randomly assigned to receive placebo in Period 1 and active drug in Period 2. Active drug regimen was MK-8150 once daily as follows: 10 mg (Days 1-2), 20 mg (Days 3-10); placebo regimen was placebo once daily on Days 1-10	Panel I - Participants With Mild to Moderate Hypertension 12 participants were randomly assigned to receive MK-8150 once daily as follows: 5 mg (Days 1-7), 10 mg (Days 8-14), 20 mg (Days 15-21), 40 mg (Days 22-28); 6 participants were randomly assigned to receive placebo once daily on Days 1-28. Dose administered could be increased or decreased based on defined criteria	Panel J - Participants With Mild to Moderate Hypertension 12 participants were randomly assigned to receive MK-8150 once daily as follows: 10 mg (Days 1-7), 20 mg (Days 8-28); 6 participants were randomly assigned to receive placebo once daily on Days 1-28. Dose administered could be increased or decreased based on defined criteria
Overall Study Adverse Event	0	0	1	0	0	1	1	0	1	0
Overall Study Physician Decision	1	0	1	0	1	1	0	1	1	3

Baseline Characteristics

A Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK-8150 (MK-8150-002)

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure	Panel A - Participants With Mild to Moderate Hypertension n=8 Participants 6 participants were randomly assigned to receive MK-8150 5 mg once daily and 2 participants were randomly assigned to receive placebo once daily for 10 days	Panel B - Participants With Mild to Moderate Hypertension n=8 Participants 6 participants were randomly assigned to receive MK-8150 10 mg once daily and 2 participants were randomly assigned to receive placebo once daily for 10 days	Panel C - Participants With Mild to Moderate Hypertension n=8 Participants 6 participants were randomly assigned to receive MK-8150 20 mg once daily and 2 participants were randomly assigned to receive placebo once daily for 10 days	Panel D - Participants With Mild to Moderate Hypertension n=7 Participants 5 participants were randomly assigned to receive MK-8150 15 mg once daily and 2 participants were randomly assigned to receive placebo once daily for 10 days	Panel E - Elderly Participants With Mild/Moderate Hypertension n=9 Participants 6 participants were randomly assigned to receive a single dose of MK-8150 3 mg on Day 1 and to also receive MK-8150 2 mg once daily on Days 6-15 (10 days of multiple dose administration); 3 participants were randomly assigned to receive placebo (single dose) on Day 1 and once daily on Days 6-15	Panel F - Elderly Participants With Mild/Moderate Hypertension n=9 Participants 6 participants were randomly assigned to receive a single dose of MK-8150 6 mg on Day 1 and to also receive MK-8150 4 mg once daily on Days 6-15 (10 days of multiple dose administration); 3 participants were randomly assigned to receive placebo (single dose) on Day 1 and once daily on Days 6-15	Panel G - Healthy Participants n=10 Participants 8 participants were randomly assigned to receive MK-8150 once daily as follows: 20 mg (Days 1-7), 30 mg (Days 8-14), 40 mg (Days 15-21), 60 mg (Days 22-28); 2 participants were randomly assigned to receive placebo once daily on Days 1-28. Dose administered could be increased or decreased based on defined criteria	Panel H - Participants With Resistant Hypertension n=8 Participants In Panel with crossover design, 4 participants were randomly assigned to receive active drug (MK-8150) in Period 1 and placebo in Period 2 and 4 participants were randomly assigned to receive placebo in Period 1 and active drug in Period 2. Active drug regimen was MK-8150 once daily as follows: 10 mg (Days 1-2), 20 mg (Days 3-10); placebo regimen was placebo once daily on Days 1-10	Panel I - Participants With Mild to Moderate Hypertension n=18 Participants 12 participants were randomly assigned to receive MK-8150 once daily as follows: 5 mg (Days 1-7), 10 mg (Days 8-14), 20 mg (Days 15-21), 40 mg (Days 22-28); 6 participants were randomly assigned to receive placebo once daily on Days 1-28. Dose administered could be increased or decreased based on defined criteria	Panel J - Participants With Mild to Moderate Hypertension n=18 Participants 12 participants were randomly assigned to receive MK-8150 once daily as follows: 10 mg (Days 1-7), 20 mg (Days 8-28); 6 participants were randomly assigned to receive placebo once daily on Days 1-28. Dose administered could be increased or decreased based on defined criteria	Total n=103 Participants Total of all reporting groups
Age, Continuous	46.1 years STANDARD_DEVIATION 6.3 • n=5 Participants	41.3 years STANDARD_DEVIATION 10.8 • n=7 Participants	42.0 years STANDARD_DEVIATION 11.4 • n=5 Participants	42.7 years STANDARD_DEVIATION 10.8 • n=4 Participants	72.6 years STANDARD_DEVIATION 4.2 • n=21 Participants	69.9 years STANDARD_DEVIATION 2.5 • n=8 Participants	41.5 years STANDARD_DEVIATION 11.2 • n=8 Participants	58.1 years STANDARD_DEVIATION 5.6 • n=24 Participants	51.5 years STANDARD_DEVIATION 8.5 • n=42 Participants	54.8 years STANDARD_DEVIATION 9.6 • n=42 Participants	52.5 years STANDARD_DEVIATION 13.2 • n=42 Participants
Sex: Female, Male Female	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	4 Participants n=21 Participants	5 Participants n=8 Participants	0 Participants n=8 Participants	3 Participants n=24 Participants	0 Participants n=42 Participants	0 Participants n=42 Participants	12 Participants n=42 Participants
Sex: Female, Male Male	8 Participants n=5 Participants	8 Participants n=7 Participants	8 Participants n=5 Participants	7 Participants n=4 Participants	5 Participants n=21 Participants	4 Participants n=8 Participants	10 Participants n=8 Participants	5 Participants n=24 Participants	18 Participants n=42 Participants	18 Participants n=42 Participants	91 Participants n=42 Participants
Central Systolic Blood Pressure (cSBP)	141 mm Hg STANDARD_DEVIATION 15 • n=5 Participants	126 mm Hg STANDARD_DEVIATION 10 • n=7 Participants	127 mm Hg STANDARD_DEVIATION 16 • n=5 Participants	126 mm Hg STANDARD_DEVIATION 7 • n=4 Participants	143 mm Hg STANDARD_DEVIATION 11 • n=21 Participants	144 mm Hg STANDARD_DEVIATION 11 • n=8 Participants	103 mm Hg STANDARD_DEVIATION 11 • n=8 Participants	130 mm Hg STANDARD_DEVIATION 12 • n=24 Participants	133 mm Hg STANDARD_DEVIATION 10 • n=42 Participants	136 mm Hg STANDARD_DEVIATION 12 • n=42 Participants	131 mm Hg STANDARD_DEVIATION 16 • n=42 Participants
Heart Rate (HR)	65 beats per minute STANDARD_DEVIATION 14 • n=5 Participants	63 beats per minute STANDARD_DEVIATION 7 • n=7 Participants	66 beats per minute STANDARD_DEVIATION 12 • n=5 Participants	61 beats per minute STANDARD_DEVIATION 10 • n=4 Participants	59 beats per minute STANDARD_DEVIATION 11 • n=21 Participants	68 beats per minute STANDARD_DEVIATION 9 • n=8 Participants	54 beats per minute STANDARD_DEVIATION 7 • n=8 Participants	63 beats per minute STANDARD_DEVIATION 9 • n=24 Participants	62 beats per minute STANDARD_DEVIATION 10 • n=42 Participants	66 beats per minute STANDARD_DEVIATION 9 • n=42 Participants	63 beats per minute STANDARD_DEVIATION 10 • n=42 Participants
Augmentation Index (AIx)	23 percent STANDARD_DEVIATION 8 • n=5 Participants	13 percent STANDARD_DEVIATION 12 • n=7 Participants	11 percent STANDARD_DEVIATION 18 • n=5 Participants	10 percent STANDARD_DEVIATION 12 • n=4 Participants	31 percent STANDARD_DEVIATION 7 • n=21 Participants	30 percent STANDARD_DEVIATION 6 • n=8 Participants	5 percent STANDARD_DEVIATION 15 • n=8 Participants	20 percent STANDARD_DEVIATION 11 • n=24 Participants	19 percent STANDARD_DEVIATION 9 • n=42 Participants	23 percent STANDARD_DEVIATION 7 • n=42 Participants	19 percent STANDARD_DEVIATION 13 • n=42 Participants
Central Diastolic Blood Pressure (cDBP)	93 mm Hg STANDARD_DEVIATION 5 • n=5 Participants	87 mm Hg STANDARD_DEVIATION 8 • n=7 Participants	87 mm Hg STANDARD_DEVIATION 10 • n=5 Participants	87 mm Hg STANDARD_DEVIATION 7 • n=4 Participants	84 mm Hg STANDARD_DEVIATION 7 • n=21 Participants	86 mm Hg STANDARD_DEVIATION 11 • n=8 Participants	73 mm Hg STANDARD_DEVIATION 9 • n=8 Participants	85 mm Hg STANDARD_DEVIATION 8 • n=24 Participants	89 mm Hg STANDARD_DEVIATION 6 • n=42 Participants	90 mm Hg STANDARD_DEVIATION 11 • n=42 Participants	87 mm Hg STANDARD_DEVIATION 10 • n=42 Participants
Peripheral Systolic Blood Pressure (pSBP)	150 mm Hg STANDARD_DEVIATION 12 • n=5 Participants	137 mm Hg STANDARD_DEVIATION 7 • n=7 Participants	142 mm Hg STANDARD_DEVIATION 17 • n=5 Participants	139 mm Hg STANDARD_DEVIATION 5 • n=4 Participants	147 mm Hg STANDARD_DEVIATION 10 • n=21 Participants	151 mm Hg STANDARD_DEVIATION 9 • n=8 Participants	117 mm Hg STANDARD_DEVIATION 7 • n=8 Participants	141 mm Hg STANDARD_DEVIATION 11 • n=24 Participants	145 mm Hg STANDARD_DEVIATION 9 • n=42 Participants	147 mm Hg STANDARD_DEVIATION 10 • n=42 Participants	142 mm Hg STANDARD_DEVIATION 13 • n=42 Participants
Peripheral Diastolic Blood Pressure (pDBP)	92 mm Hg STANDARD_DEVIATION 6 • n=5 Participants	86 mm Hg STANDARD_DEVIATION 9 • n=7 Participants	90 mm Hg STANDARD_DEVIATION 10 • n=5 Participants	86 mm Hg STANDARD_DEVIATION 7 • n=4 Participants	82 mm Hg STANDARD_DEVIATION 5 • n=21 Participants	86 mm Hg STANDARD_DEVIATION 11 • n=8 Participants	72 mm Hg STANDARD_DEVIATION 9 • n=8 Participants	84 mm Hg STANDARD_DEVIATION 8 • n=24 Participants	89 mm Hg STANDARD_DEVIATION 6 • n=42 Participants	90 mm Hg STANDARD_DEVIATION 10 • n=42 Participants	86 mm Hg STANDARD_DEVIATION 10 • n=42 Participants

PRIMARY outcome

Timeframe: Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period)

Population: All participants who received at least one dose of study drug

An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study drug, whether or not considered related to the use of the study drug. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which is temporally associated with the use of the study drug, is also an AE. The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.

Outcome measures

Outcome measures
Measure	Panel A - MK-8150 5 mg n=6 Participants MK-8150 5 mg once daily for 10 days	Panel B - MK-8150 10 mg n=6 Participants MK-8150 10 mg once daily for 10 days	Panel C - MK-8150 20 mg n=6 Participants MK-8150 20 mg once daily for 10 days	Panel D - MK-8150 15 mg n=5 Participants MK-8150 15 mg once daily for 10 days	Panel E - MK-8150 3/2 mg n=6 Participants Single dose of MK-8150 3 mg on Day 1 and MK-8150 2 mg once daily on Days 6-15	Panel F - MK-8150 6/4 mg n=6 Participants Single dose of MK-8150 6 mg on Day 1 and MK-8150 4 mg once daily on Days 6-15	Panel G - MK-8150 20/30/40/60 mg n=8 Participants MK-8150 once daily as follows: 20 mg (Days 1-7), 30 mg (Days 8-14), 40 mg (Days 15-21), 60 mg (Days 22-28)	Panel H - MK-8150 10/20 mg n=8 Participants MK-8150 once daily as follows: 10 mg (Days 1-2), 20 mg (Days 3-10)	Panel I - MK-8150 5/10/20/40 mg n=12 Participants MK-8150 once daily as follows: 5 mg (Days 1-7), 10 mg (Days 8-14), 20 mg (Days 15-21), 40 mg (Days 22-28)	Panel J - MK-8150 10/20 mg n=12 Participants MK-8150 once daily as follows: 10 mg (Days 1-7), 20 mg (Days 8-28)	Placebo (Panel A - J) n=36 Participants Combines participants who received placebo in all panels	Post Study n=103 Participants All enrolled participants, presents AEs with onset after safety follow-up period after last dose of study drug	Screening n=103 Participants All enrolled participants, presents AEs with onset before first dose of study drug
Number of Participants With an Adverse Event (AE)	4 participants	5 participants	6 participants	3 participants	4 participants	3 participants	7 participants	6 participants	12 participants	10 participants	24 participants	1 participants	12 participants

PRIMARY outcome

Timeframe: Up to 28 days

Population: All participants who received at least one dose of study drug

Hemodynamic criteria for stopping drug dosing were applied (any of the following, obtained resting and if present for ≥1 hour, unless noted). For all Panels: HR \>120 bpm; SBP ≥180 mm Hg (Panels A-D/G-J) and ≥175 mm Hg (Panels E-F); DBP ≥110 mm Hg; DBP \<50 mm Hg; SBP \<90 mm Hg or participant placed in Trendelenburg position. For Panels A-H: HR increase over identified baseline of ≥25 beats per minute; SBP reduction \>30 mm Hg versus identified baseline; \>20 mm Hg drop in SBP and \>20 beats per minute rise in HR observed together versus identified baselines; \>30 mm Hg drop in orthostatic SBP and \>30 beats per minute rise in orthostatic HR observed together. For Panels I-J, any of the following-down dosing criteria if still present 24 hours after dose decrease: HR increase ≥20 beats per minute versus identified baseline; SBP reduction \>30 mm Hg versus identified baseline; SBP \<100 mm Hg; \>30 mm Hg drop in orthostatic SBP and \>30 beats per minute rise in orthostatic HR observed together.

Outcome measures

Outcome measures
Measure	Panel A - MK-8150 5 mg n=6 Participants MK-8150 5 mg once daily for 10 days	Panel B - MK-8150 10 mg n=6 Participants MK-8150 10 mg once daily for 10 days	Panel C - MK-8150 20 mg n=6 Participants MK-8150 20 mg once daily for 10 days	Panel D - MK-8150 15 mg n=5 Participants MK-8150 15 mg once daily for 10 days	Panel E - MK-8150 3/2 mg n=6 Participants Single dose of MK-8150 3 mg on Day 1 and MK-8150 2 mg once daily on Days 6-15	Panel F - MK-8150 6/4 mg n=6 Participants Single dose of MK-8150 6 mg on Day 1 and MK-8150 4 mg once daily on Days 6-15	Panel G - MK-8150 20/30/40/60 mg n=8 Participants MK-8150 once daily as follows: 20 mg (Days 1-7), 30 mg (Days 8-14), 40 mg (Days 15-21), 60 mg (Days 22-28)	Panel H - MK-8150 10/20 mg n=8 Participants MK-8150 once daily as follows: 10 mg (Days 1-2), 20 mg (Days 3-10)	Panel I - MK-8150 5/10/20/40 mg n=12 Participants MK-8150 once daily as follows: 5 mg (Days 1-7), 10 mg (Days 8-14), 20 mg (Days 15-21), 40 mg (Days 22-28)	Panel J - MK-8150 10/20 mg n=12 Participants MK-8150 once daily as follows: 10 mg (Days 1-7), 20 mg (Days 8-28)	Placebo (Panel A - J) n=36 Participants Combines participants who received placebo in all panels	Post Study All enrolled participants, presents AEs with onset after safety follow-up period after last dose of study drug	Screening All enrolled participants, presents AEs with onset before first dose of study drug
Number of Participants Discontinued From Study Drug Due to Meeting Hemodynamic Stopping Rules	3 participants	0 participants	1 participants	0 participants	2 participants	1 participants	0 participants	1 participants	1 participants	3 participants	0 participants	—	—

PRIMARY outcome

Timeframe: Pre-dose and 2, 3, 4, 6, 8, 12 and 24 hours post dose

Population: All participants who met protocol entry criteria, received study drug and had data available for the measure

cSBP was measured by applanation tonometry of the radial artery, using the SphygmoCor System. The central pressure waveform was determined from the peripheral pressure waveform by a transfer function. Time-weighted average was obtained as follows: For all cSBP values obtained over the 24-hour observation period, multiply the length of time that the participant spent at each cSBP value by that cSBP value, add these products together, and then divide by duration of the observation period. The length of time spent at an identified cSBP value was defined as the time elapsed since previous post-dose measurement, or time elapsed since drug administration, if there is no previous post-dose measurement. Baseline was Day 1 pre-dose value.

Outcome measures

Outcome measures
Measure	Panel A - MK-8150 5 mg n=6 Participants MK-8150 5 mg once daily for 10 days	Panel B - MK-8150 10 mg n=6 Participants MK-8150 10 mg once daily for 10 days	Panel C - MK-8150 20 mg n=6 Participants MK-8150 20 mg once daily for 10 days	Panel D - MK-8150 15 mg n=5 Participants MK-8150 15 mg once daily for 10 days	Panel E - MK-8150 3/2 mg n=8 Participants Single dose of MK-8150 3 mg on Day 1 and MK-8150 2 mg once daily on Days 6-15	Panel F - MK-8150 6/4 mg Single dose of MK-8150 6 mg on Day 1 and MK-8150 4 mg once daily on Days 6-15	Panel G - MK-8150 20/30/40/60 mg MK-8150 once daily as follows: 20 mg (Days 1-7), 30 mg (Days 8-14), 40 mg (Days 15-21), 60 mg (Days 22-28)	Panel H - MK-8150 10/20 mg MK-8150 once daily as follows: 10 mg (Days 1-2), 20 mg (Days 3-10)	Panel I - MK-8150 5/10/20/40 mg MK-8150 once daily as follows: 5 mg (Days 1-7), 10 mg (Days 8-14), 20 mg (Days 15-21), 40 mg (Days 22-28)	Panel J - MK-8150 10/20 mg MK-8150 once daily as follows: 10 mg (Days 1-7), 20 mg (Days 8-28)	Placebo (Panel A - J) Combines participants who received placebo in all panels	Post Study All enrolled participants, presents AEs with onset after safety follow-up period after last dose of study drug	Screening All enrolled participants, presents AEs with onset before first dose of study drug
Change From Baseline in Time-weighted Average Across 24 Hours (TWA0-24hrs) cSBP in Male Participants With Mild to Moderate Hypertension Administered Multiple Doses of MK-8150 and Placebo (Panel A/B/C/D) Day 1 (N = 6, 6, 6, 5, 8)	-5.3 mm Hg Standard Error 2.6	-15.3 mm Hg Standard Error 2.4	-19.5 mm Hg Standard Error 2.4	-12.8 mm Hg Standard Error 2.3	-5.4 mm Hg Standard Error 2.3	—	—	—	—	—	—	—	—
Change From Baseline in Time-weighted Average Across 24 Hours (TWA0-24hrs) cSBP in Male Participants With Mild to Moderate Hypertension Administered Multiple Doses of MK-8150 and Placebo (Panel A/B/C/D) Day 10 (N = 5, 6, 4, 5, 8)	-6.2 mm Hg Standard Error 3.4	-13.9 mm Hg Standard Error 1.0	-18.4 mm Hg Standard Error 1.9	-12.1 mm Hg Standard Error 3.7	-9.7 mm Hg Standard Error 3.0	—	—	—	—	—	—	—	—

PRIMARY outcome

Timeframe: Pre-dose and 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14, 16 and 24 hours post dose

Population: All participants who met protocol entry criteria, received study drug and had data available for the measure

HR was measured with a validated automatic measuring device. Time-weighted average was obtained as follows: For all HR values obtained over the 24-hour observation period, multiply the length of time that the participant spent at each HR value by that HR value, add these products together, and then divide by duration of the observation period. The length of time spent at an identified HR value was defined as the time elapsed since previous post-dose measurement, or time elapsed since drug administration, if there is no previous post-dose measurement. Baseline was Day 1 pre-dose value.

Outcome measures

Outcome measures
Measure	Panel A - MK-8150 5 mg n=6 Participants MK-8150 5 mg once daily for 10 days	Panel B - MK-8150 10 mg n=6 Participants MK-8150 10 mg once daily for 10 days	Panel C - MK-8150 20 mg n=6 Participants MK-8150 20 mg once daily for 10 days	Panel D - MK-8150 15 mg n=5 Participants MK-8150 15 mg once daily for 10 days	Panel E - MK-8150 3/2 mg n=8 Participants Single dose of MK-8150 3 mg on Day 1 and MK-8150 2 mg once daily on Days 6-15	Panel F - MK-8150 6/4 mg Single dose of MK-8150 6 mg on Day 1 and MK-8150 4 mg once daily on Days 6-15	Panel G - MK-8150 20/30/40/60 mg MK-8150 once daily as follows: 20 mg (Days 1-7), 30 mg (Days 8-14), 40 mg (Days 15-21), 60 mg (Days 22-28)	Panel H - MK-8150 10/20 mg MK-8150 once daily as follows: 10 mg (Days 1-2), 20 mg (Days 3-10)	Panel I - MK-8150 5/10/20/40 mg MK-8150 once daily as follows: 5 mg (Days 1-7), 10 mg (Days 8-14), 20 mg (Days 15-21), 40 mg (Days 22-28)	Panel J - MK-8150 10/20 mg MK-8150 once daily as follows: 10 mg (Days 1-7), 20 mg (Days 8-28)	Placebo (Panel A - J) Combines participants who received placebo in all panels	Post Study All enrolled participants, presents AEs with onset after safety follow-up period after last dose of study drug	Screening All enrolled participants, presents AEs with onset before first dose of study drug
Change From Baseline in TWA0-24hrs HR in Male Participants With Mild to Moderate Hypertension Administered Multiple Doses of MK-8150 and Placebo (Panel A/B/C/D) Day 1 (N = 6, 6, 6, 5, 8)	0.0 beats per minute Standard Error 3.7	-7.2 beats per minute Standard Error 2.5	-12.3 beats per minute Standard Error 2.4	-4.0 beats per minute Standard Error 3.2	-1.9 beats per minute Standard Error 1.3	—	—	—	—	—	—	—	—
Change From Baseline in TWA0-24hrs HR in Male Participants With Mild to Moderate Hypertension Administered Multiple Doses of MK-8150 and Placebo (Panel A/B/C/D) Day 10 (N = 5, 6, 4, 5, 8)	-3.6 beats per minute Standard Error 1.3	-5.5 beats per minute Standard Error 2.0	-10.5 beats per minute Standard Error 1.6	-1.0 beats per minute Standard Error 2.4	-2.1 beats per minute Standard Error 2.0	—	—	—	—	—	—	—	—

PRIMARY outcome

Timeframe: Pre-dose and 2, 3, 4, 6, 8, 12 and 24 hours post dose

Population: All participants who met protocol entry criteria, received study drug and had data available for the measure

cSBP was measured by applanation tonometry of the radial artery, using the SphygmoCor System. The central pressure waveform was determined from the peripheral pressure waveform by a transfer function. Time-weighted average was obtained as follows: For all cSBP values obtained over the 24-hour observation period, multiply the length of time that the participant spent at each cSBP value by that cSBP value, add these products together, and then divide by duration of the observation period. The length of time spent at an identified cSBP value was defined as the time elapsed since previous post-dose measurement, or time elapsed since drug administration, if there is no previous post-dose measurement. Baseline for Day 1 was Day 1 pre-dose value; Baseline for Day 6-15 was Day 6 pre-dose value.

Outcome measures

Outcome measures
Measure	Panel A - MK-8150 5 mg n=6 Participants MK-8150 5 mg once daily for 10 days	Panel B - MK-8150 10 mg n=3 Participants MK-8150 10 mg once daily for 10 days	Panel C - MK-8150 20 mg MK-8150 20 mg once daily for 10 days	Panel D - MK-8150 15 mg MK-8150 15 mg once daily for 10 days	Panel E - MK-8150 3/2 mg Single dose of MK-8150 3 mg on Day 1 and MK-8150 2 mg once daily on Days 6-15	Panel F - MK-8150 6/4 mg Single dose of MK-8150 6 mg on Day 1 and MK-8150 4 mg once daily on Days 6-15	Panel G - MK-8150 20/30/40/60 mg MK-8150 once daily as follows: 20 mg (Days 1-7), 30 mg (Days 8-14), 40 mg (Days 15-21), 60 mg (Days 22-28)	Panel H - MK-8150 10/20 mg MK-8150 once daily as follows: 10 mg (Days 1-2), 20 mg (Days 3-10)	Panel I - MK-8150 5/10/20/40 mg MK-8150 once daily as follows: 5 mg (Days 1-7), 10 mg (Days 8-14), 20 mg (Days 15-21), 40 mg (Days 22-28)	Panel J - MK-8150 10/20 mg MK-8150 once daily as follows: 10 mg (Days 1-7), 20 mg (Days 8-28)	Placebo (Panel A - J) Combines participants who received placebo in all panels	Post Study All enrolled participants, presents AEs with onset after safety follow-up period after last dose of study drug	Screening All enrolled participants, presents AEs with onset before first dose of study drug
Change From Baseline in TWA0-24hrs cSBP in Elderly Male and Female Participants With Mild to Moderate Hypertension Administered Single and Multiple Doses of MK-8150 and Placebo (Panel E) Day 1 (N = 6, 3)	-16.3 mm Hg Standard Error 3.3	-15.5 mm Hg Standard Error 3.2	—	—	—	—	—	—	—	—	—	—	—
Change From Baseline in TWA0-24hrs cSBP in Elderly Male and Female Participants With Mild to Moderate Hypertension Administered Single and Multiple Doses of MK-8150 and Placebo (Panel E) Day 6 (N = 5, 3)	-11.8 mm Hg Standard Error 3.6	-15.5 mm Hg Standard Error 7.3	—	—	—	—	—	—	—	—	—	—	—
Change From Baseline in TWA0-24hrs cSBP in Elderly Male and Female Participants With Mild to Moderate Hypertension Administered Single and Multiple Doses of MK-8150 and Placebo (Panel E) Day 15 (N = 5, 3)	-10.6 mm Hg Standard Error 3.9	-16.9 mm Hg Standard Error 5.9	—	—	—	—	—	—	—	—	—	—	—

PRIMARY outcome

Timeframe: Pre-dose and 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14, 16 and 24 hours post dose

Population: All participants who met protocol entry criteria, received study drug and had data available for the measure

HR was measured with a validated automatic measuring device. Time-weighted average was obtained as follows: For all HR values obtained over the 24-hour observation period, multiply the length of time that the participant spent at each HR value by that HR value, add these products together, and then divide by duration of the observation period. The length of time spent at an identified HR value was defined as the time elapsed since previous post-dose measurement, or time elapsed since drug administration, if there is no previous post-dose measurement. Baseline for Day 1 was Day 1 pre-dose value; Baseline for Day 6-15 was Day 6 pre-dose value.

Outcome measures

Outcome measures
Measure	Panel A - MK-8150 5 mg n=6 Participants MK-8150 5 mg once daily for 10 days	Panel B - MK-8150 10 mg n=3 Participants MK-8150 10 mg once daily for 10 days	Panel C - MK-8150 20 mg MK-8150 20 mg once daily for 10 days	Panel D - MK-8150 15 mg MK-8150 15 mg once daily for 10 days	Panel E - MK-8150 3/2 mg Single dose of MK-8150 3 mg on Day 1 and MK-8150 2 mg once daily on Days 6-15	Panel F - MK-8150 6/4 mg Single dose of MK-8150 6 mg on Day 1 and MK-8150 4 mg once daily on Days 6-15	Panel G - MK-8150 20/30/40/60 mg MK-8150 once daily as follows: 20 mg (Days 1-7), 30 mg (Days 8-14), 40 mg (Days 15-21), 60 mg (Days 22-28)	Panel H - MK-8150 10/20 mg MK-8150 once daily as follows: 10 mg (Days 1-2), 20 mg (Days 3-10)	Panel I - MK-8150 5/10/20/40 mg MK-8150 once daily as follows: 5 mg (Days 1-7), 10 mg (Days 8-14), 20 mg (Days 15-21), 40 mg (Days 22-28)	Panel J - MK-8150 10/20 mg MK-8150 once daily as follows: 10 mg (Days 1-7), 20 mg (Days 8-28)	Placebo (Panel A - J) Combines participants who received placebo in all panels	Post Study All enrolled participants, presents AEs with onset after safety follow-up period after last dose of study drug	Screening All enrolled participants, presents AEs with onset before first dose of study drug
Change From Baseline in TWA0-24hrs HR in Elderly Male and Female Participants With Mild to Moderate Hypertension Administered Single and Multiple Doses of MK-8150 and Placebo (Panel E) Day 1 (N = 6, 3)	0.5 beats per minute Standard Error 1.2	2.0 beats per minute Standard Error 2.2	—	—	—	—	—	—	—	—	—	—	—
Change From Baseline in TWA0-24hrs HR in Elderly Male and Female Participants With Mild to Moderate Hypertension Administered Single and Multiple Doses of MK-8150 and Placebo (Panel E) Day 6 (N = 5, 3)	1.6 beats per minute Standard Error 0.8	0.8 beats per minute Standard Error 0.3	—	—	—	—	—	—	—	—	—	—	—
Change From Baseline in TWA0-24hrs HR in Elderly Male and Female Participants With Mild to Moderate Hypertension Administered Single and Multiple Doses of MK-8150 and Placebo (Panel E) Day 15 (N = 5, 3)	2.5 beats per minute Standard Error 1.3	0.7 beats per minute Standard Error 1.3	—	—	—	—	—	—	—	—	—	—	—

PRIMARY outcome

Timeframe: Pre-dose and 2, 3, 4, 6, 8, 12 and 24 hours post dose

Population: All participants who met protocol entry criteria, received study drug and had data available for the measure

cSBP was measured by applanation tonometry of the radial artery, using the SphygmoCor System. The central pressure waveform was determined from the peripheral pressure waveform by a transfer function. Time-weighted average was obtained as follows: For all cSBP values obtained over the 24-hour observation period, multiply the length of time that the participant spent at each cSBP value by that cSBP value, add these products together, and then divide by duration of the observation period. The length of time spent at an identified cSBP value was defined as the time elapsed since previous post-dose measurement, or time elapsed since drug administration, if there is no previous post-dose measurement. Baseline for Day 1 was Day 1 pre-dose value; Baseline for Day 6-15 was Day 6 pre-dose value.

Outcome measures

Outcome measures
Measure	Panel A - MK-8150 5 mg n=6 Participants MK-8150 5 mg once daily for 10 days	Panel B - MK-8150 10 mg n=3 Participants MK-8150 10 mg once daily for 10 days	Panel C - MK-8150 20 mg MK-8150 20 mg once daily for 10 days	Panel D - MK-8150 15 mg MK-8150 15 mg once daily for 10 days	Panel E - MK-8150 3/2 mg Single dose of MK-8150 3 mg on Day 1 and MK-8150 2 mg once daily on Days 6-15	Panel F - MK-8150 6/4 mg Single dose of MK-8150 6 mg on Day 1 and MK-8150 4 mg once daily on Days 6-15	Panel G - MK-8150 20/30/40/60 mg MK-8150 once daily as follows: 20 mg (Days 1-7), 30 mg (Days 8-14), 40 mg (Days 15-21), 60 mg (Days 22-28)	Panel H - MK-8150 10/20 mg MK-8150 once daily as follows: 10 mg (Days 1-2), 20 mg (Days 3-10)	Panel I - MK-8150 5/10/20/40 mg MK-8150 once daily as follows: 5 mg (Days 1-7), 10 mg (Days 8-14), 20 mg (Days 15-21), 40 mg (Days 22-28)	Panel J - MK-8150 10/20 mg MK-8150 once daily as follows: 10 mg (Days 1-7), 20 mg (Days 8-28)	Placebo (Panel A - J) Combines participants who received placebo in all panels	Post Study All enrolled participants, presents AEs with onset after safety follow-up period after last dose of study drug	Screening All enrolled participants, presents AEs with onset before first dose of study drug
Change From Baseline in TWA0-24hrs cSBP in Elderly Male and Female Participants With Mild to Moderate Hypertension Administered Single and Multiple Doses of MK-8150 and Placebo (Panel F) Day 1 (N = 6, 3)	-16.1 mm Hg Standard Error 3.6	-20.5 mm Hg Standard Error 3.1	—	—	—	—	—	—	—	—	—	—	—
Change From Baseline in TWA0-24hrs cSBP in Elderly Male and Female Participants With Mild to Moderate Hypertension Administered Single and Multiple Doses of MK-8150 and Placebo (Panel F) Day 6 (N = 6, 3)	-17.2 mm Hg Standard Error 3.9	-24.6 mm Hg Standard Error 2.7	—	—	—	—	—	—	—	—	—	—	—
Change From Baseline in TWA0-24hrs cSBP in Elderly Male and Female Participants With Mild to Moderate Hypertension Administered Single and Multiple Doses of MK-8150 and Placebo (Panel F) Day 15 (N = 4, 3)	-20.8 mm Hg Standard Error 3.6	-23.8 mm Hg Standard Error 3.6	—	—	—	—	—	—	—	—	—	—	—

PRIMARY outcome

Timeframe: Pre-dose and 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14, 16 and 24 hours post dose

Population: All participants who met protocol entry criteria, received study drug and had data available for the measure

HR was measured with a validated automatic measuring device. Time-weighted average was obtained as follows: For all HR values obtained over the 24-hour observation period, multiply the length of time that the participant spent at each HR value by that HR value, add these products together, and then divide by duration of the observation period. The length of time spent at an identified HR value was defined as the time elapsed since previous post-dose measurement, or time elapsed since drug administration, if there is no previous post-dose measurement. Baseline for Day 1 was Day 1 pre-dose value; Baseline for Day 6-15 was Day 6 pre-dose value.

Outcome measures

Outcome measures
Measure	Panel A - MK-8150 5 mg n=6 Participants MK-8150 5 mg once daily for 10 days	Panel B - MK-8150 10 mg n=3 Participants MK-8150 10 mg once daily for 10 days	Panel C - MK-8150 20 mg MK-8150 20 mg once daily for 10 days	Panel D - MK-8150 15 mg MK-8150 15 mg once daily for 10 days	Panel E - MK-8150 3/2 mg Single dose of MK-8150 3 mg on Day 1 and MK-8150 2 mg once daily on Days 6-15	Panel F - MK-8150 6/4 mg Single dose of MK-8150 6 mg on Day 1 and MK-8150 4 mg once daily on Days 6-15	Panel G - MK-8150 20/30/40/60 mg MK-8150 once daily as follows: 20 mg (Days 1-7), 30 mg (Days 8-14), 40 mg (Days 15-21), 60 mg (Days 22-28)	Panel H - MK-8150 10/20 mg MK-8150 once daily as follows: 10 mg (Days 1-2), 20 mg (Days 3-10)	Panel I - MK-8150 5/10/20/40 mg MK-8150 once daily as follows: 5 mg (Days 1-7), 10 mg (Days 8-14), 20 mg (Days 15-21), 40 mg (Days 22-28)	Panel J - MK-8150 10/20 mg MK-8150 once daily as follows: 10 mg (Days 1-7), 20 mg (Days 8-28)	Placebo (Panel A - J) Combines participants who received placebo in all panels	Post Study All enrolled participants, presents AEs with onset after safety follow-up period after last dose of study drug	Screening All enrolled participants, presents AEs with onset before first dose of study drug
Change From Baseline in TWA0-24hrs HR in Elderly Male and Female Participants With Mild to Moderate Hypertension Administered Single and Multiple Doses of MK-8150 and Placebo (Panel F) Day 1 (N = 6, 3)	-1.2 beats per minute Standard Error 1.7	-1.5 beats per minute Standard Error 2.4	—	—	—	—	—	—	—	—	—	—	—
Change From Baseline in TWA0-24hrs HR in Elderly Male and Female Participants With Mild to Moderate Hypertension Administered Single and Multiple Doses of MK-8150 and Placebo (Panel F) Day 6 (N = 6, 3)	-0.2 beats per minute Standard Error 1.7	-2.1 beats per minute Standard Error 3.3	—	—	—	—	—	—	—	—	—	—	—
Change From Baseline in TWA0-24hrs HR in Elderly Male and Female Participants With Mild to Moderate Hypertension Administered Single and Multiple Doses of MK-8150 and Placebo (Panel F) Day 15 (N = 4, 3)	-1.6 beats per minute Standard Error 1.5	-5.8 beats per minute Standard Error 1.1	—	—	—	—	—	—	—	—	—	—	—

PRIMARY outcome

Timeframe: Pre-dose and 2, 3, 4, 6, 8, 12 and 24 hours post dose

Population: All participants who met protocol entry criteria, received study drug and had data available for the measure

cSBP was measured by applanation tonometry of the radial artery, using the SphygmoCor System. The central pressure waveform was determined from the peripheral pressure waveform by a transfer function. Time-weighted average was obtained as follows: For all cSBP values obtained over the 24-hour observation period, multiply the length of time that the participant spent at each cSBP value by that cSBP value, add these products together, and then divide by duration of the observation period. The length of time spent at an identified cSBP value was defined as the time elapsed since previous post-dose measurement, or time elapsed since drug administration, if there is no previous post-dose measurement. Baseline was Day 1 pre-dose value.

Outcome measures

Outcome measures
Measure	Panel A - MK-8150 5 mg n=8 Participants MK-8150 5 mg once daily for 10 days	Panel B - MK-8150 10 mg n=2 Participants MK-8150 10 mg once daily for 10 days	Panel C - MK-8150 20 mg MK-8150 20 mg once daily for 10 days	Panel D - MK-8150 15 mg MK-8150 15 mg once daily for 10 days	Panel E - MK-8150 3/2 mg Single dose of MK-8150 3 mg on Day 1 and MK-8150 2 mg once daily on Days 6-15	Panel F - MK-8150 6/4 mg Single dose of MK-8150 6 mg on Day 1 and MK-8150 4 mg once daily on Days 6-15	Panel G - MK-8150 20/30/40/60 mg MK-8150 once daily as follows: 20 mg (Days 1-7), 30 mg (Days 8-14), 40 mg (Days 15-21), 60 mg (Days 22-28)	Panel H - MK-8150 10/20 mg MK-8150 once daily as follows: 10 mg (Days 1-2), 20 mg (Days 3-10)	Panel I - MK-8150 5/10/20/40 mg MK-8150 once daily as follows: 5 mg (Days 1-7), 10 mg (Days 8-14), 20 mg (Days 15-21), 40 mg (Days 22-28)	Panel J - MK-8150 10/20 mg MK-8150 once daily as follows: 10 mg (Days 1-7), 20 mg (Days 8-28)	Placebo (Panel A - J) Combines participants who received placebo in all panels	Post Study All enrolled participants, presents AEs with onset after safety follow-up period after last dose of study drug	Screening All enrolled participants, presents AEs with onset before first dose of study drug
Change From Baseline in TWA0-24hrs cSBP in Healthy Male Participants Administered Multiple Doses of MK-8150 and Placebo (Panel G) Day 1 (N = 8, 2)	-8.0 mm Hg Standard Error 1.7	2.8 mm Hg Standard Error 3.3	—	—	—	—	—	—	—	—	—	—	—
Change From Baseline in TWA0-24hrs cSBP in Healthy Male Participants Administered Multiple Doses of MK-8150 and Placebo (Panel G) Day 28 (N = 7, 2)	-8.3 mm Hg Standard Error 2.2	-2.3 mm Hg Standard Error 1.0	—	—	—	—	—	—	—	—	—	—	—

PRIMARY outcome

Timeframe: Pre-dose and 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14, 16 and 24 hours post dose

Population: All participants who met protocol entry criteria, received study drug and had data available for the measure

HR was measured with a validated automatic measuring device. Time-weighted average was obtained as follows: For all HR values obtained over the 24-hour observation period, multiply the length of time that the participant spent at each HR value by that HR value, add these products together, and then divide by duration of the observation period. The length of time spent at an identified HR value was defined as the time elapsed since previous post-dose measurement, or time elapsed since drug administration, if there is no previous post-dose measurement. Baseline was Day 1 pre-dose value.

Outcome measures

Outcome measures
Measure	Panel A - MK-8150 5 mg n=8 Participants MK-8150 5 mg once daily for 10 days	Panel B - MK-8150 10 mg n=2 Participants MK-8150 10 mg once daily for 10 days	Panel C - MK-8150 20 mg MK-8150 20 mg once daily for 10 days	Panel D - MK-8150 15 mg MK-8150 15 mg once daily for 10 days	Panel E - MK-8150 3/2 mg Single dose of MK-8150 3 mg on Day 1 and MK-8150 2 mg once daily on Days 6-15	Panel F - MK-8150 6/4 mg Single dose of MK-8150 6 mg on Day 1 and MK-8150 4 mg once daily on Days 6-15	Panel G - MK-8150 20/30/40/60 mg MK-8150 once daily as follows: 20 mg (Days 1-7), 30 mg (Days 8-14), 40 mg (Days 15-21), 60 mg (Days 22-28)	Panel H - MK-8150 10/20 mg MK-8150 once daily as follows: 10 mg (Days 1-2), 20 mg (Days 3-10)	Panel I - MK-8150 5/10/20/40 mg MK-8150 once daily as follows: 5 mg (Days 1-7), 10 mg (Days 8-14), 20 mg (Days 15-21), 40 mg (Days 22-28)	Panel J - MK-8150 10/20 mg MK-8150 once daily as follows: 10 mg (Days 1-7), 20 mg (Days 8-28)	Placebo (Panel A - J) Combines participants who received placebo in all panels	Post Study All enrolled participants, presents AEs with onset after safety follow-up period after last dose of study drug	Screening All enrolled participants, presents AEs with onset before first dose of study drug
Change From Baseline in TWA0-24hrs HR in Healthy Male Participants Administered Multiple Doses of MK-8150 and Placebo (Panel G) Day 22 (N = 7, 2)	0.8 beats per minute Standard Error 1.6	1.1 beats per minute Standard Error 1.6	—	—	—	—	—	—	—	—	—	—	—
Change From Baseline in TWA0-24hrs HR in Healthy Male Participants Administered Multiple Doses of MK-8150 and Placebo (Panel G) Day 28 (N = 7, 2)	1.8 beats per minute Standard Error 2.0	0.5 beats per minute Standard Error 1.4	—	—	—	—	—	—	—	—	—	—	—
Change From Baseline in TWA0-24hrs HR in Healthy Male Participants Administered Multiple Doses of MK-8150 and Placebo (Panel G) Day 1 (N = 8, 2)	-1.1 beats per minute Standard Error 1.4	-1.1 beats per minute Standard Error 1.4	—	—	—	—	—	—	—	—	—	—	—
Change From Baseline in TWA0-24hrs HR in Healthy Male Participants Administered Multiple Doses of MK-8150 and Placebo (Panel G) Day 8 (N = 8, 2)	0.5 beats per minute Standard Error 2.1	0.8 beats per minute Standard Error 1.4	—	—	—	—	—	—	—	—	—	—	—
Change From Baseline in TWA0-24hrs HR in Healthy Male Participants Administered Multiple Doses of MK-8150 and Placebo (Panel G) Day 15 (N = 7, 2)	2.3 beats per minute Standard Error 2.4	0.2 beats per minute Standard Error 1.4	—	—	—	—	—	—	—	—	—	—	—

PRIMARY outcome

Timeframe: Pre-dose and 2, 3, 4, 6, 8, 12 and 24 hours post dose

Population: All participants who met protocol entry criteria, received study drug and had data available for the measure

cSBP was measured by applanation tonometry of the radial artery, using the SphygmoCor System. The central pressure waveform was determined from the peripheral pressure waveform by a transfer function. Time-weighted average was obtained as follows: For all cSBP values obtained over the 24-hour observation period, multiply the length of time that the participant spent at each cSBP value by that cSBP value, add these products together, and then divide by duration of the observation period. The length of time spent at an identified cSBP value was defined as the time elapsed since previous post-dose measurement, or time elapsed since drug administration, if there is no previous post-dose measurement. Baseline was Day 1 pre-dose value (determined separately in each period).

Outcome measures

Outcome measures
Measure	Panel A - MK-8150 5 mg n=7 Participants MK-8150 5 mg once daily for 10 days	Panel B - MK-8150 10 mg n=8 Participants MK-8150 10 mg once daily for 10 days	Panel C - MK-8150 20 mg MK-8150 20 mg once daily for 10 days	Panel D - MK-8150 15 mg MK-8150 15 mg once daily for 10 days	Panel E - MK-8150 3/2 mg Single dose of MK-8150 3 mg on Day 1 and MK-8150 2 mg once daily on Days 6-15	Panel F - MK-8150 6/4 mg Single dose of MK-8150 6 mg on Day 1 and MK-8150 4 mg once daily on Days 6-15	Panel G - MK-8150 20/30/40/60 mg MK-8150 once daily as follows: 20 mg (Days 1-7), 30 mg (Days 8-14), 40 mg (Days 15-21), 60 mg (Days 22-28)	Panel H - MK-8150 10/20 mg MK-8150 once daily as follows: 10 mg (Days 1-2), 20 mg (Days 3-10)	Panel I - MK-8150 5/10/20/40 mg MK-8150 once daily as follows: 5 mg (Days 1-7), 10 mg (Days 8-14), 20 mg (Days 15-21), 40 mg (Days 22-28)	Panel J - MK-8150 10/20 mg MK-8150 once daily as follows: 10 mg (Days 1-7), 20 mg (Days 8-28)	Placebo (Panel A - J) Combines participants who received placebo in all panels	Post Study All enrolled participants, presents AEs with onset after safety follow-up period after last dose of study drug	Screening All enrolled participants, presents AEs with onset before first dose of study drug
Change From Baseline in TWA0-24hrs cSBP in Male and Female Participants With Resistant Hypertension Administered Multiple Doses of MK-8150 and Placebo (Panel H) Day 1 (N = 7, 8)	-10.1 mm Hg Standard Error 1.8	-4.5 mm Hg Standard Error 1.8	—	—	—	—	—	—	—	—	—	—	—
Change From Baseline in TWA0-24hrs cSBP in Male and Female Participants With Resistant Hypertension Administered Multiple Doses of MK-8150 and Placebo (Panel H) Day 10 (N = 6, 8)	-7.7 mm Hg Standard Error 2.2	-1.8 mm Hg Standard Error 1.0	—	—	—	—	—	—	—	—	—	—	—

PRIMARY outcome

Timeframe: Pre-dose and 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14, 16 and 24 hours post dose

Population: All participants who met protocol entry criteria, received study drug and had data available for the measure

HR was measured with a validated automatic measuring device. Time-weighted average was obtained as follows: For all HR values obtained over the 24-hour observation period, multiply the length of time that the participant spent at each HR value by that HR value, add these products together, and then divide by duration of the observation period. The length of time spent at an identified HR value was defined as the time elapsed since previous post-dose measurement, or time elapsed since drug administration, if there is no previous post-dose measurement. Baseline was Day 1 pre-dose value (determined separately in each period).

Outcome measures

Outcome measures
Measure	Panel A - MK-8150 5 mg n=7 Participants MK-8150 5 mg once daily for 10 days	Panel B - MK-8150 10 mg n=8 Participants MK-8150 10 mg once daily for 10 days	Panel C - MK-8150 20 mg MK-8150 20 mg once daily for 10 days	Panel D - MK-8150 15 mg MK-8150 15 mg once daily for 10 days	Panel E - MK-8150 3/2 mg Single dose of MK-8150 3 mg on Day 1 and MK-8150 2 mg once daily on Days 6-15	Panel F - MK-8150 6/4 mg Single dose of MK-8150 6 mg on Day 1 and MK-8150 4 mg once daily on Days 6-15	Panel G - MK-8150 20/30/40/60 mg MK-8150 once daily as follows: 20 mg (Days 1-7), 30 mg (Days 8-14), 40 mg (Days 15-21), 60 mg (Days 22-28)	Panel H - MK-8150 10/20 mg MK-8150 once daily as follows: 10 mg (Days 1-2), 20 mg (Days 3-10)	Panel I - MK-8150 5/10/20/40 mg MK-8150 once daily as follows: 5 mg (Days 1-7), 10 mg (Days 8-14), 20 mg (Days 15-21), 40 mg (Days 22-28)	Panel J - MK-8150 10/20 mg MK-8150 once daily as follows: 10 mg (Days 1-7), 20 mg (Days 8-28)	Placebo (Panel A - J) Combines participants who received placebo in all panels	Post Study All enrolled participants, presents AEs with onset after safety follow-up period after last dose of study drug	Screening All enrolled participants, presents AEs with onset before first dose of study drug
Change From Baseline in TWA0-24hrs HR in Male and Female Participants With Resistant Hypertension Administered Multiple Doses of MK-8150 and Placebo (Panel H) Day 1 (N = 7, 8)	-2.4 beats per minute Standard Error 1.3	0.0 beats per minute Standard Error 2.3	—	—	—	—	—	—	—	—	—	—	—
Change From Baseline in TWA0-24hrs HR in Male and Female Participants With Resistant Hypertension Administered Multiple Doses of MK-8150 and Placebo (Panel H) Day 10 (N = 6, 8)	-0.6 beats per minute Standard Error 1.4	-2.0 beats per minute Standard Error 1.5	—	—	—	—	—	—	—	—	—	—	—

PRIMARY outcome

Timeframe: Pre-dose and 2, 3, 4, 6, 8, 12 and 24 hours post dose

Population: All participants who met protocol entry criteria, received study drug and had data available for the measure

cSBP was measured by applanation tonometry of the radial artery, using the SphygmoCor System. The central pressure waveform was determined from the peripheral pressure waveform by a transfer function. Time-weighted average was obtained as follows: For all cSBP values obtained over the 24-hour observation period, multiply the length of time that the participant spent at each cSBP value by that cSBP value, add these products together, and then divide by duration of the observation period. The length of time spent at an identified cSBP value was defined as the time elapsed since previous post-dose measurement, or time elapsed since drug administration, if there is no previous post-dose measurement. Baseline was Day 1 pre-dose value.

Outcome measures

Outcome measures
Measure	Panel A - MK-8150 5 mg n=12 Participants MK-8150 5 mg once daily for 10 days	Panel B - MK-8150 10 mg n=6 Participants MK-8150 10 mg once daily for 10 days	Panel C - MK-8150 20 mg MK-8150 20 mg once daily for 10 days	Panel D - MK-8150 15 mg MK-8150 15 mg once daily for 10 days	Panel E - MK-8150 3/2 mg Single dose of MK-8150 3 mg on Day 1 and MK-8150 2 mg once daily on Days 6-15	Panel F - MK-8150 6/4 mg Single dose of MK-8150 6 mg on Day 1 and MK-8150 4 mg once daily on Days 6-15	Panel G - MK-8150 20/30/40/60 mg MK-8150 once daily as follows: 20 mg (Days 1-7), 30 mg (Days 8-14), 40 mg (Days 15-21), 60 mg (Days 22-28)	Panel H - MK-8150 10/20 mg MK-8150 once daily as follows: 10 mg (Days 1-2), 20 mg (Days 3-10)	Panel I - MK-8150 5/10/20/40 mg MK-8150 once daily as follows: 5 mg (Days 1-7), 10 mg (Days 8-14), 20 mg (Days 15-21), 40 mg (Days 22-28)	Panel J - MK-8150 10/20 mg MK-8150 once daily as follows: 10 mg (Days 1-7), 20 mg (Days 8-28)	Placebo (Panel A - J) Combines participants who received placebo in all panels	Post Study All enrolled participants, presents AEs with onset after safety follow-up period after last dose of study drug	Screening All enrolled participants, presents AEs with onset before first dose of study drug
Change From Baseline in TWA0-24hrs cSBP in Male Participants With Mild to Moderate Hypertension Administered Multiple Doses of MK-8150 and Placebo (Panel I) Day 1 (N = 12, 6)	-11.2 mm Hg Standard Error 1.6	-7.4 mm Hg Standard Error 2.9	—	—	—	—	—	—	—	—	—	—	—
Change From Baseline in TWA0-24hrs cSBP in Male Participants With Mild to Moderate Hypertension Administered Multiple Doses of MK-8150 and Placebo (Panel I) Day 28 (N = 10, 6)	-15.2 mm Hg Standard Error 2.3	-14.4 mm Hg Standard Error 2.6	—	—	—	—	—	—	—	—	—	—	—

PRIMARY outcome

Timeframe: Pre-dose and 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14, 16 and 24 hours post dose

Population: All participants who met protocol entry criteria, received study drug and had data available for the measure

HR was measured with a validated automatic measuring device. Time-weighted average was obtained as follows: For all HR values obtained over the 24-hour observation period, multiply the length of time that the participant spent at each HR value by that HR value, add these products together, and then divide by duration of the observation period. The length of time spent at an identified HR value was defined as the time elapsed since previous post-dose measurement, or time elapsed since drug administration, if there is no previous post-dose measurement. Baseline was Day 1 pre-dose value.

Outcome measures

Outcome measures
Measure	Panel A - MK-8150 5 mg n=12 Participants MK-8150 5 mg once daily for 10 days	Panel B - MK-8150 10 mg n=6 Participants MK-8150 10 mg once daily for 10 days	Panel C - MK-8150 20 mg MK-8150 20 mg once daily for 10 days	Panel D - MK-8150 15 mg MK-8150 15 mg once daily for 10 days	Panel E - MK-8150 3/2 mg Single dose of MK-8150 3 mg on Day 1 and MK-8150 2 mg once daily on Days 6-15	Panel F - MK-8150 6/4 mg Single dose of MK-8150 6 mg on Day 1 and MK-8150 4 mg once daily on Days 6-15	Panel G - MK-8150 20/30/40/60 mg MK-8150 once daily as follows: 20 mg (Days 1-7), 30 mg (Days 8-14), 40 mg (Days 15-21), 60 mg (Days 22-28)	Panel H - MK-8150 10/20 mg MK-8150 once daily as follows: 10 mg (Days 1-2), 20 mg (Days 3-10)	Panel I - MK-8150 5/10/20/40 mg MK-8150 once daily as follows: 5 mg (Days 1-7), 10 mg (Days 8-14), 20 mg (Days 15-21), 40 mg (Days 22-28)	Panel J - MK-8150 10/20 mg MK-8150 once daily as follows: 10 mg (Days 1-7), 20 mg (Days 8-28)	Placebo (Panel A - J) Combines participants who received placebo in all panels	Post Study All enrolled participants, presents AEs with onset after safety follow-up period after last dose of study drug	Screening All enrolled participants, presents AEs with onset before first dose of study drug
Change From Baseline in TWA0-24hrs HR in Male Participants With Mild to Moderate Hypertension Administered Multiple Doses of MK-8150 and Placebo (Panel I) Day 1 (N = 12, 6)	0.3 beats per minute Standard Error 1.9	-0.5 beats per minute Standard Error 1.4	—	—	—	—	—	—	—	—	—	—	—
Change From Baseline in TWA0-24hrs HR in Male Participants With Mild to Moderate Hypertension Administered Multiple Doses of MK-8150 and Placebo (Panel I) Day 8 (N = 12, 6)	1.2 beats per minute Standard Error 1.9	-2.8 beats per minute Standard Error 2.0	—	—	—	—	—	—	—	—	—	—	—
Change From Baseline in TWA0-24hrs HR in Male Participants With Mild to Moderate Hypertension Administered Multiple Doses of MK-8150 and Placebo (Panel I) Day 15 (N = 10, 6)	0.8 beats per minute Standard Error 2.3	-1.6 beats per minute Standard Error 1.8	—	—	—	—	—	—	—	—	—	—	—
Change From Baseline in TWA0-24hrs HR in Male Participants With Mild to Moderate Hypertension Administered Multiple Doses of MK-8150 and Placebo (Panel I) Day 22 (N = 10, 6)	0.1 beats per minute Standard Error 2.0	-2.9 beats per minute Standard Error 1.4	—	—	—	—	—	—	—	—	—	—	—
Change From Baseline in TWA0-24hrs HR in Male Participants With Mild to Moderate Hypertension Administered Multiple Doses of MK-8150 and Placebo (Panel I) Day 28 (N = 10, 6)	0.7 beats per minute Standard Error 2.7	-4.4 beats per minute Standard Error 1.3	—	—	—	—	—	—	—	—	—	—	—

PRIMARY outcome

Timeframe: Pre-dose and 2, 3, 4, 6, 8, 12 and 24 hours post dose

Population: All participants who met protocol entry criteria, received study drug and had data available for the measure

cSBP was measured by applanation tonometry of the radial artery, using the SphygmoCor System. The central pressure waveform was determined from the peripheral pressure waveform by a transfer function. Time-weighted average was obtained as follows: For all cSBP values obtained over the 24-hour observation period, multiply the length of time that the participant spent at each cSBP value by that cSBP value, add these products together, and then divide by duration of the observation period. The length of time spent at an identified cSBP value was defined as the time elapsed since previous post-dose measurement, or time elapsed since drug administration, if there is no previous post-dose measurement. Baseline was Day 1 pre-dose value.

Outcome measures

Outcome measures
Measure	Panel A - MK-8150 5 mg n=12 Participants MK-8150 5 mg once daily for 10 days	Panel B - MK-8150 10 mg n=6 Participants MK-8150 10 mg once daily for 10 days	Panel C - MK-8150 20 mg MK-8150 20 mg once daily for 10 days	Panel D - MK-8150 15 mg MK-8150 15 mg once daily for 10 days	Panel E - MK-8150 3/2 mg Single dose of MK-8150 3 mg on Day 1 and MK-8150 2 mg once daily on Days 6-15	Panel F - MK-8150 6/4 mg Single dose of MK-8150 6 mg on Day 1 and MK-8150 4 mg once daily on Days 6-15	Panel G - MK-8150 20/30/40/60 mg MK-8150 once daily as follows: 20 mg (Days 1-7), 30 mg (Days 8-14), 40 mg (Days 15-21), 60 mg (Days 22-28)	Panel H - MK-8150 10/20 mg MK-8150 once daily as follows: 10 mg (Days 1-2), 20 mg (Days 3-10)	Panel I - MK-8150 5/10/20/40 mg MK-8150 once daily as follows: 5 mg (Days 1-7), 10 mg (Days 8-14), 20 mg (Days 15-21), 40 mg (Days 22-28)	Panel J - MK-8150 10/20 mg MK-8150 once daily as follows: 10 mg (Days 1-7), 20 mg (Days 8-28)	Placebo (Panel A - J) Combines participants who received placebo in all panels	Post Study All enrolled participants, presents AEs with onset after safety follow-up period after last dose of study drug	Screening All enrolled participants, presents AEs with onset before first dose of study drug
Change From Baseline in TWA0-24hrs cSBP in Male Participants With Mild to Moderate Hypertension Administered Multiple Doses of MK-8150 and Placebo (Panel J) Day 1 (N = 12, 6)	-16.7 mm Hg Standard Error 2.4	-5.4 mm Hg Standard Error 1.6	—	—	—	—	—	—	—	—	—	—	—
Change From Baseline in TWA0-24hrs cSBP in Male Participants With Mild to Moderate Hypertension Administered Multiple Doses of MK-8150 and Placebo (Panel J) Day 28 (N = 9, 6)	-11.5 mm Hg Standard Error 2.4	-5.4 mm Hg Standard Error 2.4	—	—	—	—	—	—	—	—	—	—	—

PRIMARY outcome

Timeframe: Pre-dose and 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14, 16 and 24 hours post dose

Population: All participants who met protocol entry criteria, received study drug and had data available for the measure

HR was measured with a validated automatic measuring device. Time-weighted average was obtained as follows: For all HR values obtained over the 24-hour observation period, multiply the length of time that the participant spent at each HR value by that HR value, add these products together, and then divide by duration of the observation period. The length of time spent at an identified HR value was defined as the time elapsed since previous post-dose measurement, or time elapsed since drug administration, if there is no previous post-dose measurement. Baseline was Day 1 pre-dose value.

Outcome measures

Outcome measures
Measure	Panel A - MK-8150 5 mg n=12 Participants MK-8150 5 mg once daily for 10 days	Panel B - MK-8150 10 mg n=6 Participants MK-8150 10 mg once daily for 10 days	Panel C - MK-8150 20 mg MK-8150 20 mg once daily for 10 days	Panel D - MK-8150 15 mg MK-8150 15 mg once daily for 10 days	Panel E - MK-8150 3/2 mg Single dose of MK-8150 3 mg on Day 1 and MK-8150 2 mg once daily on Days 6-15	Panel F - MK-8150 6/4 mg Single dose of MK-8150 6 mg on Day 1 and MK-8150 4 mg once daily on Days 6-15	Panel G - MK-8150 20/30/40/60 mg MK-8150 once daily as follows: 20 mg (Days 1-7), 30 mg (Days 8-14), 40 mg (Days 15-21), 60 mg (Days 22-28)	Panel H - MK-8150 10/20 mg MK-8150 once daily as follows: 10 mg (Days 1-2), 20 mg (Days 3-10)	Panel I - MK-8150 5/10/20/40 mg MK-8150 once daily as follows: 5 mg (Days 1-7), 10 mg (Days 8-14), 20 mg (Days 15-21), 40 mg (Days 22-28)	Panel J - MK-8150 10/20 mg MK-8150 once daily as follows: 10 mg (Days 1-7), 20 mg (Days 8-28)	Placebo (Panel A - J) Combines participants who received placebo in all panels	Post Study All enrolled participants, presents AEs with onset after safety follow-up period after last dose of study drug	Screening All enrolled participants, presents AEs with onset before first dose of study drug
Change From Baseline in TWA0-24hrs HR in Male Participants With Mild to Moderate Hypertension Administered Multiple Doses of MK-8150 and Placebo (Panel J) Day 1 (N = 12, 6)	-3.0 beats per minute Standard Error 1.1	-1.6 beats per minute Standard Error 3.4	—	—	—	—	—	—	—	—	—	—	—
Change From Baseline in TWA0-24hrs HR in Male Participants With Mild to Moderate Hypertension Administered Multiple Doses of MK-8150 and Placebo (Panel J) Day 8 (N = 11, 6)	-0.6 beats per minute Standard Error 1.5	-2.8 beats per minute Standard Error 3.6	—	—	—	—	—	—	—	—	—	—	—
Change From Baseline in TWA0-24hrs HR in Male Participants With Mild to Moderate Hypertension Administered Multiple Doses of MK-8150 and Placebo (Panel J) Day 15 (N = 10, 6)	-1.2 beats per minute Standard Error 1.6	-2.6 beats per minute Standard Error 3.0	—	—	—	—	—	—	—	—	—	—	—
Change From Baseline in TWA0-24hrs HR in Male Participants With Mild to Moderate Hypertension Administered Multiple Doses of MK-8150 and Placebo (Panel J) Day 22 (N = 9, 6)	-1.0 beats per minute Standard Error 1.5	2.0 beats per minute Standard Error 4.5	—	—	—	—	—	—	—	—	—	—	—
Change From Baseline in TWA0-24hrs HR in Male Participants With Mild to Moderate Hypertension Administered Multiple Doses of MK-8150 and Placebo (Panel J) Day 28 (N = 9, 6)	-0.3 beats per minute Standard Error 1.7	-2.8 beats per minute Standard Error 3.6	—	—	—	—	—	—	—	—	—	—	—

PRIMARY outcome

Timeframe: Pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16 and 24 hours post dose

Population: All participants who met protocol entry criteria, received study drug and had data available for the measure

Serial plasma samples for determination of PK parameters were obtained from study participants. AUC0-24 of MK-8150 on Day 1 and Day 10 was determined.

Outcome measures

Outcome measures
Measure	Panel A - MK-8150 5 mg n=6 Participants MK-8150 5 mg once daily for 10 days	Panel B - MK-8150 10 mg n=6 Participants MK-8150 10 mg once daily for 10 days	Panel C - MK-8150 20 mg n=6 Participants MK-8150 20 mg once daily for 10 days	Panel D - MK-8150 15 mg n=5 Participants MK-8150 15 mg once daily for 10 days	Panel E - MK-8150 3/2 mg Single dose of MK-8150 3 mg on Day 1 and MK-8150 2 mg once daily on Days 6-15	Panel F - MK-8150 6/4 mg Single dose of MK-8150 6 mg on Day 1 and MK-8150 4 mg once daily on Days 6-15	Panel G - MK-8150 20/30/40/60 mg MK-8150 once daily as follows: 20 mg (Days 1-7), 30 mg (Days 8-14), 40 mg (Days 15-21), 60 mg (Days 22-28)	Panel H - MK-8150 10/20 mg MK-8150 once daily as follows: 10 mg (Days 1-2), 20 mg (Days 3-10)	Panel I - MK-8150 5/10/20/40 mg MK-8150 once daily as follows: 5 mg (Days 1-7), 10 mg (Days 8-14), 20 mg (Days 15-21), 40 mg (Days 22-28)	Panel J - MK-8150 10/20 mg MK-8150 once daily as follows: 10 mg (Days 1-7), 20 mg (Days 8-28)	Placebo (Panel A - J) Combines participants who received placebo in all panels	Post Study All enrolled participants, presents AEs with onset after safety follow-up period after last dose of study drug	Screening All enrolled participants, presents AEs with onset before first dose of study drug
Area Under the Plasma Concentration-time Curve From Time Zero to 24 Hours (AUC0-24) of MK-8150 in Male Participants With Mild to Moderate Hypertension Administered Multiple Doses of MK-8150 (Panel A/B/C/D) Day 1 (N = 6, 6, 6, 5)	1.84 μM*hr Geometric Coefficient of Variation 13	3.22 μM*hr Geometric Coefficient of Variation 21	6.97 μM*hr Geometric Coefficient of Variation 19	5.16 μM*hr Geometric Coefficient of Variation 18	—	—	—	—	—	—	—	—	—
Area Under the Plasma Concentration-time Curve From Time Zero to 24 Hours (AUC0-24) of MK-8150 in Male Participants With Mild to Moderate Hypertension Administered Multiple Doses of MK-8150 (Panel A/B/C/D) Day 10 (N = 5, 6, 4, 5)	6.76 μM*hr Geometric Coefficient of Variation 36	12.3 μM*hr Geometric Coefficient of Variation 30	19.2 μM*hr Geometric Coefficient of Variation 23	16.1 μM*hr Geometric Coefficient of Variation 34	—	—	—	—	—	—	—	—	—

PRIMARY outcome

Timeframe: Pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16 and 24 hours post dose, and (for Day 10 only) 48, 72 and 96 hours post dose

Population: All participants who met protocol entry criteria, received study drug and had data available for the measure

Serial plasma samples for determination of PK parameters were obtained from study participants. Cmax of MK-8150 on Day 1 and Day 10 was determined from the observed plasma concentration-time data.

Outcome measures

Outcome measures
Measure	Panel A - MK-8150 5 mg n=6 Participants MK-8150 5 mg once daily for 10 days	Panel B - MK-8150 10 mg n=6 Participants MK-8150 10 mg once daily for 10 days	Panel C - MK-8150 20 mg n=6 Participants MK-8150 20 mg once daily for 10 days	Panel D - MK-8150 15 mg n=5 Participants MK-8150 15 mg once daily for 10 days	Panel E - MK-8150 3/2 mg Single dose of MK-8150 3 mg on Day 1 and MK-8150 2 mg once daily on Days 6-15	Panel F - MK-8150 6/4 mg Single dose of MK-8150 6 mg on Day 1 and MK-8150 4 mg once daily on Days 6-15	Panel G - MK-8150 20/30/40/60 mg MK-8150 once daily as follows: 20 mg (Days 1-7), 30 mg (Days 8-14), 40 mg (Days 15-21), 60 mg (Days 22-28)	Panel H - MK-8150 10/20 mg MK-8150 once daily as follows: 10 mg (Days 1-2), 20 mg (Days 3-10)	Panel I - MK-8150 5/10/20/40 mg MK-8150 once daily as follows: 5 mg (Days 1-7), 10 mg (Days 8-14), 20 mg (Days 15-21), 40 mg (Days 22-28)	Panel J - MK-8150 10/20 mg MK-8150 once daily as follows: 10 mg (Days 1-7), 20 mg (Days 8-28)	Placebo (Panel A - J) Combines participants who received placebo in all panels	Post Study All enrolled participants, presents AEs with onset after safety follow-up period after last dose of study drug	Screening All enrolled participants, presents AEs with onset before first dose of study drug
Maximum Observed Plasma Concentration (Cmax) of MK-8150 in Male Participants With Mild to Moderate Hypertension Administered Multiple Doses of MK-8150 (Panel A/B/C/D) Day 1 (N = 6, 6, 6, 5)	0.183 μM Geometric Coefficient of Variation 7.7	0.353 μM Geometric Coefficient of Variation 18	0.656 μM Geometric Coefficient of Variation 12	0.502 μM Geometric Coefficient of Variation 32	—	—	—	—	—	—	—	—	—
Maximum Observed Plasma Concentration (Cmax) of MK-8150 in Male Participants With Mild to Moderate Hypertension Administered Multiple Doses of MK-8150 (Panel A/B/C/D) Day 10 (N = 5, 6, 4, 5)	0.440 μM Geometric Coefficient of Variation 20	0.784 μM Geometric Coefficient of Variation 26	1.25 μM Geometric Coefficient of Variation 16	1.14 μM Geometric Coefficient of Variation 35	—	—	—	—	—	—	—	—	—

PRIMARY outcome

Timeframe: Pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16 and 24 hours post dose, and (for Day 10 only) 48, 72 and 96 hours post dose

Population: All participants who met protocol entry criteria, received study drug and had data available for the measure

Serial plasma samples for determination of PK parameters were obtained from study participants. Tmax of MK-8150 on Day 1 and Day 10 was determined from the observed plasma concentration-time data.

Outcome measures

Outcome measures
Measure	Panel A - MK-8150 5 mg n=6 Participants MK-8150 5 mg once daily for 10 days	Panel B - MK-8150 10 mg n=6 Participants MK-8150 10 mg once daily for 10 days	Panel C - MK-8150 20 mg n=6 Participants MK-8150 20 mg once daily for 10 days	Panel D - MK-8150 15 mg n=5 Participants MK-8150 15 mg once daily for 10 days	Panel E - MK-8150 3/2 mg Single dose of MK-8150 3 mg on Day 1 and MK-8150 2 mg once daily on Days 6-15	Panel F - MK-8150 6/4 mg Single dose of MK-8150 6 mg on Day 1 and MK-8150 4 mg once daily on Days 6-15	Panel G - MK-8150 20/30/40/60 mg MK-8150 once daily as follows: 20 mg (Days 1-7), 30 mg (Days 8-14), 40 mg (Days 15-21), 60 mg (Days 22-28)	Panel H - MK-8150 10/20 mg MK-8150 once daily as follows: 10 mg (Days 1-2), 20 mg (Days 3-10)	Panel I - MK-8150 5/10/20/40 mg MK-8150 once daily as follows: 5 mg (Days 1-7), 10 mg (Days 8-14), 20 mg (Days 15-21), 40 mg (Days 22-28)	Panel J - MK-8150 10/20 mg MK-8150 once daily as follows: 10 mg (Days 1-7), 20 mg (Days 8-28)	Placebo (Panel A - J) Combines participants who received placebo in all panels	Post Study All enrolled participants, presents AEs with onset after safety follow-up period after last dose of study drug	Screening All enrolled participants, presents AEs with onset before first dose of study drug
Time to Maximum Observed Plasma Concentration (Tmax) of MK-8150 in Male Participants With Mild to Moderate Hypertension Administered Multiple Doses of MK-8150 (Panel A/B/C/D) Day 1 (N = 6, 6, 6, 5)	1 hr Full Range 2.6 • Interval 0.5 to 1.5	1 hr Full Range 2.4 • Interval 1.0 to 2.0	1.25 hr Full Range 2.4 • Interval 0.5 to 2.0	1 hr Full Range 2.3 • Interval 0.5 to 1.5	—	—	—	—	—	—	—	—	—
Time to Maximum Observed Plasma Concentration (Tmax) of MK-8150 in Male Participants With Mild to Moderate Hypertension Administered Multiple Doses of MK-8150 (Panel A/B/C/D) Day 10 (N = 5, 6, 4, 5)	1 hr Full Range 3.4 • Interval 0.5 to 1.5	0.75 hr Full Range 1.0 • Interval 0.5 to 2.0	1.25 hr Full Range 1.9 • Interval 0.5 to 1.5	0.5 hr Full Range 3.7 • Interval 0.5 to 1.5	—	—	—	—	—	—	—	—	—

PRIMARY outcome

Timeframe: Pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72 and 96 hours post dose

Population: All participants who met protocol entry criteria, received study drug and had data available for the measure

Serial plasma samples for determination of PK parameters were obtained from study participants. t1/2 is the time it takes for the concentration of the drug in the body to decrease by half during the elimination phase. t1/2 of MK-8150 was determined from plasma drug concentration data obtained following the last dose of study drug, administered on Day 10.

Outcome measures

Outcome measures
Measure	Panel A - MK-8150 5 mg n=5 Participants MK-8150 5 mg once daily for 10 days	Panel B - MK-8150 10 mg n=6 Participants MK-8150 10 mg once daily for 10 days	Panel C - MK-8150 20 mg n=4 Participants MK-8150 20 mg once daily for 10 days	Panel D - MK-8150 15 mg n=5 Participants MK-8150 15 mg once daily for 10 days	Panel E - MK-8150 3/2 mg Single dose of MK-8150 3 mg on Day 1 and MK-8150 2 mg once daily on Days 6-15	Panel F - MK-8150 6/4 mg Single dose of MK-8150 6 mg on Day 1 and MK-8150 4 mg once daily on Days 6-15	Panel G - MK-8150 20/30/40/60 mg MK-8150 once daily as follows: 20 mg (Days 1-7), 30 mg (Days 8-14), 40 mg (Days 15-21), 60 mg (Days 22-28)	Panel H - MK-8150 10/20 mg MK-8150 once daily as follows: 10 mg (Days 1-2), 20 mg (Days 3-10)	Panel I - MK-8150 5/10/20/40 mg MK-8150 once daily as follows: 5 mg (Days 1-7), 10 mg (Days 8-14), 20 mg (Days 15-21), 40 mg (Days 22-28)	Panel J - MK-8150 10/20 mg MK-8150 once daily as follows: 10 mg (Days 1-7), 20 mg (Days 8-28)	Placebo (Panel A - J) Combines participants who received placebo in all panels	Post Study All enrolled participants, presents AEs with onset after safety follow-up period after last dose of study drug	Screening All enrolled participants, presents AEs with onset before first dose of study drug
Apparent Terminal Half-life (t1/2) of MK-8150 Determined Following Day 10 Dose in Male Participants With Mild to Moderate Hypertension Administered Multiple Doses of MK-8150 (Panel A/B/C/D)	70.7 hr Geometric Coefficient of Variation 41	78.6 hr Geometric Coefficient of Variation 19	46.7 hr Geometric Coefficient of Variation 74	58.0 hr Geometric Coefficient of Variation 45	—	—	—	—	—	—	—	—	—

PRIMARY outcome

Timeframe: Pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16 and 24 hours post dose

Population: All participants who met protocol entry criteria, received study drug and had data available for the measure

Serial plasma samples for determination of PK parameters were obtained from study participants. AUC0-24 of MK-8150 on Day 1 was determined.

Outcome measures

Outcome measures
Measure	Panel A - MK-8150 5 mg n=6 Participants MK-8150 5 mg once daily for 10 days	Panel B - MK-8150 10 mg n=6 Participants MK-8150 10 mg once daily for 10 days	Panel C - MK-8150 20 mg MK-8150 20 mg once daily for 10 days	Panel D - MK-8150 15 mg MK-8150 15 mg once daily for 10 days	Panel E - MK-8150 3/2 mg Single dose of MK-8150 3 mg on Day 1 and MK-8150 2 mg once daily on Days 6-15	Panel F - MK-8150 6/4 mg Single dose of MK-8150 6 mg on Day 1 and MK-8150 4 mg once daily on Days 6-15	Panel G - MK-8150 20/30/40/60 mg MK-8150 once daily as follows: 20 mg (Days 1-7), 30 mg (Days 8-14), 40 mg (Days 15-21), 60 mg (Days 22-28)	Panel H - MK-8150 10/20 mg MK-8150 once daily as follows: 10 mg (Days 1-2), 20 mg (Days 3-10)	Panel I - MK-8150 5/10/20/40 mg MK-8150 once daily as follows: 5 mg (Days 1-7), 10 mg (Days 8-14), 20 mg (Days 15-21), 40 mg (Days 22-28)	Panel J - MK-8150 10/20 mg MK-8150 once daily as follows: 10 mg (Days 1-7), 20 mg (Days 8-28)	Placebo (Panel A - J) Combines participants who received placebo in all panels	Post Study All enrolled participants, presents AEs with onset after safety follow-up period after last dose of study drug	Screening All enrolled participants, presents AEs with onset before first dose of study drug
AUC0-24 of MK-8150 in Elderly Male and Female Participants With Mild to Moderate Hypertension Administered Single Doses of MK-8150 (Panel E/F, Day 1 Dose)	1.17 μM*hr Geometric Coefficient of Variation 14	2.37 μM*hr Geometric Coefficient of Variation 14	—	—	—	—	—	—	—	—	—	—	—

PRIMARY outcome

Timeframe: Pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72 and 96 hours post dose

Population: All participants who met protocol entry criteria, received study drug and had data available for the measure

Serial plasma samples for determination of PK parameters were obtained from study participants. Cmax of MK-8150 on Day 1 was determined from the observed plasma concentration-time data.

Outcome measures

Outcome measures
Measure	Panel A - MK-8150 5 mg n=6 Participants MK-8150 5 mg once daily for 10 days	Panel B - MK-8150 10 mg n=6 Participants MK-8150 10 mg once daily for 10 days	Panel C - MK-8150 20 mg MK-8150 20 mg once daily for 10 days	Panel D - MK-8150 15 mg MK-8150 15 mg once daily for 10 days	Panel E - MK-8150 3/2 mg Single dose of MK-8150 3 mg on Day 1 and MK-8150 2 mg once daily on Days 6-15	Panel F - MK-8150 6/4 mg Single dose of MK-8150 6 mg on Day 1 and MK-8150 4 mg once daily on Days 6-15	Panel G - MK-8150 20/30/40/60 mg MK-8150 once daily as follows: 20 mg (Days 1-7), 30 mg (Days 8-14), 40 mg (Days 15-21), 60 mg (Days 22-28)	Panel H - MK-8150 10/20 mg MK-8150 once daily as follows: 10 mg (Days 1-2), 20 mg (Days 3-10)	Panel I - MK-8150 5/10/20/40 mg MK-8150 once daily as follows: 5 mg (Days 1-7), 10 mg (Days 8-14), 20 mg (Days 15-21), 40 mg (Days 22-28)	Panel J - MK-8150 10/20 mg MK-8150 once daily as follows: 10 mg (Days 1-7), 20 mg (Days 8-28)	Placebo (Panel A - J) Combines participants who received placebo in all panels	Post Study All enrolled participants, presents AEs with onset after safety follow-up period after last dose of study drug	Screening All enrolled participants, presents AEs with onset before first dose of study drug
Cmax of MK-8150 in Elderly Male and Female Participants With Mild to Moderate Hypertension Administered Single Doses of MK-8150 (Panel E/F, Day 1 Dose)	0.129 μM Geometric Coefficient of Variation 25	0.268 μM Geometric Coefficient of Variation 17	—	—	—	—	—	—	—	—	—	—	—

PRIMARY outcome

Timeframe: Pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72 and 96 hours post dose

Population: All participants who met protocol entry criteria, received study drug and had data available for the measure

Serial plasma samples for determination of PK parameters were obtained from study participants. Tmax of MK-8150 on Day 1 was determined from the observed plasma concentration-time data.

Outcome measures

Outcome measures
Measure	Panel A - MK-8150 5 mg n=6 Participants MK-8150 5 mg once daily for 10 days	Panel B - MK-8150 10 mg n=6 Participants MK-8150 10 mg once daily for 10 days	Panel C - MK-8150 20 mg MK-8150 20 mg once daily for 10 days	Panel D - MK-8150 15 mg MK-8150 15 mg once daily for 10 days	Panel E - MK-8150 3/2 mg Single dose of MK-8150 3 mg on Day 1 and MK-8150 2 mg once daily on Days 6-15	Panel F - MK-8150 6/4 mg Single dose of MK-8150 6 mg on Day 1 and MK-8150 4 mg once daily on Days 6-15	Panel G - MK-8150 20/30/40/60 mg MK-8150 once daily as follows: 20 mg (Days 1-7), 30 mg (Days 8-14), 40 mg (Days 15-21), 60 mg (Days 22-28)	Panel H - MK-8150 10/20 mg MK-8150 once daily as follows: 10 mg (Days 1-2), 20 mg (Days 3-10)	Panel I - MK-8150 5/10/20/40 mg MK-8150 once daily as follows: 5 mg (Days 1-7), 10 mg (Days 8-14), 20 mg (Days 15-21), 40 mg (Days 22-28)	Panel J - MK-8150 10/20 mg MK-8150 once daily as follows: 10 mg (Days 1-7), 20 mg (Days 8-28)	Placebo (Panel A - J) Combines participants who received placebo in all panels	Post Study All enrolled participants, presents AEs with onset after safety follow-up period after last dose of study drug	Screening All enrolled participants, presents AEs with onset before first dose of study drug
Tmax of MK-8150 in Elderly Male and Female Participants With Mild to Moderate Hypertension Administered Single Doses of MK-8150 (Panel E/F, Day 1 Dose)	1 hr Full Range 2.6 • Interval 1.0 to 1.5	1 hr Full Range 2.4 • Interval 0.5 to 1.0	—	—	—	—	—	—	—	—	—	—	—

PRIMARY outcome

Timeframe: Pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72 and 96 hours post dose

Population: All participants who met protocol entry criteria, received study drug and had data available for the measure

Serial plasma samples for determination of PK parameters were obtained from study participants. t1/2 is the time it takes for the concentration of the drug in the body to decrease by half during the elimination phase. t1/2 of MK-8150 was determined from plasma drug concentration data obtained following the Day 1 dose.

Outcome measures

Outcome measures
Measure	Panel A - MK-8150 5 mg n=6 Participants MK-8150 5 mg once daily for 10 days	Panel B - MK-8150 10 mg n=6 Participants MK-8150 10 mg once daily for 10 days	Panel C - MK-8150 20 mg MK-8150 20 mg once daily for 10 days	Panel D - MK-8150 15 mg MK-8150 15 mg once daily for 10 days	Panel E - MK-8150 3/2 mg Single dose of MK-8150 3 mg on Day 1 and MK-8150 2 mg once daily on Days 6-15	Panel F - MK-8150 6/4 mg Single dose of MK-8150 6 mg on Day 1 and MK-8150 4 mg once daily on Days 6-15	Panel G - MK-8150 20/30/40/60 mg MK-8150 once daily as follows: 20 mg (Days 1-7), 30 mg (Days 8-14), 40 mg (Days 15-21), 60 mg (Days 22-28)	Panel H - MK-8150 10/20 mg MK-8150 once daily as follows: 10 mg (Days 1-2), 20 mg (Days 3-10)	Panel I - MK-8150 5/10/20/40 mg MK-8150 once daily as follows: 5 mg (Days 1-7), 10 mg (Days 8-14), 20 mg (Days 15-21), 40 mg (Days 22-28)	Panel J - MK-8150 10/20 mg MK-8150 once daily as follows: 10 mg (Days 1-7), 20 mg (Days 8-28)	Placebo (Panel A - J) Combines participants who received placebo in all panels	Post Study All enrolled participants, presents AEs with onset after safety follow-up period after last dose of study drug	Screening All enrolled participants, presents AEs with onset before first dose of study drug
t1/2 of MK-8150 in Elderly Male and Female Participants With Mild to Moderate Hypertension Administered Single Doses of MK-8150 (Panel E/F, Day 1 Dose)	85.0 hr Geometric Coefficient of Variation 35	82.1 hr Geometric Coefficient of Variation 53	—	—	—	—	—	—	—	—	—	—	—

PRIMARY outcome

Timeframe: Pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16 and 24 hours post dose

Population: All participants who met protocol entry criteria, received study drug and had data available for the measure

Serial plasma samples for determination of PK parameters were obtained from study participants. AUC0-24 of MK-8150 on Day 6 and Day 15 was determined.

Outcome measures

Outcome measures
Measure	Panel A - MK-8150 5 mg n=5 Participants MK-8150 5 mg once daily for 10 days	Panel B - MK-8150 10 mg n=6 Participants MK-8150 10 mg once daily for 10 days	Panel C - MK-8150 20 mg MK-8150 20 mg once daily for 10 days	Panel D - MK-8150 15 mg MK-8150 15 mg once daily for 10 days	Panel E - MK-8150 3/2 mg Single dose of MK-8150 3 mg on Day 1 and MK-8150 2 mg once daily on Days 6-15	Panel F - MK-8150 6/4 mg Single dose of MK-8150 6 mg on Day 1 and MK-8150 4 mg once daily on Days 6-15	Panel G - MK-8150 20/30/40/60 mg MK-8150 once daily as follows: 20 mg (Days 1-7), 30 mg (Days 8-14), 40 mg (Days 15-21), 60 mg (Days 22-28)	Panel H - MK-8150 10/20 mg MK-8150 once daily as follows: 10 mg (Days 1-2), 20 mg (Days 3-10)	Panel I - MK-8150 5/10/20/40 mg MK-8150 once daily as follows: 5 mg (Days 1-7), 10 mg (Days 8-14), 20 mg (Days 15-21), 40 mg (Days 22-28)	Panel J - MK-8150 10/20 mg MK-8150 once daily as follows: 10 mg (Days 1-7), 20 mg (Days 8-28)	Placebo (Panel A - J) Combines participants who received placebo in all panels	Post Study All enrolled participants, presents AEs with onset after safety follow-up period after last dose of study drug	Screening All enrolled participants, presents AEs with onset before first dose of study drug
AUC0-24 of MK-8150 in Elderly Male and Female Participants With Mild to Moderate Hypertension Administered Multiple Doses of MK-8150 (Panel E/F, Days 6-15) Day 6 (N = 5, 6)	1.08 μM*hr Geometric Coefficient of Variation 16	2.23 μM*hr Geometric Coefficient of Variation 16	—	—	—	—	—	—	—	—	—	—	—
AUC0-24 of MK-8150 in Elderly Male and Female Participants With Mild to Moderate Hypertension Administered Multiple Doses of MK-8150 (Panel E/F, Days 6-15) Day 15 (N = 5, 4)	2.98 μM*hr Geometric Coefficient of Variation 22	6.58 μM*hr Geometric Coefficient of Variation 26	—	—	—	—	—	—	—	—	—	—	—

PRIMARY outcome

Timeframe: Pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16 and 24 hours post dose, and (for Day 15 only) 48, 72 and 96 hours post dose

Population: All participants who met protocol entry criteria, received study drug and had data available for the measure

Serial plasma samples for determination of PK parameters were obtained from study participants. Cmax of MK-8150 on Day 6 and Day 15 was determined from the observed plasma concentration-time data.

Outcome measures

Outcome measures
Measure	Panel A - MK-8150 5 mg n=5 Participants MK-8150 5 mg once daily for 10 days	Panel B - MK-8150 10 mg n=6 Participants MK-8150 10 mg once daily for 10 days	Panel C - MK-8150 20 mg MK-8150 20 mg once daily for 10 days	Panel D - MK-8150 15 mg MK-8150 15 mg once daily for 10 days	Panel E - MK-8150 3/2 mg Single dose of MK-8150 3 mg on Day 1 and MK-8150 2 mg once daily on Days 6-15	Panel F - MK-8150 6/4 mg Single dose of MK-8150 6 mg on Day 1 and MK-8150 4 mg once daily on Days 6-15	Panel G - MK-8150 20/30/40/60 mg MK-8150 once daily as follows: 20 mg (Days 1-7), 30 mg (Days 8-14), 40 mg (Days 15-21), 60 mg (Days 22-28)	Panel H - MK-8150 10/20 mg MK-8150 once daily as follows: 10 mg (Days 1-2), 20 mg (Days 3-10)	Panel I - MK-8150 5/10/20/40 mg MK-8150 once daily as follows: 5 mg (Days 1-7), 10 mg (Days 8-14), 20 mg (Days 15-21), 40 mg (Days 22-28)	Panel J - MK-8150 10/20 mg MK-8150 once daily as follows: 10 mg (Days 1-7), 20 mg (Days 8-28)	Placebo (Panel A - J) Combines participants who received placebo in all panels	Post Study All enrolled participants, presents AEs with onset after safety follow-up period after last dose of study drug	Screening All enrolled participants, presents AEs with onset before first dose of study drug
Cmax of MK-8150 in Elderly Male and Female Participants With Mild to Moderate Hypertension Administered Multiple Doses of MK-8150 (Panel E/F, Days 6-15) Day 6 (N = 5, 6)	0.109 μM Geometric Coefficient of Variation 19	0.208 μM Geometric Coefficient of Variation 10	—	—	—	—	—	—	—	—	—	—	—
Cmax of MK-8150 in Elderly Male and Female Participants With Mild to Moderate Hypertension Administered Multiple Doses of MK-8150 (Panel E/F, Days 6-15) Day 15 (N = 5, 4)	0.192 μM Geometric Coefficient of Variation 16	0.425 μM Geometric Coefficient of Variation 25	—	—	—	—	—	—	—	—	—	—	—

PRIMARY outcome

Timeframe: Pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16 and 24 hours post dose, and (for Day 15 only) 48, 72 and 96 hours post dose

Population: All participants who met protocol entry criteria, received study drug and had data available for the measure

Serial plasma samples for determination of PK parameters were obtained from study participants. Tmax of MK-8150 on Day 6 and Day 15 was determined from the observed plasma concentration-time data.

Outcome measures

Outcome measures
Measure	Panel A - MK-8150 5 mg n=5 Participants MK-8150 5 mg once daily for 10 days	Panel B - MK-8150 10 mg n=6 Participants MK-8150 10 mg once daily for 10 days	Panel C - MK-8150 20 mg MK-8150 20 mg once daily for 10 days	Panel D - MK-8150 15 mg MK-8150 15 mg once daily for 10 days	Panel E - MK-8150 3/2 mg Single dose of MK-8150 3 mg on Day 1 and MK-8150 2 mg once daily on Days 6-15	Panel F - MK-8150 6/4 mg Single dose of MK-8150 6 mg on Day 1 and MK-8150 4 mg once daily on Days 6-15	Panel G - MK-8150 20/30/40/60 mg MK-8150 once daily as follows: 20 mg (Days 1-7), 30 mg (Days 8-14), 40 mg (Days 15-21), 60 mg (Days 22-28)	Panel H - MK-8150 10/20 mg MK-8150 once daily as follows: 10 mg (Days 1-2), 20 mg (Days 3-10)	Panel I - MK-8150 5/10/20/40 mg MK-8150 once daily as follows: 5 mg (Days 1-7), 10 mg (Days 8-14), 20 mg (Days 15-21), 40 mg (Days 22-28)	Panel J - MK-8150 10/20 mg MK-8150 once daily as follows: 10 mg (Days 1-7), 20 mg (Days 8-28)	Placebo (Panel A - J) Combines participants who received placebo in all panels	Post Study All enrolled participants, presents AEs with onset after safety follow-up period after last dose of study drug	Screening All enrolled participants, presents AEs with onset before first dose of study drug
Tmax of MK-8150 in Elderly Male and Female Participants With Mild to Moderate Hypertension Administered Multiple Doses of MK-8150 (Panel E/F, Days 6-15) Day 6 (N = 5, 6)	1 hr Full Range 2.6 • Interval 0.5 to 1.0	1 hr Full Range 2.4 • Interval 0.5 to 1.0	—	—	—	—	—	—	—	—	—	—	—
Tmax of MK-8150 in Elderly Male and Female Participants With Mild to Moderate Hypertension Administered Multiple Doses of MK-8150 (Panel E/F, Days 6-15) Day 15 (N = 5, 4)	1 hr Interval 0.5 to 1.5	1 hr Interval 1.0 to 1.5	—	—	—	—	—	—	—	—	—	—	—

PRIMARY outcome

Timeframe: Pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72 and 96 hours post dose

Population: All participants who met protocol entry criteria, received study drug and had data available for the measure

Serial plasma samples for determination of PK parameters were obtained from study participants. t1/2 is the time it takes for the concentration of the drug in the body to decrease by half during the elimination phase. t1/2 of MK-8150 was determined from plasma drug concentration data obtained following the last dose of study drug, administered on Day 15.

Outcome measures

Outcome measures
Measure	Panel A - MK-8150 5 mg n=5 Participants MK-8150 5 mg once daily for 10 days	Panel B - MK-8150 10 mg n=4 Participants MK-8150 10 mg once daily for 10 days	Panel C - MK-8150 20 mg MK-8150 20 mg once daily for 10 days	Panel D - MK-8150 15 mg MK-8150 15 mg once daily for 10 days	Panel E - MK-8150 3/2 mg Single dose of MK-8150 3 mg on Day 1 and MK-8150 2 mg once daily on Days 6-15	Panel F - MK-8150 6/4 mg Single dose of MK-8150 6 mg on Day 1 and MK-8150 4 mg once daily on Days 6-15	Panel G - MK-8150 20/30/40/60 mg MK-8150 once daily as follows: 20 mg (Days 1-7), 30 mg (Days 8-14), 40 mg (Days 15-21), 60 mg (Days 22-28)	Panel H - MK-8150 10/20 mg MK-8150 once daily as follows: 10 mg (Days 1-2), 20 mg (Days 3-10)	Panel I - MK-8150 5/10/20/40 mg MK-8150 once daily as follows: 5 mg (Days 1-7), 10 mg (Days 8-14), 20 mg (Days 15-21), 40 mg (Days 22-28)	Panel J - MK-8150 10/20 mg MK-8150 once daily as follows: 10 mg (Days 1-7), 20 mg (Days 8-28)	Placebo (Panel A - J) Combines participants who received placebo in all panels	Post Study All enrolled participants, presents AEs with onset after safety follow-up period after last dose of study drug	Screening All enrolled participants, presents AEs with onset before first dose of study drug
t1/2 of MK-8150 Determined Following Day 15 Dose in Elderly Male and Female Participants With Mild to Moderate Hypertension Administered Multiple Doses of MK-8150 (Panel E/F, Days 6-15)	68.1 hr Geometric Coefficient of Variation 36	92.6 hr Geometric Coefficient of Variation 63	—	—	—	—	—	—	—	—	—	—	—

PRIMARY outcome

Timeframe: Day 1: Pre-dose and 0.5, 1, 2, 4, 6, 8, 12 and 24 hours post dose; Day 28: Pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16 and 24 hours post dose

Population: All participants who met protocol entry criteria, received study drug and had data available for the measure

Serial plasma samples for determination of PK parameters were obtained from study participants. AUC0-24 of MK-8150 on Day 1 and Day 28 was determined.

Outcome measures

Outcome measures
Measure	Panel A - MK-8150 5 mg n=8 Participants MK-8150 5 mg once daily for 10 days	Panel B - MK-8150 10 mg MK-8150 10 mg once daily for 10 days	Panel C - MK-8150 20 mg MK-8150 20 mg once daily for 10 days	Panel D - MK-8150 15 mg MK-8150 15 mg once daily for 10 days	Panel E - MK-8150 3/2 mg Single dose of MK-8150 3 mg on Day 1 and MK-8150 2 mg once daily on Days 6-15	Panel F - MK-8150 6/4 mg Single dose of MK-8150 6 mg on Day 1 and MK-8150 4 mg once daily on Days 6-15	Panel G - MK-8150 20/30/40/60 mg MK-8150 once daily as follows: 20 mg (Days 1-7), 30 mg (Days 8-14), 40 mg (Days 15-21), 60 mg (Days 22-28)	Panel H - MK-8150 10/20 mg MK-8150 once daily as follows: 10 mg (Days 1-2), 20 mg (Days 3-10)	Panel I - MK-8150 5/10/20/40 mg MK-8150 once daily as follows: 5 mg (Days 1-7), 10 mg (Days 8-14), 20 mg (Days 15-21), 40 mg (Days 22-28)	Panel J - MK-8150 10/20 mg MK-8150 once daily as follows: 10 mg (Days 1-7), 20 mg (Days 8-28)	Placebo (Panel A - J) Combines participants who received placebo in all panels	Post Study All enrolled participants, presents AEs with onset after safety follow-up period after last dose of study drug	Screening All enrolled participants, presents AEs with onset before first dose of study drug
AUC0-24 of MK-8150 in Healthy Male Participants Administered Multiple Doses of MK-8150 (Panel G) Day 1 (N = 8)	8.08 μM*hr Geometric Coefficient of Variation 23	—	—	—	—	—	—	—	—	—	—	—	—
AUC0-24 of MK-8150 in Healthy Male Participants Administered Multiple Doses of MK-8150 (Panel G) Day 28 (N = 7)	65.5 μM*hr Geometric Coefficient of Variation 30	—	—	—	—	—	—	—	—	—	—	—	—

PRIMARY outcome

Timeframe: Day 1: Pre-dose and 0.5, 1, 2, 4, 6, 8, 12 and 24 hours post dose; Day 28: Pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72 and 96 hours post dose

Population: All participants who met protocol entry criteria, received study drug and had data available for the measure

Serial plasma samples for determination of PK parameters were obtained from study participants. Cmax of MK-8150 on Day 1 and Day 28 was determined from the observed plasma concentration-time data.

Outcome measures

Outcome measures
Measure	Panel A - MK-8150 5 mg n=8 Participants MK-8150 5 mg once daily for 10 days	Panel B - MK-8150 10 mg MK-8150 10 mg once daily for 10 days	Panel C - MK-8150 20 mg MK-8150 20 mg once daily for 10 days	Panel D - MK-8150 15 mg MK-8150 15 mg once daily for 10 days	Panel E - MK-8150 3/2 mg Single dose of MK-8150 3 mg on Day 1 and MK-8150 2 mg once daily on Days 6-15	Panel F - MK-8150 6/4 mg Single dose of MK-8150 6 mg on Day 1 and MK-8150 4 mg once daily on Days 6-15	Panel G - MK-8150 20/30/40/60 mg MK-8150 once daily as follows: 20 mg (Days 1-7), 30 mg (Days 8-14), 40 mg (Days 15-21), 60 mg (Days 22-28)	Panel H - MK-8150 10/20 mg MK-8150 once daily as follows: 10 mg (Days 1-2), 20 mg (Days 3-10)	Panel I - MK-8150 5/10/20/40 mg MK-8150 once daily as follows: 5 mg (Days 1-7), 10 mg (Days 8-14), 20 mg (Days 15-21), 40 mg (Days 22-28)	Panel J - MK-8150 10/20 mg MK-8150 once daily as follows: 10 mg (Days 1-7), 20 mg (Days 8-28)	Placebo (Panel A - J) Combines participants who received placebo in all panels	Post Study All enrolled participants, presents AEs with onset after safety follow-up period after last dose of study drug	Screening All enrolled participants, presents AEs with onset before first dose of study drug
Cmax of MK-8150 in Healthy Male Participants Administered Multiple Doses of MK-8150 (Panel G) Day 1 (N = 8)	0.664 μM Geometric Coefficient of Variation 8.5	—	—	—	—	—	—	—	—	—	—	—	—
Cmax of MK-8150 in Healthy Male Participants Administered Multiple Doses of MK-8150 (Panel G) Day 28 (N = 7)	4.05 μM Geometric Coefficient of Variation 22	—	—	—	—	—	—	—	—	—	—	—	—

PRIMARY outcome

Timeframe: Day 1: Pre-dose and 0.5, 1, 2, 4, 6, 8, 12 and 24 hours post dose; Day 28: Pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72 and 96 hours post dose

Population: All participants who met protocol entry criteria, received study drug and had data available for the measure

Serial plasma samples for determination of PK parameters were obtained from study participants. Tmax of MK-8150 on Day 1 and Day 28 was determined from the observed plasma concentration-time data.

Outcome measures

Outcome measures
Measure	Panel A - MK-8150 5 mg n=8 Participants MK-8150 5 mg once daily for 10 days	Panel B - MK-8150 10 mg MK-8150 10 mg once daily for 10 days	Panel C - MK-8150 20 mg MK-8150 20 mg once daily for 10 days	Panel D - MK-8150 15 mg MK-8150 15 mg once daily for 10 days	Panel E - MK-8150 3/2 mg Single dose of MK-8150 3 mg on Day 1 and MK-8150 2 mg once daily on Days 6-15	Panel F - MK-8150 6/4 mg Single dose of MK-8150 6 mg on Day 1 and MK-8150 4 mg once daily on Days 6-15	Panel G - MK-8150 20/30/40/60 mg MK-8150 once daily as follows: 20 mg (Days 1-7), 30 mg (Days 8-14), 40 mg (Days 15-21), 60 mg (Days 22-28)	Panel H - MK-8150 10/20 mg MK-8150 once daily as follows: 10 mg (Days 1-2), 20 mg (Days 3-10)	Panel I - MK-8150 5/10/20/40 mg MK-8150 once daily as follows: 5 mg (Days 1-7), 10 mg (Days 8-14), 20 mg (Days 15-21), 40 mg (Days 22-28)	Panel J - MK-8150 10/20 mg MK-8150 once daily as follows: 10 mg (Days 1-7), 20 mg (Days 8-28)	Placebo (Panel A - J) Combines participants who received placebo in all panels	Post Study All enrolled participants, presents AEs with onset after safety follow-up period after last dose of study drug	Screening All enrolled participants, presents AEs with onset before first dose of study drug
Tmax of MK-8150 in Healthy Male Participants Administered Multiple Doses of MK-8150 (Panel G) Day 1 (N = 8)	1.0 hr Full Range 2.6 • Interval 0.5 to 4.0	—	—	—	—	—	—	—	—	—	—	—	—
Tmax of MK-8150 in Healthy Male Participants Administered Multiple Doses of MK-8150 (Panel G) Day 28 (N = 7)	1.5 hr Interval 1.0 to 2.0	—	—	—	—	—	—	—	—	—	—	—	—

PRIMARY outcome

Timeframe: Pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72 and 96 hours post dose

Population: All participants who met protocol entry criteria, received study drug and had data available for the measure

Serial plasma samples for determination of PK parameters were obtained from study participants. t1/2 is the time it takes for the concentration of the drug in the body to decrease by half during the elimination phase. t1/2 of MK-8150 was determined from plasma drug concentration data obtained following the last dose of study drug, administered on Day 28.

Outcome measures

Outcome measures
Measure	Panel A - MK-8150 5 mg n=7 Participants MK-8150 5 mg once daily for 10 days	Panel B - MK-8150 10 mg MK-8150 10 mg once daily for 10 days	Panel C - MK-8150 20 mg MK-8150 20 mg once daily for 10 days	Panel D - MK-8150 15 mg MK-8150 15 mg once daily for 10 days	Panel E - MK-8150 3/2 mg Single dose of MK-8150 3 mg on Day 1 and MK-8150 2 mg once daily on Days 6-15	Panel F - MK-8150 6/4 mg Single dose of MK-8150 6 mg on Day 1 and MK-8150 4 mg once daily on Days 6-15	Panel G - MK-8150 20/30/40/60 mg MK-8150 once daily as follows: 20 mg (Days 1-7), 30 mg (Days 8-14), 40 mg (Days 15-21), 60 mg (Days 22-28)	Panel H - MK-8150 10/20 mg MK-8150 once daily as follows: 10 mg (Days 1-2), 20 mg (Days 3-10)	Panel I - MK-8150 5/10/20/40 mg MK-8150 once daily as follows: 5 mg (Days 1-7), 10 mg (Days 8-14), 20 mg (Days 15-21), 40 mg (Days 22-28)	Panel J - MK-8150 10/20 mg MK-8150 once daily as follows: 10 mg (Days 1-7), 20 mg (Days 8-28)	Placebo (Panel A - J) Combines participants who received placebo in all panels	Post Study All enrolled participants, presents AEs with onset after safety follow-up period after last dose of study drug	Screening All enrolled participants, presents AEs with onset before first dose of study drug
t1/2 of MK-8150 Determined Following Day 28 Dose in Healthy Male Participants Administered Multiple Doses of MK-8150 (Panel G)	51.8 hr Geometric Coefficient of Variation 48	—	—	—	—	—	—	—	—	—	—	—	—

PRIMARY outcome

Timeframe: Pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16 and 24 hours post dose

Population: All participants who met protocol entry criteria, received study drug and had data available for the measure

Serial plasma samples for determination of PK parameters were obtained from study participants. AUC0-24 of MK-8150 on Day 1 and Day 10 was determined.

Outcome measures

Outcome measures
Measure	Panel A - MK-8150 5 mg n=8 Participants MK-8150 5 mg once daily for 10 days	Panel B - MK-8150 10 mg MK-8150 10 mg once daily for 10 days	Panel C - MK-8150 20 mg MK-8150 20 mg once daily for 10 days	Panel D - MK-8150 15 mg MK-8150 15 mg once daily for 10 days	Panel E - MK-8150 3/2 mg Single dose of MK-8150 3 mg on Day 1 and MK-8150 2 mg once daily on Days 6-15	Panel F - MK-8150 6/4 mg Single dose of MK-8150 6 mg on Day 1 and MK-8150 4 mg once daily on Days 6-15	Panel G - MK-8150 20/30/40/60 mg MK-8150 once daily as follows: 20 mg (Days 1-7), 30 mg (Days 8-14), 40 mg (Days 15-21), 60 mg (Days 22-28)	Panel H - MK-8150 10/20 mg MK-8150 once daily as follows: 10 mg (Days 1-2), 20 mg (Days 3-10)	Panel I - MK-8150 5/10/20/40 mg MK-8150 once daily as follows: 5 mg (Days 1-7), 10 mg (Days 8-14), 20 mg (Days 15-21), 40 mg (Days 22-28)	Panel J - MK-8150 10/20 mg MK-8150 once daily as follows: 10 mg (Days 1-7), 20 mg (Days 8-28)	Placebo (Panel A - J) Combines participants who received placebo in all panels	Post Study All enrolled participants, presents AEs with onset after safety follow-up period after last dose of study drug	Screening All enrolled participants, presents AEs with onset before first dose of study drug
AUC0-24 of MK-8150 in Male and Female Participants With Resistant Hypertension Administered Multiple Doses of MK-8150 (Panel H) Day 1 (N = 8)	3.56 μM*hr Geometric Coefficient of Variation 20	—	—	—	—	—	—	—	—	—	—	—	—
AUC0-24 of MK-8150 in Male and Female Participants With Resistant Hypertension Administered Multiple Doses of MK-8150 (Panel H) Day 10 (N = 6)	25.1 μM*hr Geometric Coefficient of Variation 31	—	—	—	—	—	—	—	—	—	—	—	—

PRIMARY outcome

Timeframe: Pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16 and 24 hours post dose, and (for Day 10 only) 48, 72 and 96 hours post dose

Population: All participants who met protocol entry criteria, received study drug and had data available for the measure

Serial plasma samples for determination of PK parameters were obtained from study participants. Cmax of MK-8150 on Day 1 and Day 10 was determined from the observed plasma concentration-time data.

Outcome measures

Outcome measures
Measure	Panel A - MK-8150 5 mg n=8 Participants MK-8150 5 mg once daily for 10 days	Panel B - MK-8150 10 mg MK-8150 10 mg once daily for 10 days	Panel C - MK-8150 20 mg MK-8150 20 mg once daily for 10 days	Panel D - MK-8150 15 mg MK-8150 15 mg once daily for 10 days	Panel E - MK-8150 3/2 mg Single dose of MK-8150 3 mg on Day 1 and MK-8150 2 mg once daily on Days 6-15	Panel F - MK-8150 6/4 mg Single dose of MK-8150 6 mg on Day 1 and MK-8150 4 mg once daily on Days 6-15	Panel G - MK-8150 20/30/40/60 mg MK-8150 once daily as follows: 20 mg (Days 1-7), 30 mg (Days 8-14), 40 mg (Days 15-21), 60 mg (Days 22-28)	Panel H - MK-8150 10/20 mg MK-8150 once daily as follows: 10 mg (Days 1-2), 20 mg (Days 3-10)	Panel I - MK-8150 5/10/20/40 mg MK-8150 once daily as follows: 5 mg (Days 1-7), 10 mg (Days 8-14), 20 mg (Days 15-21), 40 mg (Days 22-28)	Panel J - MK-8150 10/20 mg MK-8150 once daily as follows: 10 mg (Days 1-7), 20 mg (Days 8-28)	Placebo (Panel A - J) Combines participants who received placebo in all panels	Post Study All enrolled participants, presents AEs with onset after safety follow-up period after last dose of study drug	Screening All enrolled participants, presents AEs with onset before first dose of study drug
Cmax of MK-8150 in Male and Female Participants With Resistant Hypertension Administered Multiple Doses of MK-8150 (Panel H) Day 1 (N = 8)	0.395 μM Geometric Coefficient of Variation 27	—	—	—	—	—	—	—	—	—	—	—	—
Cmax of MK-8150 in Male and Female Participants With Resistant Hypertension Administered Multiple Doses of MK-8150 (Panel H) Day 10 (N = 6)	1.71 μM Geometric Coefficient of Variation 31	—	—	—	—	—	—	—	—	—	—	—	—

PRIMARY outcome

Timeframe: Pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16 and 24 hours post dose, and (for Day 10 only) 48, 72 and 96 hours post dose

Population: All participants who met protocol entry criteria, received study drug and had data available for the measure

Serial plasma samples for determination of PK parameters were obtained from study participants. Tmax of MK-8150 on Day 1 and Day 10 was determined from the observed plasma concentration-time data.

Outcome measures

Outcome measures
Measure	Panel A - MK-8150 5 mg n=8 Participants MK-8150 5 mg once daily for 10 days	Panel B - MK-8150 10 mg MK-8150 10 mg once daily for 10 days	Panel C - MK-8150 20 mg MK-8150 20 mg once daily for 10 days	Panel D - MK-8150 15 mg MK-8150 15 mg once daily for 10 days	Panel E - MK-8150 3/2 mg Single dose of MK-8150 3 mg on Day 1 and MK-8150 2 mg once daily on Days 6-15	Panel F - MK-8150 6/4 mg Single dose of MK-8150 6 mg on Day 1 and MK-8150 4 mg once daily on Days 6-15	Panel G - MK-8150 20/30/40/60 mg MK-8150 once daily as follows: 20 mg (Days 1-7), 30 mg (Days 8-14), 40 mg (Days 15-21), 60 mg (Days 22-28)	Panel H - MK-8150 10/20 mg MK-8150 once daily as follows: 10 mg (Days 1-2), 20 mg (Days 3-10)	Panel I - MK-8150 5/10/20/40 mg MK-8150 once daily as follows: 5 mg (Days 1-7), 10 mg (Days 8-14), 20 mg (Days 15-21), 40 mg (Days 22-28)	Panel J - MK-8150 10/20 mg MK-8150 once daily as follows: 10 mg (Days 1-7), 20 mg (Days 8-28)	Placebo (Panel A - J) Combines participants who received placebo in all panels	Post Study All enrolled participants, presents AEs with onset after safety follow-up period after last dose of study drug	Screening All enrolled participants, presents AEs with onset before first dose of study drug
Tmax of MK-8150 in Male and Female Participants With Resistant Hypertension Administered Multiple Doses of MK-8150 (Panel H) Day 1 (N = 8)	1.0 hr Full Range 2.6 • Interval 0.5 to 2.0	—	—	—	—	—	—	—	—	—	—	—	—
Tmax of MK-8150 in Male and Female Participants With Resistant Hypertension Administered Multiple Doses of MK-8150 (Panel H) Day 10 (N = 6)	1.0 hr Interval 0.5 to 1.0	—	—	—	—	—	—	—	—	—	—	—	—

PRIMARY outcome

Timeframe: Pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72 and 96 hours post dose

Population: All participants who met protocol entry criteria, received study drug and had data available for the measure

Serial plasma samples for determination of PK parameters were obtained from study participants. t1/2 is the time it takes for the concentration of the drug in the body to decrease by half during the elimination phase. t1/2 of MK-8150 was determined from plasma drug concentration data obtained following the last dose of study drug, administered on Day 10.

Outcome measures

Outcome measures
Measure	Panel A - MK-8150 5 mg n=6 Participants MK-8150 5 mg once daily for 10 days	Panel B - MK-8150 10 mg MK-8150 10 mg once daily for 10 days	Panel C - MK-8150 20 mg MK-8150 20 mg once daily for 10 days	Panel D - MK-8150 15 mg MK-8150 15 mg once daily for 10 days	Panel E - MK-8150 3/2 mg Single dose of MK-8150 3 mg on Day 1 and MK-8150 2 mg once daily on Days 6-15	Panel F - MK-8150 6/4 mg Single dose of MK-8150 6 mg on Day 1 and MK-8150 4 mg once daily on Days 6-15	Panel G - MK-8150 20/30/40/60 mg MK-8150 once daily as follows: 20 mg (Days 1-7), 30 mg (Days 8-14), 40 mg (Days 15-21), 60 mg (Days 22-28)	Panel H - MK-8150 10/20 mg MK-8150 once daily as follows: 10 mg (Days 1-2), 20 mg (Days 3-10)	Panel I - MK-8150 5/10/20/40 mg MK-8150 once daily as follows: 5 mg (Days 1-7), 10 mg (Days 8-14), 20 mg (Days 15-21), 40 mg (Days 22-28)	Panel J - MK-8150 10/20 mg MK-8150 once daily as follows: 10 mg (Days 1-7), 20 mg (Days 8-28)	Placebo (Panel A - J) Combines participants who received placebo in all panels	Post Study All enrolled participants, presents AEs with onset after safety follow-up period after last dose of study drug	Screening All enrolled participants, presents AEs with onset before first dose of study drug
t1/2 of MK-8150 Determined Following Day 10 Dose in Male and Female Participants With Resistant Hypertension Administered Multiple Doses of MK-8150 (Panel H)	69.6 hr Geometric Coefficient of Variation 44	—	—	—	—	—	—	—	—	—	—	—	—

PRIMARY outcome

Timeframe: Day 1: Pre-dose and 0.5, 1, 2, 4, 6, 8, 12 and 24 hours post dose; Day 28: Pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16 and 24 hours post dose

Population: All participants who met protocol entry criteria, received study drug and completed the 28 days of treatment, and had data available for the measure

Serial plasma samples for determination of PK parameters were obtained from study participants. AUC0-24 of MK-8150 on Day 1 and Day 28 was determined.

Outcome measures

Outcome measures
Measure	Panel A - MK-8150 5 mg n=10 Participants MK-8150 5 mg once daily for 10 days	Panel B - MK-8150 10 mg n=9 Participants MK-8150 10 mg once daily for 10 days	Panel C - MK-8150 20 mg MK-8150 20 mg once daily for 10 days	Panel D - MK-8150 15 mg MK-8150 15 mg once daily for 10 days	Panel E - MK-8150 3/2 mg Single dose of MK-8150 3 mg on Day 1 and MK-8150 2 mg once daily on Days 6-15	Panel F - MK-8150 6/4 mg Single dose of MK-8150 6 mg on Day 1 and MK-8150 4 mg once daily on Days 6-15	Panel G - MK-8150 20/30/40/60 mg MK-8150 once daily as follows: 20 mg (Days 1-7), 30 mg (Days 8-14), 40 mg (Days 15-21), 60 mg (Days 22-28)	Panel H - MK-8150 10/20 mg MK-8150 once daily as follows: 10 mg (Days 1-2), 20 mg (Days 3-10)	Panel I - MK-8150 5/10/20/40 mg MK-8150 once daily as follows: 5 mg (Days 1-7), 10 mg (Days 8-14), 20 mg (Days 15-21), 40 mg (Days 22-28)	Panel J - MK-8150 10/20 mg MK-8150 once daily as follows: 10 mg (Days 1-7), 20 mg (Days 8-28)	Placebo (Panel A - J) Combines participants who received placebo in all panels	Post Study All enrolled participants, presents AEs with onset after safety follow-up period after last dose of study drug	Screening All enrolled participants, presents AEs with onset before first dose of study drug
AUC0-24 of MK-8150 in Male Participants With Mild to Moderate Hypertension Administered Multiple Doses of MK-8150 (Panel I/J, Including Only Participants Who Completed Treatment) Day 1 (N = 10, 9)	1.80 μM*hr Geometric Coefficient of Variation 19	3.80 μM*hr Geometric Coefficient of Variation 16	—	—	—	—	—	—	—	—	—	—	—
AUC0-24 of MK-8150 in Male Participants With Mild to Moderate Hypertension Administered Multiple Doses of MK-8150 (Panel I/J, Including Only Participants Who Completed Treatment) Day 28 (N = 10, 9)	39.1 μM*hr Geometric Coefficient of Variation 31	28.5 μM*hr Geometric Coefficient of Variation 40	—	—	—	—	—	—	—	—	—	—	—

PRIMARY outcome

Timeframe: Day 1: Pre-dose and 0.5, 1, 2, 4, 6, 8, 12 and 24 hours post dose; Day 28: Pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72 and 96 hours post dose

Population: All participants who met protocol entry criteria, received study drug and completed the 28 days of treatment, and had data available for the measure

Serial plasma samples for determination of PK parameters were obtained from study participants. Cmax of MK-8150 on Day 1 and Day 28 was determined from the observed plasma concentration-time data.

Outcome measures

Outcome measures
Measure	Panel A - MK-8150 5 mg n=10 Participants MK-8150 5 mg once daily for 10 days	Panel B - MK-8150 10 mg n=9 Participants MK-8150 10 mg once daily for 10 days	Panel C - MK-8150 20 mg MK-8150 20 mg once daily for 10 days	Panel D - MK-8150 15 mg MK-8150 15 mg once daily for 10 days	Panel E - MK-8150 3/2 mg Single dose of MK-8150 3 mg on Day 1 and MK-8150 2 mg once daily on Days 6-15	Panel F - MK-8150 6/4 mg Single dose of MK-8150 6 mg on Day 1 and MK-8150 4 mg once daily on Days 6-15	Panel G - MK-8150 20/30/40/60 mg MK-8150 once daily as follows: 20 mg (Days 1-7), 30 mg (Days 8-14), 40 mg (Days 15-21), 60 mg (Days 22-28)	Panel H - MK-8150 10/20 mg MK-8150 once daily as follows: 10 mg (Days 1-2), 20 mg (Days 3-10)	Panel I - MK-8150 5/10/20/40 mg MK-8150 once daily as follows: 5 mg (Days 1-7), 10 mg (Days 8-14), 20 mg (Days 15-21), 40 mg (Days 22-28)	Panel J - MK-8150 10/20 mg MK-8150 once daily as follows: 10 mg (Days 1-7), 20 mg (Days 8-28)	Placebo (Panel A - J) Combines participants who received placebo in all panels	Post Study All enrolled participants, presents AEs with onset after safety follow-up period after last dose of study drug	Screening All enrolled participants, presents AEs with onset before first dose of study drug
Cmax of MK-8150 in Male Participants With Mild to Moderate Hypertension Administered Multiple Doses of MK-8150 (Panel I/J, Including Only Participants Who Completed Treatment) Day 1 (N = 10, 9)	0.213 μM Geometric Coefficient of Variation 28	0.395 μM Geometric Coefficient of Variation 18	—	—	—	—	—	—	—	—	—	—	—
Cmax of MK-8150 in Male Participants With Mild to Moderate Hypertension Administered Multiple Doses of MK-8150 (Panel I/J, Including Only Participants Who Completed Treatment) Day 28 (N = 10, 9)	2.72 μM Geometric Coefficient of Variation 29	1.75 μM Geometric Coefficient of Variation 34	—	—	—	—	—	—	—	—	—	—	—

PRIMARY outcome

Timeframe: Day 1: Pre-dose and 0.5, 1, 2, 4, 6, 8, 12 and 24 hours post dose; Day 28: Pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72 and 96 hours post dose

Population: All participants who met protocol entry criteria, received study drug and completed the 28 days of treatment, and had data available for the measure

Serial plasma samples for determination of PK parameters were obtained from study participants. Tmax of MK-8150 on Day 1 and Day 28 was determined from the observed plasma concentration-time data.

Outcome measures

Outcome measures
Measure	Panel A - MK-8150 5 mg n=10 Participants MK-8150 5 mg once daily for 10 days	Panel B - MK-8150 10 mg n=9 Participants MK-8150 10 mg once daily for 10 days	Panel C - MK-8150 20 mg MK-8150 20 mg once daily for 10 days	Panel D - MK-8150 15 mg MK-8150 15 mg once daily for 10 days	Panel E - MK-8150 3/2 mg Single dose of MK-8150 3 mg on Day 1 and MK-8150 2 mg once daily on Days 6-15	Panel F - MK-8150 6/4 mg Single dose of MK-8150 6 mg on Day 1 and MK-8150 4 mg once daily on Days 6-15	Panel G - MK-8150 20/30/40/60 mg MK-8150 once daily as follows: 20 mg (Days 1-7), 30 mg (Days 8-14), 40 mg (Days 15-21), 60 mg (Days 22-28)	Panel H - MK-8150 10/20 mg MK-8150 once daily as follows: 10 mg (Days 1-2), 20 mg (Days 3-10)	Panel I - MK-8150 5/10/20/40 mg MK-8150 once daily as follows: 5 mg (Days 1-7), 10 mg (Days 8-14), 20 mg (Days 15-21), 40 mg (Days 22-28)	Panel J - MK-8150 10/20 mg MK-8150 once daily as follows: 10 mg (Days 1-7), 20 mg (Days 8-28)	Placebo (Panel A - J) Combines participants who received placebo in all panels	Post Study All enrolled participants, presents AEs with onset after safety follow-up period after last dose of study drug	Screening All enrolled participants, presents AEs with onset before first dose of study drug
Tmax of MK-8150 in Male Participants With Mild to Moderate Hypertension Administered Multiple Doses of MK-8150 (Panel I/J, Including Only Participants Who Completed Treatment) Day 1 (N = 10, 9)	0.75 hr Full Range 2.6 • Interval 0.5 to 2.0	1.0 hr Full Range 2.4 • Interval 0.5 to 1.0	—	—	—	—	—	—	—	—	—	—	—
Tmax of MK-8150 in Male Participants With Mild to Moderate Hypertension Administered Multiple Doses of MK-8150 (Panel I/J, Including Only Participants Who Completed Treatment) Day 28 (N = 10, 9)	0.5 hr Interval 0.5 to 1.0	1 hr Interval 0.5 to 2.0	—	—	—	—	—	—	—	—	—	—	—

PRIMARY outcome

Timeframe: Pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72 and 96 hours post dose

Population: All participants who met protocol entry criteria, received study drug and completed the 28 days of treatment, and had data available for the measure

Serial plasma samples for determination of PK parameters were obtained from study participants. t1/2 is the time it takes for the concentration of the drug in the body to decrease by half during the elimination phase. t1/2 of MK-8150 was determined from plasma drug concentration data obtained following the last dose of study drug, administered on Day 28.

Outcome measures

Outcome measures
Measure	Panel A - MK-8150 5 mg n=10 Participants MK-8150 5 mg once daily for 10 days	Panel B - MK-8150 10 mg n=9 Participants MK-8150 10 mg once daily for 10 days	Panel C - MK-8150 20 mg MK-8150 20 mg once daily for 10 days	Panel D - MK-8150 15 mg MK-8150 15 mg once daily for 10 days	Panel E - MK-8150 3/2 mg Single dose of MK-8150 3 mg on Day 1 and MK-8150 2 mg once daily on Days 6-15	Panel F - MK-8150 6/4 mg Single dose of MK-8150 6 mg on Day 1 and MK-8150 4 mg once daily on Days 6-15	Panel G - MK-8150 20/30/40/60 mg MK-8150 once daily as follows: 20 mg (Days 1-7), 30 mg (Days 8-14), 40 mg (Days 15-21), 60 mg (Days 22-28)	Panel H - MK-8150 10/20 mg MK-8150 once daily as follows: 10 mg (Days 1-2), 20 mg (Days 3-10)	Panel I - MK-8150 5/10/20/40 mg MK-8150 once daily as follows: 5 mg (Days 1-7), 10 mg (Days 8-14), 20 mg (Days 15-21), 40 mg (Days 22-28)	Panel J - MK-8150 10/20 mg MK-8150 once daily as follows: 10 mg (Days 1-7), 20 mg (Days 8-28)	Placebo (Panel A - J) Combines participants who received placebo in all panels	Post Study All enrolled participants, presents AEs with onset after safety follow-up period after last dose of study drug	Screening All enrolled participants, presents AEs with onset before first dose of study drug
t1/2 of MK-8150 Determined Following Day 28 Dose in Male Participants With Mild to Moderate Hypertension Administered Multiple Doses of MK-8150 (Panel I/J, Including Only Participants Who Completed Treatment)	73.9 hr Geometric Coefficient of Variation 37	81.0 hr Geometric Coefficient of Variation 18	—	—	—	—	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: Pre-dose and 2, 3, 4, 6, 8, 12 and 24 hours post dose

Population: All participants who met protocol entry criteria, received study drug and had data available for the measure

AIx was measured by applanation tonometry of the radial artery, using the SphygmoCor System. The central pressure waveform was determined from the peripheral pressure waveform by a transfer function. Augmentation index is the percentage of the central pulse pressure attributed to the reflected pulse wave, and is an indirect measure of systemic arterial stiffness. Time-weighted average was obtained as follows: For all AIx values obtained over the 24-hour observation period, multiply the length of time that the participant spent at each AIx value by that AIx value, add these products together, and then divide by duration of the observation period. The length of time spent at an identified AIx value was defined as the time elapsed since previous post-dose measurement, or time elapsed since drug administration, if there is no previous post-dose measurement. AIx was adjusted for HR. Baseline was Day 1 pre-dose value.

Outcome measures

Outcome measures
Measure	Panel A - MK-8150 5 mg n=6 Participants MK-8150 5 mg once daily for 10 days	Panel B - MK-8150 10 mg n=6 Participants MK-8150 10 mg once daily for 10 days	Panel C - MK-8150 20 mg n=6 Participants MK-8150 20 mg once daily for 10 days	Panel D - MK-8150 15 mg n=5 Participants MK-8150 15 mg once daily for 10 days	Panel E - MK-8150 3/2 mg n=8 Participants Single dose of MK-8150 3 mg on Day 1 and MK-8150 2 mg once daily on Days 6-15	Panel F - MK-8150 6/4 mg Single dose of MK-8150 6 mg on Day 1 and MK-8150 4 mg once daily on Days 6-15	Panel G - MK-8150 20/30/40/60 mg MK-8150 once daily as follows: 20 mg (Days 1-7), 30 mg (Days 8-14), 40 mg (Days 15-21), 60 mg (Days 22-28)	Panel H - MK-8150 10/20 mg MK-8150 once daily as follows: 10 mg (Days 1-2), 20 mg (Days 3-10)	Panel I - MK-8150 5/10/20/40 mg MK-8150 once daily as follows: 5 mg (Days 1-7), 10 mg (Days 8-14), 20 mg (Days 15-21), 40 mg (Days 22-28)	Panel J - MK-8150 10/20 mg MK-8150 once daily as follows: 10 mg (Days 1-7), 20 mg (Days 8-28)	Placebo (Panel A - J) Combines participants who received placebo in all panels	Post Study All enrolled participants, presents AEs with onset after safety follow-up period after last dose of study drug	Screening All enrolled participants, presents AEs with onset before first dose of study drug
Change From Baseline in TWA0-24hrs AIx in Male Participants With Mild to Moderate Hypertension Administered Multiple Doses of MK-8150 and Placebo (Panel A/B/C/D) Day 1 (N = 6, 6, 6, 5, 8)	-3.7 percentage of central pulse pressure Standard Error 1.7	-9.3 percentage of central pulse pressure Standard Error 0.5	-11.7 percentage of central pulse pressure Standard Error 3.3	-7.2 percentage of central pulse pressure Standard Error 1.5	-3.3 percentage of central pulse pressure Standard Error 1.0	—	—	—	—	—	—	—	—
Change From Baseline in TWA0-24hrs AIx in Male Participants With Mild to Moderate Hypertension Administered Multiple Doses of MK-8150 and Placebo (Panel A/B/C/D) Day 10 (N = 5, 6, 4, 5, 8)	-2.3 percentage of central pulse pressure Standard Error 1.4	-9.9 percentage of central pulse pressure Standard Error 2.1	-10.9 percentage of central pulse pressure Standard Error 1.7	-5.8 percentage of central pulse pressure Standard Error 1.9	-5.4 percentage of central pulse pressure Standard Error 1.4	—	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: Pre-dose and 2, 3, 4, 6, 8, 12 and 24 hours post dose

Population: All participants who met protocol entry criteria, received study drug and had data available for the measure

cDBP was measured by applanation tonometry of the radial artery, using the SphygmoCor System. The central pressure waveform was determined from the peripheral pressure waveform by a transfer function. Time-weighted average was obtained as follows: For all cDBP values obtained over the 24-hour observation period, multiply the length of time that the participant spent at each cDBP value by that cDBP value, add these products together, and then divide by duration of the observation period. The length of time spent at an identified cDBP value was defined as the time elapsed since previous post-dose measurement, or time elapsed since drug administration, if there is no previous post-dose measurement. Baseline was Day 1 pre-dose value.

Outcome measures

Outcome measures
Measure	Panel A - MK-8150 5 mg n=5 Participants MK-8150 5 mg once daily for 10 days	Panel B - MK-8150 10 mg n=6 Participants MK-8150 10 mg once daily for 10 days	Panel C - MK-8150 20 mg n=4 Participants MK-8150 20 mg once daily for 10 days	Panel D - MK-8150 15 mg n=5 Participants MK-8150 15 mg once daily for 10 days	Panel E - MK-8150 3/2 mg n=8 Participants Single dose of MK-8150 3 mg on Day 1 and MK-8150 2 mg once daily on Days 6-15	Panel F - MK-8150 6/4 mg Single dose of MK-8150 6 mg on Day 1 and MK-8150 4 mg once daily on Days 6-15	Panel G - MK-8150 20/30/40/60 mg MK-8150 once daily as follows: 20 mg (Days 1-7), 30 mg (Days 8-14), 40 mg (Days 15-21), 60 mg (Days 22-28)	Panel H - MK-8150 10/20 mg MK-8150 once daily as follows: 10 mg (Days 1-2), 20 mg (Days 3-10)	Panel I - MK-8150 5/10/20/40 mg MK-8150 once daily as follows: 5 mg (Days 1-7), 10 mg (Days 8-14), 20 mg (Days 15-21), 40 mg (Days 22-28)	Panel J - MK-8150 10/20 mg MK-8150 once daily as follows: 10 mg (Days 1-7), 20 mg (Days 8-28)	Placebo (Panel A - J) Combines participants who received placebo in all panels	Post Study All enrolled participants, presents AEs with onset after safety follow-up period after last dose of study drug	Screening All enrolled participants, presents AEs with onset before first dose of study drug
Change From Baseline in TWA0-24hrs cDBP Following Day 10 Dose in Male Participants With Mild to Moderate Hypertension Administered Multiple Doses of MK-8150 and Placebo (Panel A/B/C/D)	-3.5 mm Hg Standard Error 2.4	-8.1 mm Hg Standard Error 1.9	-9.9 mm Hg Standard Error 1.8	-7.8 mm Hg Standard Error 3.0	-5.7 mm Hg Standard Error 2.3	—	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: Pre-dose and 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14, 16 and 24 hours post dose

Population: All participants who met protocol entry criteria, received study drug and had data available for the measure

pSBP was measured with a validated automatic measuring device. Time-weighted average was obtained as follows: For all pSBP values obtained over the 24-hour observation period, multiply the length of time that the participant spent at each pSBP value by that pSBP value, add these products together, and then divide by duration of the observation period. The length of time spent at an identified pSBP value was defined as the time elapsed since previous post-dose measurement, or time elapsed since drug administration, if there is no previous post-dose measurement. Baseline was Day 1 pre-dose value.

Outcome measures

Outcome measures
Measure	Panel A - MK-8150 5 mg n=5 Participants MK-8150 5 mg once daily for 10 days	Panel B - MK-8150 10 mg n=6 Participants MK-8150 10 mg once daily for 10 days	Panel C - MK-8150 20 mg n=4 Participants MK-8150 20 mg once daily for 10 days	Panel D - MK-8150 15 mg n=5 Participants MK-8150 15 mg once daily for 10 days	Panel E - MK-8150 3/2 mg n=8 Participants Single dose of MK-8150 3 mg on Day 1 and MK-8150 2 mg once daily on Days 6-15	Panel F - MK-8150 6/4 mg Single dose of MK-8150 6 mg on Day 1 and MK-8150 4 mg once daily on Days 6-15	Panel G - MK-8150 20/30/40/60 mg MK-8150 once daily as follows: 20 mg (Days 1-7), 30 mg (Days 8-14), 40 mg (Days 15-21), 60 mg (Days 22-28)	Panel H - MK-8150 10/20 mg MK-8150 once daily as follows: 10 mg (Days 1-2), 20 mg (Days 3-10)	Panel I - MK-8150 5/10/20/40 mg MK-8150 once daily as follows: 5 mg (Days 1-7), 10 mg (Days 8-14), 20 mg (Days 15-21), 40 mg (Days 22-28)	Panel J - MK-8150 10/20 mg MK-8150 once daily as follows: 10 mg (Days 1-7), 20 mg (Days 8-28)	Placebo (Panel A - J) Combines participants who received placebo in all panels	Post Study All enrolled participants, presents AEs with onset after safety follow-up period after last dose of study drug	Screening All enrolled participants, presents AEs with onset before first dose of study drug
Change From Baseline in TWA0-24hrs pSBP Following Day 10 Dose in Male Participants With Mild to Moderate Hypertension Administered Multiple Doses of MK-8150 and Placebo (Panel A/B/C/D)	-4.5 mm Hg Standard Error 3.6	-10.6 mm Hg Standard Error 1.7	-15.3 mm Hg Standard Error 1.2	-9.0 mm Hg Standard Error 2.9	-10.0 mm Hg Standard Error 2.6	—	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: Pre-dose and 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14, 16 and 24 hours post dose

Population: All participants who met protocol entry criteria, received study drug and had data available for the measure

pDBP was measured with a validated automatic measuring device. Time-weighted average was obtained as follows: For all pDBP values obtained over the 24-hour observation period, multiply the length of time that the participant spent at each pDBP value by that pDBP value, add these products together, and then divide by duration of the observation period. The length of time spent at an identified pDBP value was defined as the time elapsed since previous post-dose measurement, or time elapsed since drug administration, if there is no previous post-dose measurement. Baseline was Day 1 pre-dose value.

Outcome measures

Outcome measures
Measure	Panel A - MK-8150 5 mg n=5 Participants MK-8150 5 mg once daily for 10 days	Panel B - MK-8150 10 mg n=6 Participants MK-8150 10 mg once daily for 10 days	Panel C - MK-8150 20 mg n=4 Participants MK-8150 20 mg once daily for 10 days	Panel D - MK-8150 15 mg n=5 Participants MK-8150 15 mg once daily for 10 days	Panel E - MK-8150 3/2 mg n=8 Participants Single dose of MK-8150 3 mg on Day 1 and MK-8150 2 mg once daily on Days 6-15	Panel F - MK-8150 6/4 mg Single dose of MK-8150 6 mg on Day 1 and MK-8150 4 mg once daily on Days 6-15	Panel G - MK-8150 20/30/40/60 mg MK-8150 once daily as follows: 20 mg (Days 1-7), 30 mg (Days 8-14), 40 mg (Days 15-21), 60 mg (Days 22-28)	Panel H - MK-8150 10/20 mg MK-8150 once daily as follows: 10 mg (Days 1-2), 20 mg (Days 3-10)	Panel I - MK-8150 5/10/20/40 mg MK-8150 once daily as follows: 5 mg (Days 1-7), 10 mg (Days 8-14), 20 mg (Days 15-21), 40 mg (Days 22-28)	Panel J - MK-8150 10/20 mg MK-8150 once daily as follows: 10 mg (Days 1-7), 20 mg (Days 8-28)	Placebo (Panel A - J) Combines participants who received placebo in all panels	Post Study All enrolled participants, presents AEs with onset after safety follow-up period after last dose of study drug	Screening All enrolled participants, presents AEs with onset before first dose of study drug
Change From Baseline in TWA0-24hrs pDBP Following Day 10 Dose in Male Participants With Mild to Moderate Hypertension Administered Multiple Doses of MK-8150 and Placebo (Panel A/B/C/D)	-2.9 mm Hg Standard Error 2.3	-8.2 mm Hg Standard Error 2.1	-13.6 mm Hg Standard Error 2.5	-8.1 mm Hg Standard Error 2.3	-5.8 mm Hg Standard Error 2.1	—	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: Pre-dose and 2, 3, 4, 6, 8, 12 and 24 hours post dose

Population: All participants who met protocol entry criteria, received study drug and had data available for the measure

AIx was measured by applanation tonometry of the radial artery, using the SphygmoCor System. The central pressure waveform was determined from the peripheral pressure waveform by a transfer function. Augmentation index is the percentage of the central pulse pressure attributed to the reflected pulse wave, and is an indirect measure of systemic arterial stiffness. Time-weighted average was obtained as follows: For all AIx values obtained over the 24-hour observation period, multiply the length of time that the participant spent at each AIx value by that AIx value, add these products together, and then divide by duration of the observation period. The length of time spent at an identified AIx value was defined as the time elapsed since previous post-dose measurement, or time elapsed since drug administration, if there is no previous post-dose measurement. AIx was adjusted for HR. Baseline for Day 1 was Day 1 pre-dose value; Baseline for Day 6-15 was Day 6 pre-dose value.

Outcome measures

Outcome measures
Measure	Panel A - MK-8150 5 mg n=6 Participants MK-8150 5 mg once daily for 10 days	Panel B - MK-8150 10 mg n=3 Participants MK-8150 10 mg once daily for 10 days	Panel C - MK-8150 20 mg MK-8150 20 mg once daily for 10 days	Panel D - MK-8150 15 mg MK-8150 15 mg once daily for 10 days	Panel E - MK-8150 3/2 mg Single dose of MK-8150 3 mg on Day 1 and MK-8150 2 mg once daily on Days 6-15	Panel F - MK-8150 6/4 mg Single dose of MK-8150 6 mg on Day 1 and MK-8150 4 mg once daily on Days 6-15	Panel G - MK-8150 20/30/40/60 mg MK-8150 once daily as follows: 20 mg (Days 1-7), 30 mg (Days 8-14), 40 mg (Days 15-21), 60 mg (Days 22-28)	Panel H - MK-8150 10/20 mg MK-8150 once daily as follows: 10 mg (Days 1-2), 20 mg (Days 3-10)	Panel I - MK-8150 5/10/20/40 mg MK-8150 once daily as follows: 5 mg (Days 1-7), 10 mg (Days 8-14), 20 mg (Days 15-21), 40 mg (Days 22-28)	Panel J - MK-8150 10/20 mg MK-8150 once daily as follows: 10 mg (Days 1-7), 20 mg (Days 8-28)	Placebo (Panel A - J) Combines participants who received placebo in all panels	Post Study All enrolled participants, presents AEs with onset after safety follow-up period after last dose of study drug	Screening All enrolled participants, presents AEs with onset before first dose of study drug
Change From Baseline in TWA0-24hrs AIx in Elderly Male and Female Participants With Mild to Moderate Hypertension Administered Single and Multiple Doses of MK-8150 and Placebo (Panel E) Day 1 (N = 6, 3)	-3.8 percentage of central pulse pressure Standard Error 2.7	-2.6 percentage of central pulse pressure Standard Error 0.9	—	—	—	—	—	—	—	—	—	—	—
Change From Baseline in TWA0-24hrs AIx in Elderly Male and Female Participants With Mild to Moderate Hypertension Administered Single and Multiple Doses of MK-8150 and Placebo (Panel E) Day 6 (N = 5, 3)	-5.2 percentage of central pulse pressure Standard Error 3.6	-1.0 percentage of central pulse pressure Standard Error 0.8	—	—	—	—	—	—	—	—	—	—	—
Change From Baseline in TWA0-24hrs AIx in Elderly Male and Female Participants With Mild to Moderate Hypertension Administered Single and Multiple Doses of MK-8150 and Placebo (Panel E) Day 15 (N = 5, 3)	-3.5 percentage of central pulse pressure Standard Error 2.6	0.3 percentage of central pulse pressure Standard Error 1.2	—	—	—	—	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: Pre-dose and 2, 3, 4, 6, 8, 12 and 24 hours post dose

Population: All participants who met protocol entry criteria, received study drug and had data available for the measure

cDBP was measured by applanation tonometry of the radial artery, using the SphygmoCor System. The central pressure waveform was determined from the peripheral pressure waveform by a transfer function. Time-weighted average was obtained as follows: For all cDBP values obtained over the 24-hour observation period, multiply the length of time that the participant spent at each cDBP value by that cDBP value, add these products together, and then divide by duration of the observation period. The length of time spent at an identified cDBP value was defined as the time elapsed since previous post-dose measurement, or time elapsed since drug administration, if there is no previous post-dose measurement. Baseline for Day 1 was Day 1 pre-dose value; Baseline for Day 6-15 was Day 6 pre-dose value.

Outcome measures

Outcome measures
Measure	Panel A - MK-8150 5 mg n=5 Participants MK-8150 5 mg once daily for 10 days	Panel B - MK-8150 10 mg n=3 Participants MK-8150 10 mg once daily for 10 days	Panel C - MK-8150 20 mg MK-8150 20 mg once daily for 10 days	Panel D - MK-8150 15 mg MK-8150 15 mg once daily for 10 days	Panel E - MK-8150 3/2 mg Single dose of MK-8150 3 mg on Day 1 and MK-8150 2 mg once daily on Days 6-15	Panel F - MK-8150 6/4 mg Single dose of MK-8150 6 mg on Day 1 and MK-8150 4 mg once daily on Days 6-15	Panel G - MK-8150 20/30/40/60 mg MK-8150 once daily as follows: 20 mg (Days 1-7), 30 mg (Days 8-14), 40 mg (Days 15-21), 60 mg (Days 22-28)	Panel H - MK-8150 10/20 mg MK-8150 once daily as follows: 10 mg (Days 1-2), 20 mg (Days 3-10)	Panel I - MK-8150 5/10/20/40 mg MK-8150 once daily as follows: 5 mg (Days 1-7), 10 mg (Days 8-14), 20 mg (Days 15-21), 40 mg (Days 22-28)	Panel J - MK-8150 10/20 mg MK-8150 once daily as follows: 10 mg (Days 1-7), 20 mg (Days 8-28)	Placebo (Panel A - J) Combines participants who received placebo in all panels	Post Study All enrolled participants, presents AEs with onset after safety follow-up period after last dose of study drug	Screening All enrolled participants, presents AEs with onset before first dose of study drug
Change From Baseline in TWA0-24hrs cDBP Following Day 15 Dose in Elderly Male and Female Participants With Mild to Moderate Hypertension Administered Single and Multiple Doses of MK-8150 and Placebo (Panel E)	-5.7 mm Hg Standard Error 1.5	-8.7 mm Hg Standard Error 2.4	—	—	—	—	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: Pre-dose and 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14, 16 and 24 hours post dose

Population: All participants who met protocol entry criteria, received study drug and had data available for the measure

pSBP was measured with a validated automatic measuring device. Time-weighted average was obtained as follows: For all pSBP values obtained over the 24-hour observation period, multiply the length of time that the participant spent at each pSBP value by that pSBP value, add these products together, and then divide by duration of the observation period. The length of time spent at an identified pSBP value was defined as the time elapsed since previous post-dose measurement, or time elapsed since drug administration, if there is no previous post-dose measurement. Baseline for Day 1 was Day 1 pre-dose value; Baseline for Day 6-15 was Day 6 pre-dose value.

Outcome measures

Outcome measures
Measure	Panel A - MK-8150 5 mg n=5 Participants MK-8150 5 mg once daily for 10 days	Panel B - MK-8150 10 mg n=3 Participants MK-8150 10 mg once daily for 10 days	Panel C - MK-8150 20 mg MK-8150 20 mg once daily for 10 days	Panel D - MK-8150 15 mg MK-8150 15 mg once daily for 10 days	Panel E - MK-8150 3/2 mg Single dose of MK-8150 3 mg on Day 1 and MK-8150 2 mg once daily on Days 6-15	Panel F - MK-8150 6/4 mg Single dose of MK-8150 6 mg on Day 1 and MK-8150 4 mg once daily on Days 6-15	Panel G - MK-8150 20/30/40/60 mg MK-8150 once daily as follows: 20 mg (Days 1-7), 30 mg (Days 8-14), 40 mg (Days 15-21), 60 mg (Days 22-28)	Panel H - MK-8150 10/20 mg MK-8150 once daily as follows: 10 mg (Days 1-2), 20 mg (Days 3-10)	Panel I - MK-8150 5/10/20/40 mg MK-8150 once daily as follows: 5 mg (Days 1-7), 10 mg (Days 8-14), 20 mg (Days 15-21), 40 mg (Days 22-28)	Panel J - MK-8150 10/20 mg MK-8150 once daily as follows: 10 mg (Days 1-7), 20 mg (Days 8-28)	Placebo (Panel A - J) Combines participants who received placebo in all panels	Post Study All enrolled participants, presents AEs with onset after safety follow-up period after last dose of study drug	Screening All enrolled participants, presents AEs with onset before first dose of study drug
Change From Baseline in TWA0-24hrs pSBP Following Day 15 Dose in Elderly Male and Female Participants With Mild to Moderate Hypertension Administered Single and Multiple Doses of MK-8150 and Placebo (Panel E)	-0.4 mm Hg Standard Error 3.5	-7.1 mm Hg Standard Error 1.3	—	—	—	—	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: Pre-dose and 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14, 16 and 24 hours post dose

Population: All participants who met protocol entry criteria, received study drug and had data available for the measure

pDBP was measured with a validated automatic measuring device. Time-weighted average was obtained as follows: For all pDBP values obtained over the 24-hour observation period, multiply the length of time that the participant spent at each pDBP value by that pDBP value, add these products together, and then divide by duration of the observation period. The length of time spent at an identified pDBP value was defined as the time elapsed since previous post-dose measurement, or time elapsed since drug administration, if there is no previous post-dose measurement. Baseline for Day 1 was Day 1 pre-dose value; Baseline for Day 6-15 was Day 6 pre-dose value.

Outcome measures

Outcome measures
Measure	Panel A - MK-8150 5 mg n=5 Participants MK-8150 5 mg once daily for 10 days	Panel B - MK-8150 10 mg n=3 Participants MK-8150 10 mg once daily for 10 days	Panel C - MK-8150 20 mg MK-8150 20 mg once daily for 10 days	Panel D - MK-8150 15 mg MK-8150 15 mg once daily for 10 days	Panel E - MK-8150 3/2 mg Single dose of MK-8150 3 mg on Day 1 and MK-8150 2 mg once daily on Days 6-15	Panel F - MK-8150 6/4 mg Single dose of MK-8150 6 mg on Day 1 and MK-8150 4 mg once daily on Days 6-15	Panel G - MK-8150 20/30/40/60 mg MK-8150 once daily as follows: 20 mg (Days 1-7), 30 mg (Days 8-14), 40 mg (Days 15-21), 60 mg (Days 22-28)	Panel H - MK-8150 10/20 mg MK-8150 once daily as follows: 10 mg (Days 1-2), 20 mg (Days 3-10)	Panel I - MK-8150 5/10/20/40 mg MK-8150 once daily as follows: 5 mg (Days 1-7), 10 mg (Days 8-14), 20 mg (Days 15-21), 40 mg (Days 22-28)	Panel J - MK-8150 10/20 mg MK-8150 once daily as follows: 10 mg (Days 1-7), 20 mg (Days 8-28)	Placebo (Panel A - J) Combines participants who received placebo in all panels	Post Study All enrolled participants, presents AEs with onset after safety follow-up period after last dose of study drug	Screening All enrolled participants, presents AEs with onset before first dose of study drug
Change From Baseline in TWA0-24hrs pDBP Following Day 15 Dose in Elderly Male and Female Participants With Mild to Moderate Hypertension Administered Single and Multiple Doses of MK-8150 and Placebo (Panel E)	-0.9 mm Hg Standard Error 1.5	-4.1 mm Hg Standard Error 1.4	—	—	—	—	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: Pre-dose and 2, 3, 4, 6, 8, 12 and 24 hours post dose

Population: All participants who met protocol entry criteria, received study drug and had data available for the measure

AIx was measured by applanation tonometry of the radial artery, using the SphygmoCor System. The central pressure waveform was determined from the peripheral pressure waveform by a transfer function. Augmentation index is the percentage of the central pulse pressure attributed to the reflected pulse wave, and is an indirect measure of systemic arterial stiffness. Time-weighted average was obtained as follows: For all AIx values obtained over the 24-hour observation period, multiply the length of time that the participant spent at each AIx value by that AIx value, add these products together, and then divide by duration of the observation period. The length of time spent at an identified AIx value was defined as the time elapsed since previous post-dose measurement, or time elapsed since drug administration, if there is no previous post-dose measurement. AIx was adjusted for HR. Baseline for Day 1 was Day 1 pre-dose value; Baseline for Day 6-15 was Day 6 pre-dose value.

Outcome measures

Outcome measures
Measure	Panel A - MK-8150 5 mg n=6 Participants MK-8150 5 mg once daily for 10 days	Panel B - MK-8150 10 mg n=3 Participants MK-8150 10 mg once daily for 10 days	Panel C - MK-8150 20 mg MK-8150 20 mg once daily for 10 days	Panel D - MK-8150 15 mg MK-8150 15 mg once daily for 10 days	Panel E - MK-8150 3/2 mg Single dose of MK-8150 3 mg on Day 1 and MK-8150 2 mg once daily on Days 6-15	Panel F - MK-8150 6/4 mg Single dose of MK-8150 6 mg on Day 1 and MK-8150 4 mg once daily on Days 6-15	Panel G - MK-8150 20/30/40/60 mg MK-8150 once daily as follows: 20 mg (Days 1-7), 30 mg (Days 8-14), 40 mg (Days 15-21), 60 mg (Days 22-28)	Panel H - MK-8150 10/20 mg MK-8150 once daily as follows: 10 mg (Days 1-2), 20 mg (Days 3-10)	Panel I - MK-8150 5/10/20/40 mg MK-8150 once daily as follows: 5 mg (Days 1-7), 10 mg (Days 8-14), 20 mg (Days 15-21), 40 mg (Days 22-28)	Panel J - MK-8150 10/20 mg MK-8150 once daily as follows: 10 mg (Days 1-7), 20 mg (Days 8-28)	Placebo (Panel A - J) Combines participants who received placebo in all panels	Post Study All enrolled participants, presents AEs with onset after safety follow-up period after last dose of study drug	Screening All enrolled participants, presents AEs with onset before first dose of study drug
Change From Baseline in TWA0-24hrs AIx in Elderly Male and Female Participants With Mild to Moderate Hypertension Administered Single and Multiple Doses of MK-8150 and Placebo (Panel F) Day 1 (N = 6, 3)	-4.8 percentage of central pulse pressure Standard Error 2.3	-2.5 percentage of central pulse pressure Standard Error 2.1	—	—	—	—	—	—	—	—	—	—	—
Change From Baseline in TWA0-24hrs AIx in Elderly Male and Female Participants With Mild to Moderate Hypertension Administered Single and Multiple Doses of MK-8150 and Placebo (Panel F) Day 6 (N = 6, 3)	-5.1 percentage of central pulse pressure Standard Error 1.5	0.5 percentage of central pulse pressure Standard Error 2.6	—	—	—	—	—	—	—	—	—	—	—
Change From Baseline in TWA0-24hrs AIx in Elderly Male and Female Participants With Mild to Moderate Hypertension Administered Single and Multiple Doses of MK-8150 and Placebo (Panel F) Day 15 (N = 4, 3)	-6.8 percentage of central pulse pressure Standard Error 2.1	0.9 percentage of central pulse pressure Standard Error 2.2	—	—	—	—	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: Pre-dose and 2, 3, 4, 6, 8, 12 and 24 hours post dose

Population: All participants who met protocol entry criteria, received study drug and had data available for the measure

cDBP was measured by applanation tonometry of the radial artery, using the SphygmoCor System. The central pressure waveform was determined from the peripheral pressure waveform by a transfer function. Time-weighted average was obtained as follows: For all cDBP values obtained over the 24-hour observation period, multiply the length of time that the participant spent at each cDBP value by that cDBP value, add these products together, and then divide by duration of the observation period. The length of time spent at an identified cDBP value was defined as the time elapsed since previous post-dose measurement, or time elapsed since drug administration, if there is no previous post-dose measurement. Baseline for Day 1 was Day 1 pre-dose value; Baseline for Day 6-15 was Day 6 pre-dose value.

Outcome measures

Outcome measures
Measure	Panel A - MK-8150 5 mg n=4 Participants MK-8150 5 mg once daily for 10 days	Panel B - MK-8150 10 mg n=3 Participants MK-8150 10 mg once daily for 10 days	Panel C - MK-8150 20 mg MK-8150 20 mg once daily for 10 days	Panel D - MK-8150 15 mg MK-8150 15 mg once daily for 10 days	Panel E - MK-8150 3/2 mg Single dose of MK-8150 3 mg on Day 1 and MK-8150 2 mg once daily on Days 6-15	Panel F - MK-8150 6/4 mg Single dose of MK-8150 6 mg on Day 1 and MK-8150 4 mg once daily on Days 6-15	Panel G - MK-8150 20/30/40/60 mg MK-8150 once daily as follows: 20 mg (Days 1-7), 30 mg (Days 8-14), 40 mg (Days 15-21), 60 mg (Days 22-28)	Panel H - MK-8150 10/20 mg MK-8150 once daily as follows: 10 mg (Days 1-2), 20 mg (Days 3-10)	Panel I - MK-8150 5/10/20/40 mg MK-8150 once daily as follows: 5 mg (Days 1-7), 10 mg (Days 8-14), 20 mg (Days 15-21), 40 mg (Days 22-28)	Panel J - MK-8150 10/20 mg MK-8150 once daily as follows: 10 mg (Days 1-7), 20 mg (Days 8-28)	Placebo (Panel A - J) Combines participants who received placebo in all panels	Post Study All enrolled participants, presents AEs with onset after safety follow-up period after last dose of study drug	Screening All enrolled participants, presents AEs with onset before first dose of study drug
Change From Baseline in TWA0-24hrs cDBP Following Day 15 Dose in Elderly Male and Female Participants With Mild to Moderate Hypertension Administered Single and Multiple Doses of MK-8150 and Placebo (Panel F)	-10.0 mm Hg Standard Error 2.0	-9.6 mm Hg Standard Error 1.6	—	—	—	—	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: Pre-dose and 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14, 16 and 24 hours post dose

Population: All participants who met protocol entry criteria, received study drug and had data available for the measure

pSBP was measured with a validated automatic measuring device. Time-weighted average was obtained as follows: For all pSBP values obtained over the 24-hour observation period, multiply the length of time that the participant spent at each pSBP value by that pSBP value, add these products together, and then divide by duration of the observation period. The length of time spent at an identified pSBP value was defined as the time elapsed since previous post-dose measurement, or time elapsed since drug administration, if there is no previous post-dose measurement. Baseline for Day 1 was Day 1 pre-dose value; Baseline for Day 6-15 was Day 6 pre-dose value.

Outcome measures

Outcome measures
Measure	Panel A - MK-8150 5 mg n=4 Participants MK-8150 5 mg once daily for 10 days	Panel B - MK-8150 10 mg n=3 Participants MK-8150 10 mg once daily for 10 days	Panel C - MK-8150 20 mg MK-8150 20 mg once daily for 10 days	Panel D - MK-8150 15 mg MK-8150 15 mg once daily for 10 days	Panel E - MK-8150 3/2 mg Single dose of MK-8150 3 mg on Day 1 and MK-8150 2 mg once daily on Days 6-15	Panel F - MK-8150 6/4 mg Single dose of MK-8150 6 mg on Day 1 and MK-8150 4 mg once daily on Days 6-15	Panel G - MK-8150 20/30/40/60 mg MK-8150 once daily as follows: 20 mg (Days 1-7), 30 mg (Days 8-14), 40 mg (Days 15-21), 60 mg (Days 22-28)	Panel H - MK-8150 10/20 mg MK-8150 once daily as follows: 10 mg (Days 1-2), 20 mg (Days 3-10)	Panel I - MK-8150 5/10/20/40 mg MK-8150 once daily as follows: 5 mg (Days 1-7), 10 mg (Days 8-14), 20 mg (Days 15-21), 40 mg (Days 22-28)	Panel J - MK-8150 10/20 mg MK-8150 once daily as follows: 10 mg (Days 1-7), 20 mg (Days 8-28)	Placebo (Panel A - J) Combines participants who received placebo in all panels	Post Study All enrolled participants, presents AEs with onset after safety follow-up period after last dose of study drug	Screening All enrolled participants, presents AEs with onset before first dose of study drug
Change From Baseline in TWA0-24hrs pSBP Following Day 15 Dose in Elderly Male and Female Participants With Mild to Moderate Hypertension Administered Single and Multiple Doses of MK-8150 and Placebo (Panel F)	-12.8 mm Hg Standard Error 2.8	-11.7 mm Hg Standard Error 3.2	—	—	—	—	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: Pre-dose and 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14, 16 and 24 hours post dose

Population: All participants who met protocol entry criteria, received study drug and had data available for the measure

pDBP was measured with a validated automatic measuring device. Time-weighted average was obtained as follows: For all pDBP values obtained over the 24-hour observation period, multiply the length of time that the participant spent at each pDBP value by that pDBP value, add these products together, and then divide by duration of the observation period. The length of time spent at an identified pDBP value was defined as the time elapsed since previous post-dose measurement, or time elapsed since drug administration, if there is no previous post-dose measurement. Baseline for Day 1 was Day 1 pre-dose value; Baseline for Day 6-15 was Day 6 pre-dose value.

Outcome measures

Outcome measures
Measure	Panel A - MK-8150 5 mg n=4 Participants MK-8150 5 mg once daily for 10 days	Panel B - MK-8150 10 mg n=3 Participants MK-8150 10 mg once daily for 10 days	Panel C - MK-8150 20 mg MK-8150 20 mg once daily for 10 days	Panel D - MK-8150 15 mg MK-8150 15 mg once daily for 10 days	Panel E - MK-8150 3/2 mg Single dose of MK-8150 3 mg on Day 1 and MK-8150 2 mg once daily on Days 6-15	Panel F - MK-8150 6/4 mg Single dose of MK-8150 6 mg on Day 1 and MK-8150 4 mg once daily on Days 6-15	Panel G - MK-8150 20/30/40/60 mg MK-8150 once daily as follows: 20 mg (Days 1-7), 30 mg (Days 8-14), 40 mg (Days 15-21), 60 mg (Days 22-28)	Panel H - MK-8150 10/20 mg MK-8150 once daily as follows: 10 mg (Days 1-2), 20 mg (Days 3-10)	Panel I - MK-8150 5/10/20/40 mg MK-8150 once daily as follows: 5 mg (Days 1-7), 10 mg (Days 8-14), 20 mg (Days 15-21), 40 mg (Days 22-28)	Panel J - MK-8150 10/20 mg MK-8150 once daily as follows: 10 mg (Days 1-7), 20 mg (Days 8-28)	Placebo (Panel A - J) Combines participants who received placebo in all panels	Post Study All enrolled participants, presents AEs with onset after safety follow-up period after last dose of study drug	Screening All enrolled participants, presents AEs with onset before first dose of study drug
Change From Baseline in TWA0-24hrs pDBP Following Day 15 Dose in Elderly Male and Female Participants With Mild to Moderate Hypertension Administered Single and Multiple Doses of MK-8150 and Placebo (Panel F)	-9.3 mm Hg Standard Error 1.7	-4.1 mm Hg Standard Error 2.9	—	—	—	—	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: Pre-dose and 2, 3, 4, 6, 8, 12 and 24 hours post dose

Population: All participants who met protocol entry criteria, received study drug and had data available for the measure

AIx was measured by applanation tonometry of the radial artery, using the SphygmoCor System. The central pressure waveform was determined from the peripheral pressure waveform by a transfer function. Augmentation index is the percentage of the central pulse pressure attributed to the reflected pulse wave, and is an indirect measure of systemic arterial stiffness. Time-weighted average was obtained as follows: For all AIx values obtained over the 24-hour observation period, multiply the length of time that the participant spent at each AIx value by that AIx value, add these products together, and then divide by duration of the observation period. The length of time spent at an identified AIx value was defined as the time elapsed since previous post-dose measurement, or time elapsed since drug administration, if there is no previous post-dose measurement. AIx was adjusted for HR. Baseline was Day 1 pre-dose value.

Outcome measures

Outcome measures
Measure	Panel A - MK-8150 5 mg n=8 Participants MK-8150 5 mg once daily for 10 days	Panel B - MK-8150 10 mg n=2 Participants MK-8150 10 mg once daily for 10 days	Panel C - MK-8150 20 mg MK-8150 20 mg once daily for 10 days	Panel D - MK-8150 15 mg MK-8150 15 mg once daily for 10 days	Panel E - MK-8150 3/2 mg Single dose of MK-8150 3 mg on Day 1 and MK-8150 2 mg once daily on Days 6-15	Panel F - MK-8150 6/4 mg Single dose of MK-8150 6 mg on Day 1 and MK-8150 4 mg once daily on Days 6-15	Panel G - MK-8150 20/30/40/60 mg MK-8150 once daily as follows: 20 mg (Days 1-7), 30 mg (Days 8-14), 40 mg (Days 15-21), 60 mg (Days 22-28)	Panel H - MK-8150 10/20 mg MK-8150 once daily as follows: 10 mg (Days 1-2), 20 mg (Days 3-10)	Panel I - MK-8150 5/10/20/40 mg MK-8150 once daily as follows: 5 mg (Days 1-7), 10 mg (Days 8-14), 20 mg (Days 15-21), 40 mg (Days 22-28)	Panel J - MK-8150 10/20 mg MK-8150 once daily as follows: 10 mg (Days 1-7), 20 mg (Days 8-28)	Placebo (Panel A - J) Combines participants who received placebo in all panels	Post Study All enrolled participants, presents AEs with onset after safety follow-up period after last dose of study drug	Screening All enrolled participants, presents AEs with onset before first dose of study drug
Change From Baseline in TWA0-24hrs AIx in Healthy Male Participants Administered Multiple Doses of MK-8150 and Placebo (Panel G) Day 1 (N = 8, 2)	-11.8 percentage of central pulse pressure Standard Error 2.1	-1.3 percentage of central pulse pressure Standard Error 3.8	—	—	—	—	—	—	—	—	—	—	—
Change From Baseline in TWA0-24hrs AIx in Healthy Male Participants Administered Multiple Doses of MK-8150 and Placebo (Panel G) Day 28 (N = 7, 2)	-14.2 percentage of central pulse pressure Standard Error 2.1	-1.4 percentage of central pulse pressure Standard Error 0.5	—	—	—	—	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: Pre-dose and 2, 3, 4, 6, 8, 12 and 24 hours post dose

Population: All participants who met protocol entry criteria, received study drug and had data available for the measure

cDBP was measured by applanation tonometry of the radial artery, using the SphygmoCor System. The central pressure waveform was determined from the peripheral pressure waveform by a transfer function. Time-weighted average was obtained as follows: For all cDBP values obtained over the 24-hour observation period, multiply the length of time that the participant spent at each cDBP value by that cDBP value, add these products together, and then divide by duration of the observation period. The length of time spent at an identified cDBP value was defined as the time elapsed since previous post-dose measurement, or time elapsed since drug administration, if there is no previous post-dose measurement. Baseline was Day 1 pre-dose value.

Outcome measures

Outcome measures
Measure	Panel A - MK-8150 5 mg n=7 Participants MK-8150 5 mg once daily for 10 days	Panel B - MK-8150 10 mg n=2 Participants MK-8150 10 mg once daily for 10 days	Panel C - MK-8150 20 mg MK-8150 20 mg once daily for 10 days	Panel D - MK-8150 15 mg MK-8150 15 mg once daily for 10 days	Panel E - MK-8150 3/2 mg Single dose of MK-8150 3 mg on Day 1 and MK-8150 2 mg once daily on Days 6-15	Panel F - MK-8150 6/4 mg Single dose of MK-8150 6 mg on Day 1 and MK-8150 4 mg once daily on Days 6-15	Panel G - MK-8150 20/30/40/60 mg MK-8150 once daily as follows: 20 mg (Days 1-7), 30 mg (Days 8-14), 40 mg (Days 15-21), 60 mg (Days 22-28)	Panel H - MK-8150 10/20 mg MK-8150 once daily as follows: 10 mg (Days 1-2), 20 mg (Days 3-10)	Panel I - MK-8150 5/10/20/40 mg MK-8150 once daily as follows: 5 mg (Days 1-7), 10 mg (Days 8-14), 20 mg (Days 15-21), 40 mg (Days 22-28)	Panel J - MK-8150 10/20 mg MK-8150 once daily as follows: 10 mg (Days 1-7), 20 mg (Days 8-28)	Placebo (Panel A - J) Combines participants who received placebo in all panels	Post Study All enrolled participants, presents AEs with onset after safety follow-up period after last dose of study drug	Screening All enrolled participants, presents AEs with onset before first dose of study drug
Change From Baseline in TWA0-24hrs cDBP Following Day 28 Dose in Healthy Male Participants Administered Multiple Doses of MK-8150 and Placebo (Panel G)	-5.3 mm Hg Standard Error 1.7	-5.6 mm Hg Standard Error 1.4	—	—	—	—	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: Pre-dose and 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14, 16 and 24 hours post dose

Population: All participants who met protocol entry criteria, received study drug and had data available for the measure

pSBP was measured with a validated automatic measuring device. Time-weighted average was obtained as follows: For all pSBP values obtained over the 24-hour observation period, multiply the length of time that the participant spent at each pSBP value by that pSBP value, add these products together, and then divide by duration of the observation period. The length of time spent at an identified pSBP value was defined as the time elapsed since previous post-dose measurement, or time elapsed since drug administration, if there is no previous post-dose measurement. Baseline was Day 1 pre-dose value.

Outcome measures

Outcome measures
Measure	Panel A - MK-8150 5 mg n=7 Participants MK-8150 5 mg once daily for 10 days	Panel B - MK-8150 10 mg n=2 Participants MK-8150 10 mg once daily for 10 days	Panel C - MK-8150 20 mg MK-8150 20 mg once daily for 10 days	Panel D - MK-8150 15 mg MK-8150 15 mg once daily for 10 days	Panel E - MK-8150 3/2 mg Single dose of MK-8150 3 mg on Day 1 and MK-8150 2 mg once daily on Days 6-15	Panel F - MK-8150 6/4 mg Single dose of MK-8150 6 mg on Day 1 and MK-8150 4 mg once daily on Days 6-15	Panel G - MK-8150 20/30/40/60 mg MK-8150 once daily as follows: 20 mg (Days 1-7), 30 mg (Days 8-14), 40 mg (Days 15-21), 60 mg (Days 22-28)	Panel H - MK-8150 10/20 mg MK-8150 once daily as follows: 10 mg (Days 1-2), 20 mg (Days 3-10)	Panel I - MK-8150 5/10/20/40 mg MK-8150 once daily as follows: 5 mg (Days 1-7), 10 mg (Days 8-14), 20 mg (Days 15-21), 40 mg (Days 22-28)	Panel J - MK-8150 10/20 mg MK-8150 once daily as follows: 10 mg (Days 1-7), 20 mg (Days 8-28)	Placebo (Panel A - J) Combines participants who received placebo in all panels	Post Study All enrolled participants, presents AEs with onset after safety follow-up period after last dose of study drug	Screening All enrolled participants, presents AEs with onset before first dose of study drug
Change From Baseline in TWA0-24hrs pSBP Following Day 28 Dose in Healthy Male Participants Administered Multiple Doses of MK-8150 and Placebo (Panel G)	-6.9 mm Hg Standard Error 2.5	-6.5 mm Hg Standard Error 2.1	—	—	—	—	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: Pre-dose and 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14, 16 and 24 hours post dose

Population: All participants who met protocol entry criteria, received study drug and had data available for the measure

pDBP was measured with a validated automatic measuring device. Time-weighted average was obtained as follows: For all pDBP values obtained over the 24-hour observation period, multiply the length of time that the participant spent at each pDBP value by that pDBP value, add these products together, and then divide by duration of the observation period. The length of time spent at an identified pDBP value was defined as the time elapsed since previous post-dose measurement, or time elapsed since drug administration, if there is no previous post-dose measurement. Baseline was Day 1 pre-dose value.

Outcome measures

Outcome measures
Measure	Panel A - MK-8150 5 mg n=7 Participants MK-8150 5 mg once daily for 10 days	Panel B - MK-8150 10 mg n=2 Participants MK-8150 10 mg once daily for 10 days	Panel C - MK-8150 20 mg MK-8150 20 mg once daily for 10 days	Panel D - MK-8150 15 mg MK-8150 15 mg once daily for 10 days	Panel E - MK-8150 3/2 mg Single dose of MK-8150 3 mg on Day 1 and MK-8150 2 mg once daily on Days 6-15	Panel F - MK-8150 6/4 mg Single dose of MK-8150 6 mg on Day 1 and MK-8150 4 mg once daily on Days 6-15	Panel G - MK-8150 20/30/40/60 mg MK-8150 once daily as follows: 20 mg (Days 1-7), 30 mg (Days 8-14), 40 mg (Days 15-21), 60 mg (Days 22-28)	Panel H - MK-8150 10/20 mg MK-8150 once daily as follows: 10 mg (Days 1-2), 20 mg (Days 3-10)	Panel I - MK-8150 5/10/20/40 mg MK-8150 once daily as follows: 5 mg (Days 1-7), 10 mg (Days 8-14), 20 mg (Days 15-21), 40 mg (Days 22-28)	Panel J - MK-8150 10/20 mg MK-8150 once daily as follows: 10 mg (Days 1-7), 20 mg (Days 8-28)	Placebo (Panel A - J) Combines participants who received placebo in all panels	Post Study All enrolled participants, presents AEs with onset after safety follow-up period after last dose of study drug	Screening All enrolled participants, presents AEs with onset before first dose of study drug
Change From Baseline in TWA0-24hrs pDBP Following Day 28 Dose in Healthy Male Participants Administered Multiple Doses of MK-8150 and Placebo (Panel G)	-6.5 mm Hg Standard Error 1.6	-6.1 mm Hg Standard Error 1.1	—	—	—	—	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: Pre-dose and 2, 3, 4, 6, 8, 12 and 24 hours post dose

Population: All participants who met protocol entry criteria, received study drug and had data available for the measure

AIx was measured by applanation tonometry of the radial artery, using the SphygmoCor System. The central pressure waveform was determined from the peripheral pressure waveform by a transfer function. Augmentation index is the percentage of the central pulse pressure attributed to the reflected pulse wave, and is an indirect measure of systemic arterial stiffness. Time-weighted average was obtained as follows: For all AIx values obtained over the 24-hour observation period, multiply the length of time that the participant spent at each AIx value by that AIx value, add these products together, and then divide by duration of the observation period. The length of time spent at an identified AIx value was defined as the time elapsed since previous post-dose measurement, or time elapsed since drug administration, if there is no previous post-dose measurement. AIx was adjusted for HR. Baseline was Day 1 pre-dose value (determined separately in each period).

Outcome measures

Outcome measures
Measure	Panel A - MK-8150 5 mg n=7 Participants MK-8150 5 mg once daily for 10 days	Panel B - MK-8150 10 mg n=8 Participants MK-8150 10 mg once daily for 10 days	Panel C - MK-8150 20 mg MK-8150 20 mg once daily for 10 days	Panel D - MK-8150 15 mg MK-8150 15 mg once daily for 10 days	Panel E - MK-8150 3/2 mg Single dose of MK-8150 3 mg on Day 1 and MK-8150 2 mg once daily on Days 6-15	Panel F - MK-8150 6/4 mg Single dose of MK-8150 6 mg on Day 1 and MK-8150 4 mg once daily on Days 6-15	Panel G - MK-8150 20/30/40/60 mg MK-8150 once daily as follows: 20 mg (Days 1-7), 30 mg (Days 8-14), 40 mg (Days 15-21), 60 mg (Days 22-28)	Panel H - MK-8150 10/20 mg MK-8150 once daily as follows: 10 mg (Days 1-2), 20 mg (Days 3-10)	Panel I - MK-8150 5/10/20/40 mg MK-8150 once daily as follows: 5 mg (Days 1-7), 10 mg (Days 8-14), 20 mg (Days 15-21), 40 mg (Days 22-28)	Panel J - MK-8150 10/20 mg MK-8150 once daily as follows: 10 mg (Days 1-7), 20 mg (Days 8-28)	Placebo (Panel A - J) Combines participants who received placebo in all panels	Post Study All enrolled participants, presents AEs with onset after safety follow-up period after last dose of study drug	Screening All enrolled participants, presents AEs with onset before first dose of study drug
Change From Baseline in TWA0-24hrs AIx in Male and Female Participants With Resistant Hypertension Administered Multiple Doses of MK-8150 and Placebo (Panel H) Day 1 (N = 7, 8)	-3.9 percentage of central pulse pressure Standard Error 0.9	0.4 percentage of central pulse pressure Standard Error 0.9	—	—	—	—	—	—	—	—	—	—	—
Change From Baseline in TWA0-24hrs AIx in Male and Female Participants With Resistant Hypertension Administered Multiple Doses of MK-8150 and Placebo (Panel H) Day 10 (N = 6, 8)	-5.8 percentage of central pulse pressure Standard Error 1.3	2.4 percentage of central pulse pressure Standard Error 1.1	—	—	—	—	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: Pre-dose and 2, 3, 4, 6, 8, 12 and 24 hours post dose

Population: All participants who met protocol entry criteria, received study drug and had data available for the measure

cDBP was measured by applanation tonometry of the radial artery, using the SphygmoCor System. The central pressure waveform was determined from the peripheral pressure waveform by a transfer function. Time-weighted average was obtained as follows: For all cDBP values obtained over the 24-hour observation period, multiply the length of time that the participant spent at each cDBP value by that cDBP value, add these products together, and then divide by duration of the observation period. The length of time spent at an identified cDBP value was defined as the time elapsed since previous post-dose measurement, or time elapsed since drug administration, if there is no previous post-dose measurement. Baseline was Day 1 pre-dose value (determined separately in each period).

Outcome measures

Outcome measures
Measure	Panel A - MK-8150 5 mg n=6 Participants MK-8150 5 mg once daily for 10 days	Panel B - MK-8150 10 mg n=8 Participants MK-8150 10 mg once daily for 10 days	Panel C - MK-8150 20 mg MK-8150 20 mg once daily for 10 days	Panel D - MK-8150 15 mg MK-8150 15 mg once daily for 10 days	Panel E - MK-8150 3/2 mg Single dose of MK-8150 3 mg on Day 1 and MK-8150 2 mg once daily on Days 6-15	Panel F - MK-8150 6/4 mg Single dose of MK-8150 6 mg on Day 1 and MK-8150 4 mg once daily on Days 6-15	Panel G - MK-8150 20/30/40/60 mg MK-8150 once daily as follows: 20 mg (Days 1-7), 30 mg (Days 8-14), 40 mg (Days 15-21), 60 mg (Days 22-28)	Panel H - MK-8150 10/20 mg MK-8150 once daily as follows: 10 mg (Days 1-2), 20 mg (Days 3-10)	Panel I - MK-8150 5/10/20/40 mg MK-8150 once daily as follows: 5 mg (Days 1-7), 10 mg (Days 8-14), 20 mg (Days 15-21), 40 mg (Days 22-28)	Panel J - MK-8150 10/20 mg MK-8150 once daily as follows: 10 mg (Days 1-7), 20 mg (Days 8-28)	Placebo (Panel A - J) Combines participants who received placebo in all panels	Post Study All enrolled participants, presents AEs with onset after safety follow-up period after last dose of study drug	Screening All enrolled participants, presents AEs with onset before first dose of study drug
Change From Baseline in TWA0-24hrs cDBP Following Day 10 Dose in Male and Female Participants With Resistant Hypertension Administered Multiple Doses of MK-8150 and Placebo (Panel H)	-4.6 mm Hg Standard Error 1.8	-1.8 mm Hg Standard Error 1.3	—	—	—	—	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: Pre-dose and 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14, 16 and 24 hours post dose

Population: All participants who met protocol entry criteria, received study drug and had data available for the measure

pSBP was measured with a validated automatic measuring device. Time-weighted average was obtained as follows: For all pSBP values obtained over the 24-hour observation period, multiply the length of time that the participant spent at each pSBP value by that pSBP value, add these products together, and then divide by duration of the observation period. The length of time spent at an identified pSBP value was defined as the time elapsed since previous post-dose measurement, or time elapsed since drug administration, if there is no previous post-dose measurement. Baseline was Day 1 pre-dose value (determined separately in each period).

Outcome measures

Outcome measures
Measure	Panel A - MK-8150 5 mg n=6 Participants MK-8150 5 mg once daily for 10 days	Panel B - MK-8150 10 mg n=8 Participants MK-8150 10 mg once daily for 10 days	Panel C - MK-8150 20 mg MK-8150 20 mg once daily for 10 days	Panel D - MK-8150 15 mg MK-8150 15 mg once daily for 10 days	Panel E - MK-8150 3/2 mg Single dose of MK-8150 3 mg on Day 1 and MK-8150 2 mg once daily on Days 6-15	Panel F - MK-8150 6/4 mg Single dose of MK-8150 6 mg on Day 1 and MK-8150 4 mg once daily on Days 6-15	Panel G - MK-8150 20/30/40/60 mg MK-8150 once daily as follows: 20 mg (Days 1-7), 30 mg (Days 8-14), 40 mg (Days 15-21), 60 mg (Days 22-28)	Panel H - MK-8150 10/20 mg MK-8150 once daily as follows: 10 mg (Days 1-2), 20 mg (Days 3-10)	Panel I - MK-8150 5/10/20/40 mg MK-8150 once daily as follows: 5 mg (Days 1-7), 10 mg (Days 8-14), 20 mg (Days 15-21), 40 mg (Days 22-28)	Panel J - MK-8150 10/20 mg MK-8150 once daily as follows: 10 mg (Days 1-7), 20 mg (Days 8-28)	Placebo (Panel A - J) Combines participants who received placebo in all panels	Post Study All enrolled participants, presents AEs with onset after safety follow-up period after last dose of study drug	Screening All enrolled participants, presents AEs with onset before first dose of study drug
Change From Baseline in TWA0-24hrs pSBP Following Day 10 Dose in Male and Female Participants With Resistant Hypertension Administered Multiple Doses of MK-8150 and Placebo (Panel H)	-15.0 mm Hg Standard Error 3.5	-12.6 mm Hg Standard Error 1.8	—	—	—	—	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: Pre-dose and 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14, 16 and 24 hours post dose

Population: All participants who met protocol entry criteria, received study drug and had data available for the measure

pDBP was measured with a validated automatic measuring device. Time-weighted average was obtained as follows: For all pDBP values obtained over the 24-hour observation period, multiply the length of time that the participant spent at each pDBP value by that pDBP value, add these products together, and then divide by duration of the observation period. The length of time spent at an identified pDBP value was defined as the time elapsed since previous post-dose measurement, or time elapsed since drug administration, if there is no previous post-dose measurement. Baseline was Day 1 pre-dose value (determined separately in each period).

Outcome measures

Outcome measures
Measure	Panel A - MK-8150 5 mg n=6 Participants MK-8150 5 mg once daily for 10 days	Panel B - MK-8150 10 mg n=8 Participants MK-8150 10 mg once daily for 10 days	Panel C - MK-8150 20 mg MK-8150 20 mg once daily for 10 days	Panel D - MK-8150 15 mg MK-8150 15 mg once daily for 10 days	Panel E - MK-8150 3/2 mg Single dose of MK-8150 3 mg on Day 1 and MK-8150 2 mg once daily on Days 6-15	Panel F - MK-8150 6/4 mg Single dose of MK-8150 6 mg on Day 1 and MK-8150 4 mg once daily on Days 6-15	Panel G - MK-8150 20/30/40/60 mg MK-8150 once daily as follows: 20 mg (Days 1-7), 30 mg (Days 8-14), 40 mg (Days 15-21), 60 mg (Days 22-28)	Panel H - MK-8150 10/20 mg MK-8150 once daily as follows: 10 mg (Days 1-2), 20 mg (Days 3-10)	Panel I - MK-8150 5/10/20/40 mg MK-8150 once daily as follows: 5 mg (Days 1-7), 10 mg (Days 8-14), 20 mg (Days 15-21), 40 mg (Days 22-28)	Panel J - MK-8150 10/20 mg MK-8150 once daily as follows: 10 mg (Days 1-7), 20 mg (Days 8-28)	Placebo (Panel A - J) Combines participants who received placebo in all panels	Post Study All enrolled participants, presents AEs with onset after safety follow-up period after last dose of study drug	Screening All enrolled participants, presents AEs with onset before first dose of study drug
Change From Baseline in TWA0-24hrs pDBP Following Day 10 Dose in Male and Female Participants With Resistant Hypertension Administered Multiple Doses of MK-8150 and Placebo (Panel H)	-8.9 mm Hg Standard Error 1.8	-6.3 mm Hg Standard Error 1.5	—	—	—	—	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: Pre-dose and 2, 3, 4, 6, 8, 12 and 24 hours post dose

Population: All participants who met protocol entry criteria, received study drug and had data available for the measure

AIx was measured by applanation tonometry of the radial artery, using the SphygmoCor System. The central pressure waveform was determined from the peripheral pressure waveform by a transfer function. Augmentation index is the percentage of the central pulse pressure attributed to the reflected pulse wave, and is an indirect measure of systemic arterial stiffness. Time-weighted average was obtained as follows: For all AIx values obtained over the 24-hour observation period, multiply the length of time that the participant spent at each AIx value by that AIx value, add these products together, and then divide by duration of the observation period. The length of time spent at an identified AIx value was defined as the time elapsed since previous post-dose measurement, or time elapsed since drug administration, if there is no previous post-dose measurement. AIx was adjusted for HR. Baseline was Day 1 pre-dose value.

Outcome measures

Outcome measures
Measure	Panel A - MK-8150 5 mg n=12 Participants MK-8150 5 mg once daily for 10 days	Panel B - MK-8150 10 mg n=6 Participants MK-8150 10 mg once daily for 10 days	Panel C - MK-8150 20 mg MK-8150 20 mg once daily for 10 days	Panel D - MK-8150 15 mg MK-8150 15 mg once daily for 10 days	Panel E - MK-8150 3/2 mg Single dose of MK-8150 3 mg on Day 1 and MK-8150 2 mg once daily on Days 6-15	Panel F - MK-8150 6/4 mg Single dose of MK-8150 6 mg on Day 1 and MK-8150 4 mg once daily on Days 6-15	Panel G - MK-8150 20/30/40/60 mg MK-8150 once daily as follows: 20 mg (Days 1-7), 30 mg (Days 8-14), 40 mg (Days 15-21), 60 mg (Days 22-28)	Panel H - MK-8150 10/20 mg MK-8150 once daily as follows: 10 mg (Days 1-2), 20 mg (Days 3-10)	Panel I - MK-8150 5/10/20/40 mg MK-8150 once daily as follows: 5 mg (Days 1-7), 10 mg (Days 8-14), 20 mg (Days 15-21), 40 mg (Days 22-28)	Panel J - MK-8150 10/20 mg MK-8150 once daily as follows: 10 mg (Days 1-7), 20 mg (Days 8-28)	Placebo (Panel A - J) Combines participants who received placebo in all panels	Post Study All enrolled participants, presents AEs with onset after safety follow-up period after last dose of study drug	Screening All enrolled participants, presents AEs with onset before first dose of study drug
Change From Baseline in TWA0-24hrs AIx in Male Participants With Mild to Moderate Hypertension Administered Multiple Doses of MK-8150 and Placebo (Panel I) Day 1 (N = 12, 6)	-4.9 percentage of pulse pressure Standard Error 1.0	-4.5 percentage of pulse pressure Standard Error 1.2	—	—	—	—	—	—	—	—	—	—	—
Change From Baseline in TWA0-24hrs AIx in Male Participants With Mild to Moderate Hypertension Administered Multiple Doses of MK-8150 and Placebo (Panel I) Day 28 (N = 10, 6)	-10.6 percentage of pulse pressure Standard Error 1.9	-4.8 percentage of pulse pressure Standard Error 2.1	—	—	—	—	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: Pre-dose and 2, 3, 4, 6, 8, 12 and 24 hours post dose

Population: All participants who met protocol entry criteria, received study drug and had data available for the measure

cDBP was measured by applanation tonometry of the radial artery, using the SphygmoCor System. The central pressure waveform was determined from the peripheral pressure waveform by a transfer function. Time-weighted average was obtained as follows: For all cDBP values obtained over the 24-hour observation period, multiply the length of time that the participant spent at each cDBP value by that cDBP value, add these products together, and then divide by duration of the observation period. The length of time spent at an identified cDBP value was defined as the time elapsed since previous post-dose measurement, or time elapsed since drug administration, if there is no previous post-dose measurement. Baseline was Day 1 pre-dose value.

Outcome measures

Outcome measures
Measure	Panel A - MK-8150 5 mg n=10 Participants MK-8150 5 mg once daily for 10 days	Panel B - MK-8150 10 mg n=6 Participants MK-8150 10 mg once daily for 10 days	Panel C - MK-8150 20 mg MK-8150 20 mg once daily for 10 days	Panel D - MK-8150 15 mg MK-8150 15 mg once daily for 10 days	Panel E - MK-8150 3/2 mg Single dose of MK-8150 3 mg on Day 1 and MK-8150 2 mg once daily on Days 6-15	Panel F - MK-8150 6/4 mg Single dose of MK-8150 6 mg on Day 1 and MK-8150 4 mg once daily on Days 6-15	Panel G - MK-8150 20/30/40/60 mg MK-8150 once daily as follows: 20 mg (Days 1-7), 30 mg (Days 8-14), 40 mg (Days 15-21), 60 mg (Days 22-28)	Panel H - MK-8150 10/20 mg MK-8150 once daily as follows: 10 mg (Days 1-2), 20 mg (Days 3-10)	Panel I - MK-8150 5/10/20/40 mg MK-8150 once daily as follows: 5 mg (Days 1-7), 10 mg (Days 8-14), 20 mg (Days 15-21), 40 mg (Days 22-28)	Panel J - MK-8150 10/20 mg MK-8150 once daily as follows: 10 mg (Days 1-7), 20 mg (Days 8-28)	Placebo (Panel A - J) Combines participants who received placebo in all panels	Post Study All enrolled participants, presents AEs with onset after safety follow-up period after last dose of study drug	Screening All enrolled participants, presents AEs with onset before first dose of study drug
Change From Baseline in TWA0-24hrs cDBP Following Day 28 Dose in Male Participants With Mild to Moderate Hypertension Administered Multiple Doses of MK-8150 and Placebo (Panel I)	-7.7 mm Hg Standard Error 1.4	-7.2 mm Hg Standard Error 3.4	—	—	—	—	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: Pre-dose and 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14, 16 and 24 hours post dose

Population: All participants who met protocol entry criteria, received study drug and had data available for the measure

pSBP was measured with a validated automatic measuring device. Time-weighted average was obtained as follows: For all pSBP values obtained over the 24-hour observation period, multiply the length of time that the participant spent at each pSBP value by that pSBP value, add these products together, and then divide by duration of the observation period. The length of time spent at an identified pSBP value was defined as the time elapsed since previous post-dose measurement, or time elapsed since drug administration, if there is no previous post-dose measurement. Baseline was Day 1 pre-dose value.

Outcome measures

Outcome measures
Measure	Panel A - MK-8150 5 mg n=10 Participants MK-8150 5 mg once daily for 10 days	Panel B - MK-8150 10 mg n=6 Participants MK-8150 10 mg once daily for 10 days	Panel C - MK-8150 20 mg MK-8150 20 mg once daily for 10 days	Panel D - MK-8150 15 mg MK-8150 15 mg once daily for 10 days	Panel E - MK-8150 3/2 mg Single dose of MK-8150 3 mg on Day 1 and MK-8150 2 mg once daily on Days 6-15	Panel F - MK-8150 6/4 mg Single dose of MK-8150 6 mg on Day 1 and MK-8150 4 mg once daily on Days 6-15	Panel G - MK-8150 20/30/40/60 mg MK-8150 once daily as follows: 20 mg (Days 1-7), 30 mg (Days 8-14), 40 mg (Days 15-21), 60 mg (Days 22-28)	Panel H - MK-8150 10/20 mg MK-8150 once daily as follows: 10 mg (Days 1-2), 20 mg (Days 3-10)	Panel I - MK-8150 5/10/20/40 mg MK-8150 once daily as follows: 5 mg (Days 1-7), 10 mg (Days 8-14), 20 mg (Days 15-21), 40 mg (Days 22-28)	Panel J - MK-8150 10/20 mg MK-8150 once daily as follows: 10 mg (Days 1-7), 20 mg (Days 8-28)	Placebo (Panel A - J) Combines participants who received placebo in all panels	Post Study All enrolled participants, presents AEs with onset after safety follow-up period after last dose of study drug	Screening All enrolled participants, presents AEs with onset before first dose of study drug
Change From Baseline in TWA0-24hrs pSBP Following Day 28 Dose in Male Participants With Mild to Moderate Hypertension Administered Multiple Doses of MK-8150 and Placebo (Panel I)	-12.4 mm Hg Standard Error 2.4	-14.2 mm Hg Standard Error 1.8	—	—	—	—	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: Pre-dose and 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14, 16 and 24 hours post dose

Population: All participants who met protocol entry criteria, received study drug and had data available for the measure

pDBP was measured with a validated automatic measuring device. Time-weighted average was obtained as follows: For all pDBP values obtained over the 24-hour observation period, multiply the length of time that the participant spent at each pDBP value by that pDBP value, add these products together, and then divide by duration of the observation period. The length of time spent at an identified pDBP value was defined as the time elapsed since previous post-dose measurement, or time elapsed since drug administration, if there is no previous post-dose measurement. Baseline was Day 1 pre-dose value.

Outcome measures

Outcome measures
Measure	Panel A - MK-8150 5 mg n=10 Participants MK-8150 5 mg once daily for 10 days	Panel B - MK-8150 10 mg n=6 Participants MK-8150 10 mg once daily for 10 days	Panel C - MK-8150 20 mg MK-8150 20 mg once daily for 10 days	Panel D - MK-8150 15 mg MK-8150 15 mg once daily for 10 days	Panel E - MK-8150 3/2 mg Single dose of MK-8150 3 mg on Day 1 and MK-8150 2 mg once daily on Days 6-15	Panel F - MK-8150 6/4 mg Single dose of MK-8150 6 mg on Day 1 and MK-8150 4 mg once daily on Days 6-15	Panel G - MK-8150 20/30/40/60 mg MK-8150 once daily as follows: 20 mg (Days 1-7), 30 mg (Days 8-14), 40 mg (Days 15-21), 60 mg (Days 22-28)	Panel H - MK-8150 10/20 mg MK-8150 once daily as follows: 10 mg (Days 1-2), 20 mg (Days 3-10)	Panel I - MK-8150 5/10/20/40 mg MK-8150 once daily as follows: 5 mg (Days 1-7), 10 mg (Days 8-14), 20 mg (Days 15-21), 40 mg (Days 22-28)	Panel J - MK-8150 10/20 mg MK-8150 once daily as follows: 10 mg (Days 1-7), 20 mg (Days 8-28)	Placebo (Panel A - J) Combines participants who received placebo in all panels	Post Study All enrolled participants, presents AEs with onset after safety follow-up period after last dose of study drug	Screening All enrolled participants, presents AEs with onset before first dose of study drug
Change From Baseline in TWA0-24hrs pDBP Following Day 28 Dose in Male Participants With Mild to Moderate Hypertension Administered Multiple Doses of MK-8150 and Placebo (Panel I)	-10.3 mm Hg Standard Error 1.4	-9.6 mm Hg Standard Error 2.4	—	—	—	—	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: Pre-dose and 2, 3, 4, 6, 8, 12 and 24 hours post dose

Population: All participants who met protocol entry criteria, received study drug and had data available for the measure

AIx was measured by applanation tonometry of the radial artery, using the SphygmoCor System. The central pressure waveform was determined from the peripheral pressure waveform by a transfer function. Augmentation index is the percentage of the central pulse pressure attributed to the reflected pulse wave, and is an indirect measure of systemic arterial stiffness. Time-weighted average was obtained as follows: For all AIx values obtained over the 24-hour observation period, multiply the length of time that the participant spent at each AIx value by that AIx value, add these products together, and then divide by duration of the observation period. The length of time spent at an identified AIx value was defined as the time elapsed since previous post-dose measurement, or time elapsed since drug administration, if there is no previous post-dose measurement. AIx was adjusted for HR. Baseline was Day 1 pre-dose value.

Outcome measures

Outcome measures
Measure	Panel A - MK-8150 5 mg n=12 Participants MK-8150 5 mg once daily for 10 days	Panel B - MK-8150 10 mg n=6 Participants MK-8150 10 mg once daily for 10 days	Panel C - MK-8150 20 mg MK-8150 20 mg once daily for 10 days	Panel D - MK-8150 15 mg MK-8150 15 mg once daily for 10 days	Panel E - MK-8150 3/2 mg Single dose of MK-8150 3 mg on Day 1 and MK-8150 2 mg once daily on Days 6-15	Panel F - MK-8150 6/4 mg Single dose of MK-8150 6 mg on Day 1 and MK-8150 4 mg once daily on Days 6-15	Panel G - MK-8150 20/30/40/60 mg MK-8150 once daily as follows: 20 mg (Days 1-7), 30 mg (Days 8-14), 40 mg (Days 15-21), 60 mg (Days 22-28)	Panel H - MK-8150 10/20 mg MK-8150 once daily as follows: 10 mg (Days 1-2), 20 mg (Days 3-10)	Panel I - MK-8150 5/10/20/40 mg MK-8150 once daily as follows: 5 mg (Days 1-7), 10 mg (Days 8-14), 20 mg (Days 15-21), 40 mg (Days 22-28)	Panel J - MK-8150 10/20 mg MK-8150 once daily as follows: 10 mg (Days 1-7), 20 mg (Days 8-28)	Placebo (Panel A - J) Combines participants who received placebo in all panels	Post Study All enrolled participants, presents AEs with onset after safety follow-up period after last dose of study drug	Screening All enrolled participants, presents AEs with onset before first dose of study drug
Change From Baseline in TWA0-24hrs AIx Following Day 28 Dose in Male Participants With Mild to Moderate Hypertension Administered Multiple Doses of MK-8150 and Placebo (Panel J) Day 1 (N = 12, 6)	-10.4 percentage of central pulse pressure Standard Error 1.8	-5.9 percentage of central pulse pressure Standard Error 1.0	—	—	—	—	—	—	—	—	—	—	—
Change From Baseline in TWA0-24hrs AIx Following Day 28 Dose in Male Participants With Mild to Moderate Hypertension Administered Multiple Doses of MK-8150 and Placebo (Panel J) Day 28 (N = 9, 6)	-9.9 percentage of central pulse pressure Standard Error 2.1	-6.1 percentage of central pulse pressure Standard Error 1.0	—	—	—	—	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: Pre-dose and 2, 3, 4, 6, 8, 12 and 24 hours post dose

Population: All participants who met protocol entry criteria, received study drug and had data available for the measure

cDBP was measured by applanation tonometry of the radial artery, using the SphygmoCor System. The central pressure waveform was determined from the peripheral pressure waveform by a transfer function. Time-weighted average was obtained as follows: For all cDBP values obtained over the 24-hour observation period, multiply the length of time that the participant spent at each cDBP value by that cDBP value, add these products together, and then divide by duration of the observation period. The length of time spent at an identified cDBP value was defined as the time elapsed since previous post-dose measurement, or time elapsed since drug administration, if there is no previous post-dose measurement. Baseline was Day 1 pre-dose value.

Outcome measures

Outcome measures
Measure	Panel A - MK-8150 5 mg n=9 Participants MK-8150 5 mg once daily for 10 days	Panel B - MK-8150 10 mg n=6 Participants MK-8150 10 mg once daily for 10 days	Panel C - MK-8150 20 mg MK-8150 20 mg once daily for 10 days	Panel D - MK-8150 15 mg MK-8150 15 mg once daily for 10 days	Panel E - MK-8150 3/2 mg Single dose of MK-8150 3 mg on Day 1 and MK-8150 2 mg once daily on Days 6-15	Panel F - MK-8150 6/4 mg Single dose of MK-8150 6 mg on Day 1 and MK-8150 4 mg once daily on Days 6-15	Panel G - MK-8150 20/30/40/60 mg MK-8150 once daily as follows: 20 mg (Days 1-7), 30 mg (Days 8-14), 40 mg (Days 15-21), 60 mg (Days 22-28)	Panel H - MK-8150 10/20 mg MK-8150 once daily as follows: 10 mg (Days 1-2), 20 mg (Days 3-10)	Panel I - MK-8150 5/10/20/40 mg MK-8150 once daily as follows: 5 mg (Days 1-7), 10 mg (Days 8-14), 20 mg (Days 15-21), 40 mg (Days 22-28)	Panel J - MK-8150 10/20 mg MK-8150 once daily as follows: 10 mg (Days 1-7), 20 mg (Days 8-28)	Placebo (Panel A - J) Combines participants who received placebo in all panels	Post Study All enrolled participants, presents AEs with onset after safety follow-up period after last dose of study drug	Screening All enrolled participants, presents AEs with onset before first dose of study drug
Change From Baseline in TWA0-24hrs cDBP Following Day 28 Dose in Male Participants With Mild to Moderate Hypertension Administered Multiple Doses of MK-8150 and Placebo (Panel J)	-4.9 mmHg Standard Error 1.4	-4.3 mmHg Standard Error 1.5	—	—	—	—	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: Pre-dose and 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14, 16 and 24 hours post dose

Population: All participants who met protocol entry criteria, received study drug and had data available for the measure

pSBP was measured with a validated automatic measuring device. Time-weighted average was obtained as follows: For all pSBP values obtained over the 24-hour observation period, multiply the length of time that the participant spent at each pSBP value by that pSBP value, add these products together, and then divide by duration of the observation period. The length of time spent at an identified pSBP value was defined as the time elapsed since previous post-dose measurement, or time elapsed since drug administration, if there is no previous post-dose measurement. Baseline was Day 1 pre-dose value.

Outcome measures

Outcome measures
Measure	Panel A - MK-8150 5 mg n=9 Participants MK-8150 5 mg once daily for 10 days	Panel B - MK-8150 10 mg n=6 Participants MK-8150 10 mg once daily for 10 days	Panel C - MK-8150 20 mg MK-8150 20 mg once daily for 10 days	Panel D - MK-8150 15 mg MK-8150 15 mg once daily for 10 days	Panel E - MK-8150 3/2 mg Single dose of MK-8150 3 mg on Day 1 and MK-8150 2 mg once daily on Days 6-15	Panel F - MK-8150 6/4 mg Single dose of MK-8150 6 mg on Day 1 and MK-8150 4 mg once daily on Days 6-15	Panel G - MK-8150 20/30/40/60 mg MK-8150 once daily as follows: 20 mg (Days 1-7), 30 mg (Days 8-14), 40 mg (Days 15-21), 60 mg (Days 22-28)	Panel H - MK-8150 10/20 mg MK-8150 once daily as follows: 10 mg (Days 1-2), 20 mg (Days 3-10)	Panel I - MK-8150 5/10/20/40 mg MK-8150 once daily as follows: 5 mg (Days 1-7), 10 mg (Days 8-14), 20 mg (Days 15-21), 40 mg (Days 22-28)	Panel J - MK-8150 10/20 mg MK-8150 once daily as follows: 10 mg (Days 1-7), 20 mg (Days 8-28)	Placebo (Panel A - J) Combines participants who received placebo in all panels	Post Study All enrolled participants, presents AEs with onset after safety follow-up period after last dose of study drug	Screening All enrolled participants, presents AEs with onset before first dose of study drug
Change From Baseline in TWA0-24hrs pSBP Following Day 28 Dose in Male Participants With Mild to Moderate Hypertension Administered Multiple Doses of MK-8150 and Placebo (Panel J)	-9.2 mm Hg Standard Error 2.2	-5.5 mm Hg Standard Error 2.2	—	—	—	—	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: Pre-dose and 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14, 16 and 24 hours post dose

Population: All participants who met protocol entry criteria, received study drug and had data available for the measure

pDBP was measured with a validated automatic measuring device. Time-weighted average was obtained as follows: For all pDBP values obtained over the 24-hour observation period, multiply the length of time that the participant spent at each pDBP value by that pDBP value, add these products together, and then divide by duration of the observation period. The length of time spent at an identified pDBP value was defined as the time elapsed since previous post-dose measurement, or time elapsed since drug administration, if there is no previous post-dose measurement. Baseline was Day 1 pre-dose value.

Outcome measures

Outcome measures
Measure	Panel A - MK-8150 5 mg n=9 Participants MK-8150 5 mg once daily for 10 days	Panel B - MK-8150 10 mg n=6 Participants MK-8150 10 mg once daily for 10 days	Panel C - MK-8150 20 mg MK-8150 20 mg once daily for 10 days	Panel D - MK-8150 15 mg MK-8150 15 mg once daily for 10 days	Panel E - MK-8150 3/2 mg Single dose of MK-8150 3 mg on Day 1 and MK-8150 2 mg once daily on Days 6-15	Panel F - MK-8150 6/4 mg Single dose of MK-8150 6 mg on Day 1 and MK-8150 4 mg once daily on Days 6-15	Panel G - MK-8150 20/30/40/60 mg MK-8150 once daily as follows: 20 mg (Days 1-7), 30 mg (Days 8-14), 40 mg (Days 15-21), 60 mg (Days 22-28)	Panel H - MK-8150 10/20 mg MK-8150 once daily as follows: 10 mg (Days 1-2), 20 mg (Days 3-10)	Panel I - MK-8150 5/10/20/40 mg MK-8150 once daily as follows: 5 mg (Days 1-7), 10 mg (Days 8-14), 20 mg (Days 15-21), 40 mg (Days 22-28)	Panel J - MK-8150 10/20 mg MK-8150 once daily as follows: 10 mg (Days 1-7), 20 mg (Days 8-28)	Placebo (Panel A - J) Combines participants who received placebo in all panels	Post Study All enrolled participants, presents AEs with onset after safety follow-up period after last dose of study drug	Screening All enrolled participants, presents AEs with onset before first dose of study drug
Change From Baseline in TWA0-24hrs pDBP in Male Participants With Mild to Moderate Hypertension Administered Multiple Doses of MK-8150 and Placebo (Panel J)	-6.5 mm Hg Standard Error 1.3	-5.3 mm Hg Standard Error 1.5	—	—	—	—	—	—	—	—	—	—	—

Adverse Events

Panel A - MK-8150 5 mg

Serious events: 0 serious events

Other events: 4 other events

Deaths: 0 deaths

Panel B - MK-8150 10 mg

Serious events: 0 serious events

Other events: 5 other events

Deaths: 0 deaths

Panel C - MK-8150 20 mg

Serious events: 0 serious events

Other events: 6 other events

Deaths: 0 deaths

Panel D - MK-8150 15 mg

Serious events: 0 serious events

Other events: 3 other events

Deaths: 0 deaths

Panel E - MK-8150 3/2 mg

Serious events: 0 serious events

Other events: 4 other events

Deaths: 0 deaths

Panel F - MK-8150 6/4 mg

Serious events: 0 serious events

Other events: 3 other events

Deaths: 0 deaths

Panel G - MK-8150 20/30/40/60 mg

Serious events: 0 serious events

Other events: 7 other events

Deaths: 0 deaths

Panel H - MK-8150 10/20 mg

Serious events: 0 serious events

Other events: 6 other events

Deaths: 0 deaths

Panel I - MK-8150 5/10/20/40 mg

Serious events: 0 serious events

Other events: 12 other events

Deaths: 0 deaths

Panel J - MK-8150 10/20 mgEdit

Serious events: 0 serious events

Other events: 10 other events

Deaths: 0 deaths

Placebo (Panel A - J)

Serious events: 0 serious events

Other events: 23 other events

Deaths: 0 deaths

Post Study

Serious events: 0 serious events

Other events: 1 other events

Deaths: 0 deaths

Screening

Serious events: 0 serious events

Other events: 11 other events

Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Other adverse events
Measure	Panel A - MK-8150 5 mg n=6 participants at risk MK-8150 5 mg once daily for 10 days	Panel B - MK-8150 10 mg n=6 participants at risk MK-8150 10 mg once daily for 10 days	Panel C - MK-8150 20 mg n=6 participants at risk MK-8150 20 mg once daily for 10 days	Panel D - MK-8150 15 mg n=5 participants at risk MK-8150 15 mg once daily for 10 days	Panel E - MK-8150 3/2 mg n=6 participants at risk Single dose of MK-8150 3 mg on Day 1 and MK-8150 2 mg once daily on Days 6-15	Panel F - MK-8150 6/4 mg n=6 participants at risk Single dose of MK-8150 6 mg on Day 1 and MK-8150 4 mg once daily on Days 6-15	Panel G - MK-8150 20/30/40/60 mg n=8 participants at risk MK-8150 once daily as follows: 20 mg (Days 1-7), 30 mg (Days 8-14), 40 mg (Days 15-21), 60 mg (Days 22-28)	Panel H - MK-8150 10/20 mg n=8 participants at risk MK-8150 once daily as follows: 10 mg (Days 1-2), 20 mg (Days 3-10)	Panel I - MK-8150 5/10/20/40 mg n=12 participants at risk MK-8150 once daily as follows: 5 mg (Days 1-7), 10 mg (Days 8-14), 20 mg (Days 15-21), 40 mg (Days 22-28)	Panel J - MK-8150 10/20 mgEdit n=12 participants at risk MK-8150 once daily as follows: 10 mg (Days 1-7), 20 mg (Days 8-28)	Placebo (Panel A - J) n=36 participants at risk Combines participants who received placebo in all panels	Post Study n=103 participants at risk All enrolled participants, presents AEs with onset after safety follow-up period after last dose of study drug	Screening n=103 participants at risk All enrolled participants, presents AEs with onset before first dose of study drug
Vascular disorders Systolic hypertension	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/5 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	8.3% 1/12 • Number of events 1 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/12 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/36 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.97% 1/103 • Number of events 1 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/103 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.
General disorders Puncture site pain	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/5 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/12 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	8.3% 1/12 • Number of events 1 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/36 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/103 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/103 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.
Cardiac disorders Postural orthostatic tachycardia syndrome	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	16.7% 1/6 • Number of events 2 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/5 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/12 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/12 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	2.8% 1/36 • Number of events 1 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/103 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/103 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.
Ear and labyrinth disorders Ear pain	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	20.0% 1/5 • Number of events 1 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/12 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/12 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/36 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/103 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/103 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.
Ear and labyrinth disorders Vertigo	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/5 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	12.5% 1/8 • Number of events 1 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/12 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/12 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/36 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/103 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/103 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.
Eye disorders Corneal irritation	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	16.7% 1/6 • Number of events 1 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/5 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/12 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/12 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/36 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/103 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/103 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.
Gastrointestinal disorders Abdominal pain	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/5 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	8.3% 1/12 • Number of events 1 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/12 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/36 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/103 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/103 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.
Gastrointestinal disorders Constipation	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	16.7% 1/6 • Number of events 1 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/5 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	33.3% 2/6 • Number of events 2 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	12.5% 1/8 • Number of events 1 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/12 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/12 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/36 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/103 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/103 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.
Gastrointestinal disorders Diarrhoea	16.7% 1/6 • Number of events 1 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/5 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	8.3% 1/12 • Number of events 1 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/12 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/36 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/103 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/103 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.
Gastrointestinal disorders Dry mouth	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/5 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/12 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/12 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	5.6% 2/36 • Number of events 2 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/103 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/103 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.
Gastrointestinal disorders Loose stools	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	20.0% 1/5 • Number of events 1 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	25.0% 2/8 • Number of events 2 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/12 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/12 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/36 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/103 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/103 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.
Gastrointestinal disorders Nausea	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/5 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	25.0% 2/8 • Number of events 2 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	8.3% 1/12 • Number of events 1 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	8.3% 1/12 • Number of events 4 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/36 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/103 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/103 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.
Gastrointestinal disorders Pyrosis	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/5 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/12 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/12 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	5.6% 2/36 • Number of events 2 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/103 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/103 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.
Gastrointestinal disorders Reflux oesophagitis	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/5 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	16.7% 1/6 • Number of events 1 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/12 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/12 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/36 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/103 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/103 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.
Gastrointestinal disorders Regurgitation	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	20.0% 1/5 • Number of events 1 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/12 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/12 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/36 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/103 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/103 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.
Gastrointestinal disorders Upset stomach	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/5 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	25.0% 2/8 • Number of events 3 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/12 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/12 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/36 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/103 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/103 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.
Gastrointestinal disorders Vomiting	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/5 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	16.7% 1/6 • Number of events 2 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	12.5% 1/8 • Number of events 1 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	16.7% 2/12 • Number of events 2 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	8.3% 1/12 • Number of events 1 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	2.8% 1/36 • Number of events 1 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/103 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/103 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.
General disorders Asthenia	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/5 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	8.3% 1/12 • Number of events 1 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/12 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/36 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/103 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/103 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.
General disorders Chills	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/5 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	12.5% 1/8 • Number of events 1 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/12 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/12 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/36 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/103 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/103 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.
General disorders Fatigue	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/5 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	25.0% 2/8 • Number of events 4 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/12 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	8.3% 1/12 • Number of events 1 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	13.9% 5/36 • Number of events 7 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/103 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/103 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.
General disorders Flu-like symptoms	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/5 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	8.3% 1/12 • Number of events 1 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/12 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/36 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/103 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/103 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.
General disorders Vessel puncture site haematoma	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/5 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	12.5% 1/8 • Number of events 1 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/12 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/12 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/36 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/103 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/103 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.
Infections and infestations Cold	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/5 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/12 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	8.3% 1/12 • Number of events 1 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	2.8% 1/36 • Number of events 1 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/103 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/103 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.
Infections and infestations Common cold	16.7% 1/6 • Number of events 1 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	16.7% 1/6 • Number of events 1 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	20.0% 1/5 • Number of events 1 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	16.7% 1/6 • Number of events 1 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	25.0% 2/8 • Number of events 2 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	25.0% 2/8 • Number of events 2 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	8.3% 1/12 • Number of events 1 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	25.0% 3/12 • Number of events 3 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	11.1% 4/36 • Number of events 4 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/103 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	5.8% 6/103 • Number of events 6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.
Injury, poisoning and procedural complications Abdominal wall strained	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/5 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	12.5% 1/8 • Number of events 1 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/12 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/12 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/36 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/103 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/103 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.
Injury, poisoning and procedural complications Skin wound	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/5 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	12.5% 1/8 • Number of events 1 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/12 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/12 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/36 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/103 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/103 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.
Investigations Blood pressure systolic decreased	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/5 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/12 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	16.7% 2/12 • Number of events 3 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/36 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/103 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/103 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.
Investigations C-reactive protein increased	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	16.7% 1/6 • Number of events 2 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/5 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	12.5% 1/8 • Number of events 1 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/12 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	16.7% 2/12 • Number of events 2 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/36 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/103 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/103 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.
Investigations Creatinine increased	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	16.7% 1/6 • Number of events 1 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/5 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/12 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/12 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/36 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/103 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/103 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.
Investigations Glucose increased	16.7% 1/6 • Number of events 2 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/5 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/12 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/12 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/36 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.97% 1/103 • Number of events 1 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/103 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.
Investigations Red blood cell sedimentation rate increased	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	16.7% 1/6 • Number of events 2 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/5 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/12 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	8.3% 1/12 • Number of events 1 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/36 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/103 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/103 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.
Investigations Red blood cells urine positive	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	20.0% 1/5 • Number of events 1 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/12 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/12 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/36 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/103 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/103 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.
Metabolism and nutrition disorders Fasting hyperglycaemia	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/5 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/12 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	8.3% 1/12 • Number of events 1 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/36 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/103 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/103 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.
Musculoskeletal and connective tissue disorders Back pain	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/5 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	16.7% 1/6 • Number of events 1 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/12 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/12 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/36 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/103 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/103 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.
Musculoskeletal and connective tissue disorders Cervical pain	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/5 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	16.7% 2/12 • Number of events 2 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/12 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/36 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/103 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/103 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.
Musculoskeletal and connective tissue disorders Gouty arthritis	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/5 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	8.3% 1/12 • Number of events 1 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/12 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/36 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/103 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/103 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.
Musculoskeletal and connective tissue disorders Knee pain	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/5 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	8.3% 1/12 • Number of events 1 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/12 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/36 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/103 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/103 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.
Musculoskeletal and connective tissue disorders Low back pain	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/5 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	8.3% 1/12 • Number of events 1 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/12 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	2.8% 1/36 • Number of events 1 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/103 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/103 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.
Musculoskeletal and connective tissue disorders Muscle stiffness	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/5 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	8.3% 1/12 • Number of events 1 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/12 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/36 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/103 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/103 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.
Musculoskeletal and connective tissue disorders Musculoskeletal pain	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/5 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/12 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	8.3% 1/12 • Number of events 1 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/36 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/103 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/103 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.
Musculoskeletal and connective tissue disorders Neck pain	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	33.3% 2/6 • Number of events 2 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/5 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	12.5% 1/8 • Number of events 2 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	12.5% 1/8 • Number of events 1 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/12 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	16.7% 2/12 • Number of events 8 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	2.8% 1/36 • Number of events 1 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/103 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/103 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.
Musculoskeletal and connective tissue disorders Pain in leg	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/5 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	16.7% 1/6 • Number of events 1 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/12 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/12 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/36 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/103 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/103 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.
Musculoskeletal and connective tissue disorders Shoulder bursitis	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/5 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	16.7% 1/6 • Number of events 1 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/12 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/12 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/36 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/103 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/103 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.
Nervous system disorders Dizziness	16.7% 1/6 • Number of events 2 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	33.3% 2/6 • Number of events 3 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/5 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	16.7% 1/6 • Number of events 2 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	8.3% 1/12 • Number of events 1 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/12 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	11.1% 4/36 • Number of events 5 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/103 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.97% 1/103 • Number of events 2 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.
Nervous system disorders Dizziness postural	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/5 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/12 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	8.3% 1/12 • Number of events 1 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	8.3% 3/36 • Number of events 3 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/103 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/103 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.
Nervous system disorders Dizziness upon standing	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/5 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	12.5% 1/8 • Number of events 1 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/12 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/12 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	2.8% 1/36 • Number of events 1 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/103 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/103 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.
Nervous system disorders Dysgeusia	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	20.0% 1/5 • Number of events 1 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/12 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/12 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	2.8% 1/36 • Number of events 1 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/103 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/103 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.
Nervous system disorders Head discomfort	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	16.7% 1/6 • Number of events 2 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/5 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/12 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/12 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/36 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/103 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/103 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.
Nervous system disorders Headache	16.7% 1/6 • Number of events 1 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	66.7% 4/6 • Number of events 4 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	16.7% 1/6 • Number of events 3 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	40.0% 2/5 • Number of events 3 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	33.3% 2/6 • Number of events 5 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	50.0% 4/8 • Number of events 15 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	62.5% 5/8 • Number of events 15 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	100.0% 12/12 • Number of events 25 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	33.3% 4/12 • Number of events 36 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	47.2% 17/36 • Number of events 38 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/103 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.97% 1/103 • Number of events 1 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.
Nervous system disorders Intermittent headache	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	16.7% 1/6 • Number of events 1 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/5 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	12.5% 1/8 • Number of events 1 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	8.3% 1/12 • Number of events 1 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	16.7% 2/12 • Number of events 2 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	2.8% 1/36 • Number of events 1 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/103 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/103 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.
Nervous system disorders Ischialgia	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/5 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	12.5% 1/8 • Number of events 1 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/12 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/12 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/36 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/103 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/103 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.
Nervous system disorders Lightheadedness	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	16.7% 1/6 • Number of events 1 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/5 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	16.7% 1/6 • Number of events 2 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/12 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/12 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/36 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/103 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/103 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.
Nervous system disorders Migraine	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	16.7% 1/6 • Number of events 2 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/5 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	8.3% 1/12 • Number of events 1 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/12 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/36 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/103 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/103 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.
Nervous system disorders Short-term memory impairment	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/5 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	8.3% 1/12 • Number of events 1 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/12 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/36 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/103 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/103 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.
Nervous system disorders Syncope	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/5 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	8.3% 1/12 • Number of events 1 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/12 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/36 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/103 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/103 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.
Psychiatric disorders Anxiety	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/5 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	16.7% 1/6 • Number of events 1 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/12 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/12 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/36 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/103 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/103 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.
Renal and urinary disorders Microalbuminuria	16.7% 1/6 • Number of events 4 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/5 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/12 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/12 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/36 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.97% 1/103 • Number of events 1 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/103 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.
Respiratory, thoracic and mediastinal disorders Cough	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	16.7% 1/6 • Number of events 1 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/5 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/12 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	8.3% 1/12 • Number of events 1 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	5.6% 2/36 • Number of events 2 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/103 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.97% 1/103 • Number of events 1 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.
Respiratory, thoracic and mediastinal disorders Dry throat	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	16.7% 1/6 • Number of events 1 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/5 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/12 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	8.3% 1/12 • Number of events 1 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/36 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/103 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/103 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.
Respiratory, thoracic and mediastinal disorders Nasal congestion	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	16.7% 1/6 • Number of events 2 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/5 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	12.5% 1/8 • Number of events 1 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/12 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	8.3% 1/12 • Number of events 1 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	2.8% 1/36 • Number of events 1 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/103 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/103 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.
Respiratory, thoracic and mediastinal disorders Sore throat	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/5 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/12 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	25.0% 3/12 • Number of events 3 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	8.3% 3/36 • Number of events 4 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/103 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/103 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.
Respiratory, thoracic and mediastinal disorders Throat irritation	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/5 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/12 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	8.3% 1/12 • Number of events 2 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	2.8% 1/36 • Number of events 1 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/103 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.97% 1/103 • Number of events 1 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.
Respiratory, thoracic and mediastinal disorders Throat pain	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/5 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	8.3% 1/12 • Number of events 1 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/12 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/36 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/103 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.97% 1/103 • Number of events 1 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.
Skin and subcutaneous tissue disorders Dermatitis irritant contact	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	20.0% 1/5 • Number of events 1 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/12 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/12 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/36 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/103 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/103 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.
Skin and subcutaneous tissue disorders Eczematous rash	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/5 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	16.7% 1/6 • Number of events 1 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/12 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/12 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/36 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/103 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/103 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.
Skin and subcutaneous tissue disorders Localised erythema	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/5 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	12.5% 1/8 • Number of events 2 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/12 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/12 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/36 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/103 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/103 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.
Vascular disorders Diastolic hypertension	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	20.0% 1/5 • Number of events 1 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	8.3% 1/12 • Number of events 1 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/12 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	2.8% 1/36 • Number of events 1 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.97% 1/103 • Number of events 1 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.97% 1/103 • Number of events 1 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.
Vascular disorders Haematoma	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/5 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	16.7% 1/6 • Number of events 1 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/12 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/12 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/36 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/103 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/103 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.
Vascular disorders Hot flush	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/5 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	16.7% 1/6 • Number of events 1 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/12 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/12 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/36 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/103 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/103 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.
Vascular disorders Orthostatic hypotension	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/5 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/6 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/8 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/12 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	8.3% 1/12 • Number of events 1 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/36 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/103 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.	0.00% 0/103 • Up to 14 days after the last dose (Up to approximately 42 days, excluding pre-dose/screening period) The 8 crossover Panel H participants are represented in both Panel H - MK-8150 10/20 mg column and Placebo (Panel A - J) column.

Additional Information

Senior Vice President, Global Clinical Development

Merck Sharp & Dohme Corp.

Phone: 1-800-672-6372

Email: [email protected]

Results disclosure agreements

Principal investigator is a sponsor employee The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission. Sponsor review can be expedited to meet publication timelines.
Publication restrictions are in place

Restriction type: OTHER